Radiopharmaceutical conjugate compositions and uses thereof

JP2023551539A5Inactive Publication Date: 2024-12-06RAYZEBIO INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023533236
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-11-30
Filing Date
2021-11-30
Publication Date
2024-12-06
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Traditional radiation therapy is ineffective for many cancer patients, and metastatic tumor cells in the bloodstream reduce treatment efficacy, necessitating targeted radiotherapy with improved affinity, stability, and performance.

Method used

Development of radiopharmaceutical conjugates using monocyclic peptides coupled with metal chelators and alpha-emitting radionuclides, avoiding disulfide bonds for enhanced stability and optimal pharmacodynamic profiles.

Benefits of technology

The conjugates provide targeted delivery with improved tumor penetration and stability, offering superior efficacy over existing radiopharmaceuticals by optimizing peptide stability, receptor binding, and elimination half-life.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2022115778000001
    Figure 2022115778000001
  • Figure 2022115778000002
    Figure 2022115778000002
Patent Text Reader

Abstract

Provided herein are radiopharmaceutical conjugate compositions and uses thereof. In one aspect, provided herein are conjugates comprising a monocyclic peptide of 5 to 40 amino acid residues and a metal chelator configured to bind to a radionuclide. In some embodiments, the monocyclic peptide is cyclized by a non-disulfide bond. In some embodiments, the monocyclic peptide does not contain a non-disulfide bond. The monocyclic peptide can be configured to bind to a structure on a cell. Further provided herein are methods of treating cancer by administering the conjugates and compositions described.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] Cross-reference of related applications This application claims the interests of U.S. Provisional Patent Application No. 63 / 119,555, filed on 30 November 2020, which is incorporated herein by reference in its entirety.

[0002] Sequence List This application includes an electronically submitted sequence listing in ASCII format, the entire listing of which is incorporated herein by reference. The above ASCII copy, created on November 23, 2021, is named 59541-707_601_SL.txt and has a size of 5,686 bytes. [Background technology]

[0003] In the United States, cancer is the leading cause of death for those under 65, accounting for approximately 21% of all deaths in 2018. Conventional radiotherapy, such as external beam radiation therapy, has been used for decades as the standard treatment for patients diagnosed with cancer. While some patients respond favorably to external beam radiation therapy, many others do not. Furthermore, metastatic and circulating tumor cells can spread and remain in the bloodstream or bodily fluids after standard treatment, leading to resistance to treatment. The presence of cancer cells in various parts of the body reduces the effectiveness of conventional radiotherapy. Therefore, strategies for targeted radiotherapy have been developed, and there remains a need for targeted radiotherapy with the desired affinity, stability, and implementation profile. [Overview of the Initiative]

[0004] In one embodiment, the present disclosure relates to a peptide such as a monocyclic peptide, a metal chelating agent, optionally a linker, and optionally a linker bound to the metal chelating agent. 225This invention relates to radiopharmaceutical conjugates containing alpha-emitting radionuclides, such as Ac. In some embodiments, the peptide consists of 5–40, 10–20, or 10–15 amino acid residues. In some embodiments, the peptide does not contain or is not cyclized by typical disulfide bonds, such as those formed by L-cysteine. The conjugates of this disclosure offer several advantages over existing radiopharmaceuticals. For example, by adjusting the number and type of amino acid residues in the peptide to suit the needs, an optimal balance of peptide stability, receptor binding, tumor penetration, and efflux profile can be achieved. Conventionally, radiopharmaceuticals utilize small molecules or antibodies to target receptors. Small molecule ligands tend to have low target specificity, while antibody-based conjugates have poor tumor penetration. Furthermore, the efflux half-life of small molecule ligand-based conjugates tends to be very short, while the efflux half-life of antibody-based conjugates can be too long. This disclosure reveals that peptide (such as macrocyclic peptides)-based conjugates are ideal for radiopharmaceuticals. In some embodiments, the conjugates of this disclosure may be superior to existing cyclic peptide-based conjugates (such as DOTA-TATE) in terms of stability and other properties. In other embodiments, peptides having disulfide bonds may be susceptible to reduction reactions, leading to destabilization, followed by metabolism of the disulfide-bonded peptide. Therefore, in some cases, conjugates containing peptides not cyclized by disulfide bonds are more stable with respect to proteolyticity, heat, and pH than the corresponding conjugates containing disulfide-bridged peptides. The resulting conjugates have a more optimal pharmacodynamic profile and, therefore, a more optimal pharmacological profile.

[0005] In one embodiment, a conjugate comprising a monocyclic peptide of 5 to 40 amino acid residues, a metal chelating agent configured to bind to a radionuclide, and optionally a radionuclide is disclosed herein. In one embodiment, a conjugate comprising a monocyclic peptide of 5 to 40 amino acid residues, a metal chelating agent configured to bind to a radionuclide, and optionally a radionuclide is disclosed herein. In one embodiment, a conjugate comprising a monocyclic peptide of 5 to 40 amino acid residues cyclized by a non-disulfide bond and a metal chelating agent configured to bind to a radionuclide is disclosed herein. In one embodiment, a conjugate comprising a monocyclic peptide of 6 to 40 amino acid residues and a metal chelating agent configured to bind to a radionuclide, wherein the monocyclic peptide does not contain a disulfide bond, is disclosed herein. In some embodiments, the monocyclic peptide consists of 5 to 20 amino acid residues. In some embodiments, the monocyclic peptide consists of 10 to 20 amino acid residues. In some embodiments, the monocyclic peptide consists of 5, 6, 7, 8, or 9 amino acid residues. In some embodiments, the monocyclic peptide consists of 10, 11, 12, 13, 14, or 15 amino acid residues. In some embodiments, the peptide binds to a structure on the cell. In some embodiments, the conjugate is 225 Includes Ac. In some embodiments, the conjugate is 177 Includes Lu.

[0006] In one embodiment, a conjugate is disclosed herein comprising a cyclic binding peptide that binds to a cell surface protein, is cyclized by a non-disulfide bond, and consists of 5 to 40 amino acid residues, and a metal chelating agent configured to bind to a radionuclide, wherein the cell surface protein is a transmembrane glycoprotein. In another embodiment, a conjugate is disclosed herein comprising a binding peptide that binds to a cell surface protein, a metal chelating agent configured to bind to a radionuclide, and a linker that covalently binds the binding peptide to the metal chelating agent, wherein the cell surface protein is a carcinoembryonic antigen, a tight junction protein, an adhesion protein, a transporter receptor, or a tyrosine kinase receptor (TKR). In some embodiments, the peptide consists of 5 to 20 amino acid residues. In some embodiments, the peptide consists of 10 to 20 amino acid residues. In some embodiments, the binding peptide consists of 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 amino acid residues. In some embodiments, the peptide binds to a structure on the cell. In some embodiments, the conjugate is 225 Includes Ac. In some embodiments, the conjugate is 177 Includes Lu.

[0007] In one embodiment, a conjugate is disclosed herein comprising a target moiety containing a monocyclic peptide of 5 to 40 amino acid residues, a metal chelating agent configured to bind to a radionuclide, and an alpha-emitting radionuclide bound to the metal chelating agent, wherein the monocyclic peptide does not contain disulfide bonds. In some embodiments, the alpha-emitting radionuclide is actinium-225, astatine-211, thorium-227, or radium-223. In some embodiments, the alpha-emitting radionuclide is actinium-225. In some embodiments, the monocyclic peptide consists of 10, 11, 12, 13, 14, or 15 amino acid residues. In some embodiments, the monocyclic peptide consists of 5, 6, 7, 8, 9, 10, 11, or 12 amino acid residues. In some embodiments, the target moiety binds to fetal cancer antigens, tight junction proteins, adhesion proteins, EPH-related tyrosine kinase receptors (TKRs), or transporter proteins. In some embodiments, the target moiety binds to transmembrane glycoproteins. In some embodiments, the target moiety binds to prostate-specific membrane antigen (PSMA), tumor-associated calcium signaling transducer 2 (Trop-2), folate receptor 1 (FOLR1), nectin cell adhesion molecule 4 (Nectin-4), fetal cancer antigen-associated cell adhesion molecule 5 (CEACAM5), mesoserine, EPH receptor A2 (EPHA2), tumor-associated calcium signaling transducer 2 (Trop-2), somatostatin receptor type 2 (SSTR2), carbonic anhydrase IX (CAIX), delta-like 3 (DLL3), fibroblast-activating protein α (FAP-α), B7-H4, tumor endothelial marker 8 (TEM8), NaPi2b, claudin 18.2, tumor-associated glycoprotein 72 (TAG72), or CD70. In some embodiments, the target moiety binds to cancer embryo proteins, tumor surface markers, receptor proteins, ligand proteins, cell adhesion proteins, or immunomodulatory proteins.In some embodiments, cyclic peptides are cyclized by peptide bonds, alkyl bonds, alkenyl bonds, ester bonds, thioester bonds, ether bonds, thioether bonds, phosphate ether bonds, azo bonds, CNC bonds, C=NC bonds, C=NO bonds, amide bonds, lactam crosslinks, carbamoyl bonds, urea bonds, thiourea bonds, amine bonds, or thioamide bonds. In some embodiments, cyclic peptides are cyclized by thioether bonds. In some embodiments, cyclic peptides are cyclized via oxime cyclization or cyclization between cysteine ​​and haloacyl. In some embodiments, cyclic peptides have a chloroacetyl group at the N-terminus and a Cys at the C-terminus, and are cyclized via a thioether bond between them. In some embodiments, the metal chelating agent includes DOTA, DOTP, DOTMA, DOTAM, DOTAGA, DTPA, NTA, EDTA, DO3A, DO2A, NOC, NOTA, TETA, DiAmSar, CB-Cyclam, CB-TE2A, DOTA-4AMP, H4pypa, H4octox, H4octapa, p-NO2-Bn-neunpa, or NOTP. In some embodiments, the metal chelating agent is DOTA. In some embodiments, the conjugate includes a linker that covalently bonds the cyclic peptide to the metal chelating agent. In some embodiments, the cyclic peptide is directly bonded to the metal chelating agent via covalent bonding without a linker.

[0008] In one embodiment, a conjugate is disclosed herein comprising a cyclic linked peptide that binds to a cell surface protein, is cyclized by a non-disulfide bond, and consists of 5 to 40 amino acid residues, and a metal chelating agent configured to bind to a radionuclide, wherein the cell surface protein is a transmembrane glycoprotein. In some embodiments, the transmembrane glycoprotein is prostate-specific membrane antigen (PSMA), tumor-associated calcium signaling transducer 2 (Trop-2), somatostatin receptor 2 (SSTR2), or carbonic anhydrase IX (CAIX). In some embodiments, the metal chelating agent includes DOTA, DOTP, DOTMA, DOTAM, DOTAGA, DTPA, NTA, EDTA, DO3A, DO2A, NOC, NOTA, TETA, DiAmSar, CB-Cyclam, CB-TE2A, DOTA-4AMP, H4pypa, H4octox, H4octapa, p-NO2-Bn-neunpa, or NOTP. In some embodiments, the metal chelating agent is DOTA. In some embodiments, the conjugate includes a linker that covalently bonds a cyclic peptide to the metal chelating agent.

[0009] In one embodiment, a conjugate is disclosed herein, comprising a binding peptide that binds to a cell surface protein, a metal chelating agent configured to bind to a radionuclide, and a linker that covalently binds the binding peptide to the metal chelating agent, wherein the cell surface protein is a fetal carcinoma antigen, a tight junction protein, an adhesion protein, a transporter receptor, or a tyrosine kinase receptor (TKR). In some embodiments, the binding peptide is a cyclic peptide. In some embodiments, the conjugate further comprises an alpha-emitting radionuclide bound to the metal chelating agent. In some embodiments, the cell surface protein is a fetal carcinoma antigen. In some embodiments, the fetal carcinoma antigen is fetal carcinoma antigen (CEA) or α-fetal protein (AFP). In some embodiments, the fetal carcinoma antigen is fetal carcinoma antigen-associated cell adhesion molecule 5 (CEACAM5). In some embodiments, the fetal carcinoma antigen is tumor-associated calcium signaling transducer 2 (Trop-2). In some embodiments, the cell surface protein is an eph-associated tight junction protein. In some embodiments, the tight junction protein is a claudin (e.g., claudin 2, 3, 4, 7, 8, 12, 15, or 18), an occludin, an oligodendrocyte-specific protein (OSP), a peripheral myelin protein (PMP), or a junction adhesion molecule. In some embodiments, the cell surface protein is an adhesion protein. In some embodiments, the adhesion protein is nectin cell adhesion molecule 4 (nectin 4). In some embodiments, the adhesion protein is selected from integrins, cadherins, selectins, and immunoglobulin-like cell adhesion molecules. In some embodiments, the cell surface protein is a tyrosine kinase receptor (TKR). In some embodiments, the tyrosine kinase receptor is an EPH-related tyrosine kinase receptor. In some embodiments, the EPH-related tyrosine kinase receptor is an ephrin A receptor or an ephrin B receptor. In some embodiments, the Eph receptor is EPH receptor A2 (EPHA2).In some embodiments, the tyrosine kinase receptor is the epidermal growth factor receptor (EGFR), fibroblast growth factor receptor (FGFR), vascular endothelial growth factor receptor (VEGFR), ErbB receptor, RET receptor, or discoidin domain receptor (DDR). In some embodiments, the ErbB receptor is the Her2 receptor. In some embodiments, the cell surface protein is the transport receptor. In some embodiments, the transport receptor is the folate receptor 1 (FOLR1).

[0010] In some embodiments, the binding peptide described herein consists of 5 to 40 amino acid residues. In some embodiments, the binding peptide consists of 5 to 20 amino acid residues. In some embodiments, the binding peptide consists of 5 to 14 amino acid residues. In some embodiments, the binding peptide consists of 7 to 14 amino acid residues. In some embodiments, the binding peptide consists of 10 to 14 amino acid residues. In some embodiments, the binding peptide consists of 5, 6, 7, 8, 9, 10, 11, or 12 amino acid residues. In some embodiments, the binding peptide is a monocyclic peptide. In some embodiments, the cyclic peptide is cyclized by peptide bonds, alkyl bonds, alkenyl bonds, ester bonds, thioester bonds, ether bonds, thioether bonds, phosphate ether bonds, azo bonds, CNC bonds, C=NC bonds, C=NO bonds, amide bonds, lactam crosslinks, carbamoyl bonds, urea bonds, thiourea bonds, amine bonds, or thioamide bonds. In some embodiments, the cyclic peptide is cyclized by thioether bonds. In some embodiments, the cyclic peptide is cyclized via oxime cyclization or cyclization between cysteine ​​and haloacyl. In some embodiments, the cyclic peptide contains a chloroacetyl group at the N-terminus and a Cys at the C-terminus, and is cyclized via a thioether bond between them. In some embodiments, the metal chelating agent includes DOTA, DOTP, DOTMA, DOTAM, DOTAGA, DTPA, NTA, EDTA, DO3A, DO2A, NOC, NOTA, TETA, DiAmSar, CB-Cyclam, CB-TE2A, DOTA-4AMP, H4pypa, H4octox, H4octapa, p-NO2-Bn-neunpa, or NOTP. In some embodiments, the metal chelating agent is DOTA. In some embodiments, the conjugate includes a linker that covalently bonds the cyclic peptide to the metal chelating agent. In some embodiments, the linker includes one or more lysine residues. In some embodiments, the linker is a lysine residue.In some embodiments, the linker comprises one or more of a substituted or unsubstituted alkyl, a substituted or unsubstituted heteroalkyl, a substituted or unsubstituted cycloalkyl, a substituted or unsubstituted heterocycloalkyl, a substituted or unsubstituted aryl, and a substituted or unsubstituted heteroaryl. In some embodiments, the linker is attached to a linking peptide or a monocyclic peptide via the N-terminus of the peptide. In some embodiments, the linker is attached to a linking peptide or a monocyclic peptide via the C-terminus of the peptide. In some embodiments, the linker is attached to a linking peptide or a monocyclic peptide via a non-terminal amino acid of the peptide. In some embodiments, the cyclic peptide is directly attached to the metal chelating agent via a covalent bond without a linker.

[0011] In one aspect, conjugates are disclosed herein that include a targeting moiety comprising a cyclic peptide having the structure of formula (III) and a metal chelating agent configured to bind to a radionuclide.

[0012]

Chemical Formula

[0013] In some embodiments, L N and L CThese are each a bond. In some embodiments, the conjugate contains an alpha-emitting radionuclide bonded to a metal chelating agent. In some embodiments, the alpha-emitting radionuclide is actinium-225. In some embodiments, the ring-closing group is -C(=O)-CH2-S-, -C(=O)-CH2-NH-, or -C(=O)-CH2-O-. In some embodiments, the ring-closing group is -C(=O)-CH2-S-. In some embodiments, each of the amino acids is independently selected from native amino acids or from the amino acids in Tables 4A to 4G. In some embodiments, the monocyclic peptide is

[0014] [ka] It has the following structure. In some embodiments, the metal chelating agent includes DOTA, DOTP, DOTMA, DOTAM, DOTAGA, DTPA, NTA, EDTA, DO3A, DO2A, NOC, NOTA, TETA, DiAmSar, CB-Cyclam, CB-TE2A, DOTA-4AMP, H4pypa, H4octox, H4octapa, p-NO2-Bn-neunpa, or NOTP. In some embodiments, the metal chelating agent is DOTA. In some embodiments, the conjugate includes a linker that covalently bonds the cyclic peptide to the metal chelating agent. In some embodiments, the linker includes one or more lysine residues. In some embodiments, the linker is a lysine residue. In some embodiments, the linker includes one or more substituted or unsubstituted alkyls, substituted or unsubstituted heteroalkyls, substituted or unsubstituted cycloalkyls, substituted or unsubstituted heterocycloalkyls, substituted or unsubstituted aryls, and substituted or unsubstituted heteroaryls. In some embodiments, the linker is attached to the binding peptide or monocyclic peptide via the N-terminus of the peptide. In some embodiments, the linker is attached to the binding peptide or monocyclic peptide via the C-terminus of the peptide. In some embodiments, the linker is attached to the binding peptide or monocyclic peptide via the non-terminal amino acids of the peptide. In some embodiments, the cyclic peptide is attached directly to the metal chelating agent via covalent bonds without a linker.

[0015] In one embodiment, the following: a) A step of synthesizing a peptide sequence by solid-phase peptide synthesis, b) A step of cyclizing a peptide by forming an intramolecular non-peptide bond, c) A step of binding a metal chelating agent to a peptide, and d) Conjugates prepared by one or more of the steps of optionally labeling a conjugate with a radionuclide are disclosed herein. In some embodiments, the step of synthesizing the peptide sequence includes synthesizing the peptide sequence in a protected form and carrying out a deprotection reaction. In some embodiments, the step of cyclizing the peptide includes forming a non-peptide bond between the N-terminus and C-terminus of the peptide. In some embodiments, the step of cyclizing the peptide includes forming a non-peptide bond between the N-terminus of the peptide and cysteine ​​or homocysteine. In some embodiments, the step of cyclizing the peptide includes forming a ring-closing group selected from -C(=O)-CH2-S-, -S-, -CH=CH-, -NH-, -succinimide-S-, -C(=O)-CH2-NH-, and -C(=O)-CH2-O-. In some embodiments, the peptide has an effective charge of -3, -2, -1, 0, or +1. In some embodiments, the metal chelating agent includes DOTA, DOTP, DOTMA, DOTAM, DOTAGA, DTPA, NTA, EDTA, DO3A, DO2A, NOC, NOTA, TETA, DiAmSar, CB-Cyclam, CB-TE2A, DOTA-4AMP, H4pypa, H4octox, H4octapa, p-NO2-Bn-neunpa, or NOTP. In some embodiments, the metal chelating agent is DOTA. In some embodiments, the conjugate includes a linker that covalently bonds the cyclic peptide to the metal chelating agent. In some embodiments, the linker includes one or more lysine residues. In some embodiments, the linker is a lysine residue. In some embodiments, the linker includes one or more substituted or unsubstituted alkyls, substituted or unsubstituted heteroalkyls, substituted or unsubstituted cycloalkyls, substituted or unsubstituted heterocycloalkyls, substituted or unsubstituted aryls, and substituted or unsubstituted heteroaryls. In some embodiments, the linker is attached to the binding peptide or monocyclic peptide via the N-terminus of the peptide. In some embodiments, the linker is attached to the binding peptide or monocyclic peptide via the C-terminus of the peptide. In some embodiments, the linker is attached to the binding peptide or monocyclic peptide via the non-terminal amino acids of the peptide.In some embodiments, the cyclic peptide is directly bound to the metal chelating agent via covalent bonds without a linker.

[0016] In some embodiments, the conjugates disclosed herein comprise two or more metal chelating agents. In some embodiments, the conjugate comprises two radionuclides bound to the metal chelating agent.

[0017] In some embodiments, the conjugates disclosed herein have an elimination half-life of about 1 to 120 hours in rats. In some embodiments, the conjugates disclosed herein have an elimination half-life of about 2 to 8 hours in rats.

[0018] In some embodiments, the conjugates disclosed herein, when administered to a subject having a tumor, have a residence time of approximately 4 to 7 days within the tumor.

[0019] In some embodiments, 2% to 99% of the conjugates or peptides disclosed herein bind to human serum albumin (HSA) in vitro, as measured by HSA-HPLC. In some embodiments, about 40% to about 80% of the conjugates or peptides bind to HSA in vitro, as measured by HSA-HPLC.

[0020] In one embodiment, a pharmaceutical composition comprising a conjugate described herein and a pharmaceutically acceptable excipient or carrier is disclosed herein.

[0021] In one embodiment, a method for treating cancer in a subject requiring such treatment is disclosed herein, comprising administering a conjugate or a pharmaceutical composition described herein to the subject.

[0022] Embedding by reference All publications, patents, and patent applications referenced herein are incorporated herein by reference for the specific purposes identified herein. [Brief explanation of the drawing]

[0023] Novel features of this disclosure are described in detail in the appended claims. A better understanding of the features and advantages of this disclosure will be gained by referring to the following detailed description illustrating exemplary embodiments in which the principles of this disclosure are utilized, and to the appended drawings (also referred to as "figures (FIG.)"). [Figure 1A] This figure shows the structure of an exemplary conjugate of the present disclosure. This figure shows a conjugate comprising an 11-amino acid monocyclic peptide, a linker, and a metal chelating agent. [Figure 1B] This figure shows the structure of an exemplary conjugate of the present disclosure. The figure shows a conjugate comprising a monocyclic peptide of 12 amino acid residues, a linker, a metal chelating agent, and 225-Ac bound to the metal chelating agent. [Figure 1C] This figure shows the structure of an exemplary conjugate of the present disclosure. This figure shows a conjugate containing a monocyclic peptide of 12 amino acid residues directly bound to a metal chelating agent. [Figure 1D] This figure shows the structure of an exemplary conjugate of the present disclosure. This figure shows a conjugate comprising a linker having three motifs, a metal chelating agent, and two peptides. [Figure 2] This diagram shows the structure of a typical metal chelating agent. [Figure 3-1] This diagram shows the structure of a typical metal chelating agent. [Figure 3-2] This diagram shows the structure of a typical metal chelating agent. [Figure 4-1] This diagram shows the structure of a typical metal chelating agent. [Figure 4-2] This diagram shows the structure of a typical metal chelating agent. [Figure 5-1] This diagram shows the structure of a typical metal chelating agent. [Figure 5-2] This diagram shows the structure of a typical metal chelating agent. [Figure 6-1] This diagram shows the structure of a typical metal chelating agent. [Figure 6-2] This diagram shows the structure of a typical metal chelating agent. [Figure 7-1] This diagram shows the structure of a typical metal chelating agent. [Figure 7-2] This diagram shows the structure of a typical metal chelating agent. [Figure 8-1] This diagram shows the structure of a typical metal chelating agent. [Figure 8-2] This diagram shows the structure of a typical metal chelating agent. [Figure 9] This diagram shows the structure of a typical metal chelating agent. [Figure 10-1] This diagram shows the structure of a typical metal chelating agent. [Figure 10-2] This diagram shows the structure of a typical metal chelating agent. [Figure 10-3] This diagram shows the structure of a typical metal chelating agent. [Figure 11-1] This diagram shows the structure of a typical metal chelating agent. [Figure 11-2] This diagram shows the structure of a typical metal chelating agent. [Figure 12] This diagram shows the structure of a typical metal chelating agent. [Figure 13-1] This diagram shows the structure of a typical metal chelating agent. [Figure 13-2] This diagram shows the structure of a typical metal chelating agent. [Figure 14-1] This diagram shows the structure of a typical metal chelating agent. [Figure 14-2] This diagram shows the structure of a typical metal chelating agent. [Figure 15-1] This diagram shows the structure of a typical metal chelating agent. [Figure 15-2] This diagram shows the structure of a typical metal chelating agent. [Figure 16]This diagram shows the structure of a typical metal chelating agent. [Figure 17A] This figure shows the structure of an exemplary conjugate of the present disclosure, comprising a 12-amino acid cyclic peptide including a C-terminal cysteine ​​residue. [Figure 17B] The structure of an exemplary conjugate of this disclosure, comprising a nine-amino acid cyclic peptide including a C-terminal cysteine ​​residue, is shown. [Modes for carrying out the invention]

[0024] The following description and examples illustrate embodiments of the present disclosure in detail. It should be understood that the present disclosure is not limited to the specific embodiments described herein and can therefore be modified. Those skilled in the art will recognize that there are numerous variations and modifications of the present disclosure, which are encompassed within the scope of the present disclosure.

[0025] Various features of this disclosure may be described in relation to a single embodiment, but these features may be provided individually or in any preferred combination. Conversely, although this disclosure may be described in relation to separate embodiments for clarity, this disclosure can also be implemented in a single embodiment.

[0026] The section headings used in this specification are for organizational purposes only and should not be interpreted as limiting the subject matter being discussed.

[0027] All terms are intended to be understood as they would be understood by those skilled in the art. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as they would be generally understood by those skilled in the art in which this disclosure relates.

[0028] The following definitions supplement the definitions in the art and apply to this application, and do not belong to any related or unrelated cases, such as shared patents or applications. Any methods and materials similar or equivalent to those described herein may be used to carry out the tests of this disclosure, but preferred materials and methods are described herein. Accordingly, the terms used herein are for the sole purpose of describing specific embodiments and are not intended to limit them.

[0029] I. Definition As used in this specification and the appended claims, unless otherwise specified, the following terms have the meanings set forth below.

[0030] Where used herein and in the appended claims, the singular forms “a,” “an,” and “the” include multiple references unless the context clearly indicates otherwise. For example, a reference to “one drug” includes multiple such drugs, and a reference to “the cell” includes one or more cells and their equivalents known to those skilled in the art. Where a range is used herein with respect to physical properties such as molecular weight or chemical properties such as chemical formula, it is intended to include the range and all combinations and partial combinations of the range and any particular embodiment within that range.

[0031] The terms “about” or “approximately” can mean within a range of tolerance for a particular value as determined by those skilled in the art, which will vary in part depending on how the value is measured or determined, i.e., the limits of the measuring system. For example, “about” may mean within 1 or more than 1 standard deviation, according to convention in the art. Alternatively, “about” may mean a range of up to 20%, up to 15%, up to 10%, up to 5%, or up to 1% of a given value. Or, particularly with respect to biological systems or processes, the term may mean within a certain multiple of the value, up to 5 times, or up to 2 times.

[0032] The term “comprising” (and related terms such as “comprise” or “comprises” or “having” or “including”) is not intended to exclude other particular embodiments, such as any composition, composition, method, or process of a substance, however the described features “consist of” or “consist essentially of” are intended to exclude such features.

[0033] "Amino" refers to the -NH2 radical.

[0034] "Cyano" refers to the -CN radical.

[0035] "Nitro" refers to the -NO2 radical.

[0036] "Oxo" refers to the =O radical.

[0037] "Imino" refers to the NH radical.

[0038] "Oxymo" refers to the =N-OH radical.

[0039] "Hydrazino" refers to the =N-NH2 radical.

[0040] "Hydroxy" or "hydroxyl" refers to the -OH radical.

[0041] "Hydroxyamino" refers to the -NH-OH radical.

[0042] "Acyl" refers to substituted or unsubstituted alkylcarbonyl, substituted or unsubstituted alkenylcarbonyl, substituted or unsubstituted alkynylcarbonyl, substituted or unsubstituted cycloalkylcarbonyl, substituted or unsubstituted heterocycloalkylcarbonyl, substituted or unsubstituted arylcarbonyl, substituted or unsubstituted heteroarylcarbonyl, amide, or ester, where the carbonyl atom of the carbonyl group is a bonding site. Unless otherwise specified herein, alkylcarbonyl groups, alkenylcarbonyl groups, alkynylcarbonyl groups, cycloalkylcarbonyl groups, amide groups, or ester groups are optionally substituted with, for example, oxo, halogen, amino, nitrile, nitro, hydroxyl, haloalkyl, alkoxy, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, etc.

[0043] "Alkyl" refers to a linear or branched saturated hydrocarbon monoradical that is optionally substituted. Alkyl groups can have 1 to approximately 20 carbon atoms, 1 to approximately 10 carbon atoms, or 1 to 6 carbon atoms. Examples include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, 2-methyl-1-propyl, 2-methyl-2-propyl, 2-methyl-1-butyl, 3-methyl-1-butyl, 2-methyl-3-butyl, 2,2-dimethyl-1-propyl, 2-methyl-1-pentyl, 3-methyl-1-pentyl, 4-methyl-1-pentyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 2,2-dimethyl-1-butyl, 3,3-dimethyl-1-butyl, 2-ethyl-1-butyl, n-butyl, isobutyl, sec-butyl, t-butyl, n-pentyl, isopentyl, neopentyl, tert-amyl, and hexyl, as well as longer-chain alkyl groups such as heptyl and octyl. Whenever a numerical range such as "C1-C6 alkyl" appears in this specification, it means that the alkyl group consists of one carbon atom, two carbon atoms, three carbon atoms, four carbon atoms, five carbon atoms, or six carbon atoms; however, this definition also includes appearances of the term "alkyl" where no numerical range is specified. In some embodiments, alkyl is C1-C 10The alkyl group is an alkyl, C1-C9 alkyl, C1-C8 alkyl, C1-C7 alkyl, C1-C6 alkyl, C1-C5 alkyl, C1-C4 alkyl, C1-C3 alkyl, C1-C2 alkyl, or C1 alkyl. Unless otherwise specified herein, alkyl groups are optionally substituted with, for example, oxo, halogen, amino, nitrile, nitro, hydroxyl, haloalkyl, alkoxy, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, etc. In some embodiments, alkyl groups are optionally substituted with oxo, halogen, -CN, -CF3, -OH, -OMe, -NH2, -NO2, or -C≡CH. In some embodiments, alkyl groups are optionally substituted with oxo, halogen, -CN, -CF3, -OH, or -OMe. In some embodiments, alkyl groups are optionally substituted with halogens.

[0044] "Alkylene" refers to a straight or branched divalent hydrocarbon chain. Unless otherwise specified herein, alkylene groups may be optionally substituted with, for example, oxo, halogen, amino, nitrile, nitro, hydroxyl, haloalkyl, alkoxy, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, etc. In some embodiments, alkylene is optionally substituted with oxo, halogen, -CN, -CF3, -OH, -OMe, -NH2, or -NO2. In some embodiments, alkylene is optionally substituted with oxo, halogen, -CN, -CF3, -OH, or -OMe. In some embodiments, alkylene is optionally substituted with halogen. In some embodiments, alkylene is -CH2-, -CH2CH2-, -CH2CH2CH2-, or -CH2CH(CH3)CH2-. In some embodiments, alkylene is -CH2-. In some embodiments, alkylene is -CH2CH2-. In some embodiments, the alkylene is -CH2CH2CH2-.

[0045] An "alkenyl" refers to an optionally substituted linear or optionally substituted branched hydrocarbon monoradical having one or more carbon-carbon double bonds. In some embodiments, the alkenyl group has 2 to about 10 carbon atoms, or 2 to about 6 carbon atoms. The alkenyl group may be in either a cis or trans configuration with respect to the double bond(s), but should be understood to include both isomers. Examples include, but are not limited to, ethenyl (-CH=CH2), 1-propenyl (-CH2CH=CH2), isopropenyl [-C(CH3)=CH2], butenyl, and 1,3-butadienyl. Whenever a numerical range such as "C2-C6 alkenyl" appears herein, it means that the C2-C6 alkenyl can consist of an alkenyl group with 2, 3, 4, 5, or 6 carbon atoms; however, this definition also includes instances of the term "alkenyl" where no numerical range is specified. In some embodiments, the alkenyl is C2-C 10 The alkenyl groups are C2-C9 alkenyls, C2-C8 alkenyls, C2-C7 alkenyls, C2-C6 alkenyls, C2-C5 alkenyls, C2-C4 alkenyls, C2-C3 alkenyls, or C2 alkenyls. Unless otherwise specified herein, the alkenyl groups are optionally substituted with, for example, oxo, halogen, amino, nitrile, nitro, hydroxyl, haloalkyl, alkoxy, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, etc. In some embodiments, the alkenyl is optionally substituted with oxo, halogen, -CN, -CF3, -OH, -OMe, -NH2, or -NO2. In some embodiments, the alkenyl is optionally substituted with oxo, halogen, -CN, -CF3, -OH, or -OMe. In some embodiments, the alkenyl is optionally substituted with halogen.

[0046] The term "alkenylene" or "alkenylene chain" refers to an optionally substituted straight or branched divalent hydrocarbon chain having at least one carbon-carbon double bond that links the rest of the molecule to a radical group. In some embodiments, the alkenylene is -CH=CH-, -CH2CH=CH-, or -CH=CHCH2-. In some embodiments, the alkenylene is -CH=CH-. In some embodiments, the alkenylene is -CH2CH=CH-. In some embodiments, the alkenylene is -CH=CHCH2-.

[0047] "Alkynyl" refers to an optionally substituted linear or optionally substituted branched hydrocarbon monoradical having one or more carbon-carbon triple bonds. In some embodiments, the alkynyl group has 2 to about 10 carbon atoms, more preferably 2 to about 6 carbon atoms. Examples include, but are not limited to, ethynyl, 2-propynyl, 2-butynyl, and 1,3-butadiinyl. Whenever a numerical range such as "C2-C6 alkynyl" appears herein, it means that the C2-C6 alkynyl can consist of 2, 3, 4, 5, or 6 carbon atoms in the alkynyl group; however, this definition also includes instances of the term "alkynyl" where no numerical range is specified. In some embodiments, the alkynyl has C2-C 10The alkynyl group is either C2-C9 alkynyl, C2-C8 alkynyl, C2-C7 alkynyl, C2-C6 alkynyl, C2-C5 alkynyl, C2-C4 alkynyl, C2-C3 alkynyl, or C2 alkynyl. Unless otherwise specified herein, the alkynyl group is optionally substituted with, for example, oxo, halogen, amino, nitrile, nitro, hydroxyl, haloalkyl, alkoxy, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, etc. In some embodiments, the alkynyl is optionally substituted with oxo, halogen, -CN, -CF3, -OH, -OMe, -NH2, or -NO2. In some embodiments, the alkynyl is optionally substituted with oxo, halogen, -CN, -CF3, -OH, or -OMe. In some embodiments, the alkynyl is optionally substituted with halogen. The term "alkynylene" refers to a selectively substituted linear or selectively substituted branched divalent hydrocarbon having one or more carbon-carbon triple bonds.

[0048] "Alkylamino" refers to the formula -N(R a )2(wherein, R a is either a defined alkyl radical or two R a This refers to a radical (which, together with a nitrogen atom, can form a substituted or unsubstituted C2-C7 heterocycloalkyl ring). Unless otherwise specified herein, alkylamino groups may be optionally substituted with, for example, oxo, halogen, amino, nitrile, nitro, hydroxyl, haloalkyl, alkoxy, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, etc. In some embodiments, alkylaminos are optionally substituted with oxo, halogen, -CN, -CF3, -OH, -OMe, -NH2, or -NO2. In some embodiments, alkylaminos are optionally substituted with oxo, halogen, -CN, -CF3, -OH, or -OMe. In some embodiments, alkylaminos are optionally substituted with halogens.

[0049] "Alkoxy" refers to the formula -ORa (In the formula, R a The radical refers to an alkyl radical as defined. Unless otherwise specified herein, the alkoxy group may be optionally substituted with, for example, oxo, halogen, amino, nitrile, nitro, hydroxyl, haloalkyl, alkoxy, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, etc. In some embodiments, the alkoxy is optionally substituted with oxo, halogen, -CN, -CF3, -OH, -OMe, -NH2, or -NO2. In some embodiments, the alkoxy is optionally substituted with oxo, halogen, -CN, -CF3, -OH, or -OMe. In some embodiments, the alkoxy is optionally substituted with halogen.

[0050] "Aminoalkyl" refers to an alkyl radical as defined above, which is substituted with one or more amines. In some embodiments, the alkyl is optionally substituted with one amine. In some embodiments, the alkyl is substituted with one, two, or three amines. Examples of hydroxyalkyls include aminomethyl, aminoethyl, aminopropyl, aminobutyl, or aminopentyl. In some embodiments, the hydroxyalkyl is aminomethyl.

[0051] The term "aryl" refers to a radical containing at least one aromatic ring, where each atom forming the ring is a carbon atom. The aryl group can be optionally substituted. Examples of aryl groups include, but are not limited to, phenyl and naphthyl. In some embodiments, the aryl is phenyl. Depending on the structure, the aryl group can be a monoradical or a diradical (i.e., an arylene group). Unless otherwise specified herein, the term "aryl" or the prefix "ar-" (as in "aralkyl") means that the aryl radical may be optionally substituted. In some embodiments, the aryl group contains a partially reduced cycloalkyl group as defined herein (e.g., 1,2-dihydronaphthalene). In some embodiments, the aryl group contains a fully reduced cycloalkyl group as defined herein (e.g., 1,2,3,4-tetrahydronaphthalene). When the aryl contains a cycloalkyl group, the aryl is bonded to the rest of the molecule via the aromatic ring carbon atoms. The aryl radical may be a monocyclic or polycyclic (e.g., bicyclic, tricyclic, or tetracyclic) ring system, which may include condensed, spirocyclic, or crosslinked ring systems. Unless otherwise specified herein, aryls may be optionally substituted with, for example, halogens, aminos, alkylaminos, aminoalkyls, nitriles, nitros, hydroxyls, alkyls, alkenyls, alkynyls, haloalkyls, heteroalkyls, alkoxys, aryls, cycloalkyls, heterocycloalkyls, heteroaryls, -S(O)2NH-C1~C6 alkyls, etc. In some embodiments, the aryl is halogen, methyl, ethyl, -CN, -CF3, -OH, -OMe, -NH2, -NO2, -S(O)2NH2, -S(O)2NHCH 3、 -S(O)2NHCH2CH3, -S(O)2NHCH (The aryl group is optionally substituted with CH3)2, -S(O)2N(CH3)2, or -S(O)2NHC(CH3)3. In some embodiments, the aryl group is optionally substituted with a halogen, methyl, ethyl, -CN, -CF3, -OH, or -OMe. In some embodiments, the aryl group is optionally substituted with a halogen. In some embodiments, the aryl group is substituted with an alkyl, alkenyl, alkynyl, haloalkyl, or heteroalkyl group, where each alkyl, alkenyl, alkynyl, haloalkyl, or heteroalkyl group is independently unsubstituted or substituted with a halogen, methyl, ethyl, -CN, -CF3, -OH, -OMe, -NH2, or -NO2.

[0052] The term "cycloalkyl" refers to a monocyclic or polycyclic non-aromatic radical in which each of the ring-forming atoms (i.e., skeletal atoms) is a carbon atom. In some embodiments, cycloalkyls are saturated or partially unsaturated. In some embodiments, cycloalkyls are spirocyclic or crosslinked compounds. In some embodiments, cycloalkyls are condensed with an aromatic ring (in this case, the cycloalkyl is bonded via a non-aromatic ring carbon atom). Examples of cycloalkyl groups include those having 3 to 10 ring atoms. Representative cycloalkyls include, but are not limited to, those having 3 to 10 carbon atoms, 3 to 8 carbon atoms, 3 to 6 carbon atoms, or 3 to 5 carbon atoms. Examples of monocyclic cycloalkyl radicals include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. In some embodiments, the monocyclic cycloalkyl is cyclopentyl. In some embodiments, the monocyclic cycloalkyl is cyclopentenyl or cyclohexenyl. In some embodiments, the monocyclic cycloalkyl is cyclopentenyl. Examples of polycyclic radicals include adamantyl, 1,2-dihydronaphthalenyl, 1,4-dihydronaphthalenyl, tetrainyl, dekalinyl, 3,4-dihydronaphthalenyl-1(2H)-one, spiro[2.2]pentyl, norbornyl, and bicyclu[1.1.1]pentyl. Unless otherwise specified herein, cycloalkyl groups may be optionally substituted. Typical cycloalkyl groups include cycloalkyl groups having 3 to 15 carbon atoms (C3-C3). 15 Cycloalkyl (C3-C) 10Examples of monocyclic cycloalkyls include, but are not limited to, cycloalkyls having 3 to 8 carbon atoms (C3-C8 cycloalkyls), cycloalkyls having 3 to 6 carbon atoms (C3-C6 cycloalkyls), cycloalkyls having 3 to 5 carbon atoms (C3-C5 cycloalkyls), or cycloalkyls having 3 to 4 carbon atoms (C3-C4 cycloalkyls). In some embodiments, the cycloalkyl is a three- to six-membered cycloalkyl. In some embodiments, the cycloalkyl is a five- to six-membered cycloalkyl. Examples of monocyclic cycloalkyls include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. Examples of polycyclic cycloalkyl or carbocyclic compounds include adamantyl, norbornyl, dekalinyl, bicyclo[3.3.0]octane, bicyclo[4.3.0]nonane, cis-decalin, trans-decalin, bicyclo[2.1.1]hexane, bicyclo[2.2.1]heptane, bicyclo[2.2.2]octane, bicyclo[3.2.2]nonane, and bicyclo[3.3.2]decane, and 7,7-dimethyl-bicyclo[2.2.1]heptanyl. Examples of partially saturated cycloalkyl compounds include cyclopentenyl, cyclohexenyl, cycloheptenyl, and cyclooctenyl. Unless otherwise specified herein, cycloalkyl compounds are optionally substituted with, for example, oxo, halogen, amino, nitrile, nitro, hydroxyl, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, aryl, cycloalkyl, heterocycloalkyl, and heteroaryl compounds. In some embodiments, the cycloalkyl group is optionally substituted with oxo, halogen, methyl, ethyl, -CN, -CF3, -OH, -OMe, -NH2, or -NO2. In some embodiments, the cycloalkyl group is optionally substituted with oxo, halogen, methyl, ethyl, -CN, -CF3, -OH, or -OMe. In some embodiments, the cycloalkyl group is optionally substituted with halogen.

[0053] "Halo" or "halogen" refers to bromo, chloro, fluoro, or iodine. In some embodiments, the halogen is fluoro or chloro. In some embodiments, the halogen is fluoro.

[0054] A "haloalkyl" refers to an alkyl radical as defined above, which is substituted with one or more halogens. In some embodiments, the alkyl is substituted with one, two, or three halogens. In some embodiments, the alkyl is substituted with one, two, three, four, five, or six halogens. Examples of haloalkyls include iodoalkyls, bromoalkyls, chloroalkyls, and fluoroalkyls. For example, a "fluoroalkyl" refers to an alkyl radical as defined above, which is substituted with one or more fluoro radicals as defined above, such as trifluoromethyl, difluoromethyl, fluoromethyl, 2,2,2-trifluoroethyl, 1-fluoromethyl-2-fluoroethyl, etc. In some embodiments, the alkyl portion of the fluoroalkyl radical is optionally substituted as defined above for the alkyl group.

[0055] A "heteroalkyl" refers to an alkyl group in which one or more of the alkyl backbone atoms are atoms other than carbon, such as oxygen, nitrogen (e.g., -NH-, -N(alkyl)-), sulfur, or a combination thereof. In one embodiment, the heteroalkyl is a C1-C6 heteroalkyl, which consists of 1-6 carbon atoms and one or more atoms other than carbon, such as oxygen, nitrogen (e.g., -NH-, -N(alkyl)-), sulfur, or a combination thereof, and the heteroalkyl is bonded to the rest of the molecule by the carbon atoms of the heteroalkyl. Examples of such heteroalkyls are, for example, -CH2-O-CH2-, -CH2-N(alkyl)-CH2-, -CH2-N(aryl)-CH2-, -OCH2CH2O-CH2CH2O-, or -OCH2CH2OCH2CH2OCH2CH2O-. Unless otherwise specified herein, heteroalkyls are optionally substituted with, for example, oxo, halogen, amino, nitrile, nitro, hydroxyl, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, etc. In some embodiments, heteroalkyls are optionally substituted with oxo, halogen, methyl, ethyl, -CN, -CF3, -OH, -OMe, -NH2, or -NO2. In some embodiments, heteroalkyls are optionally substituted with oxo, halogen, methyl, ethyl, -CN, -CF3, -OH, or -OMe. In some embodiments, heteroalkyls are optionally substituted with halogens.

[0056] The term "heterocycloalkyl" refers to a cycloalkyl group comprising at least one heterocyclic atom, for example, a heteroatom selected from nitrogen, oxygen, and sulfur. Unless otherwise specified herein, heterocycloalkyl radicals may be monocyclic or bicyclic ring systems, including fused ring systems (when fused with an aryl or heteroaryl ring, the heterocycloalkyl is bonded via a non-aromatic ring atom) or bridging ring systems. The nitrogen, carbon, or sulfur atom in the heterocycloalkyl radical may be optionally oxidized. The nitrogen atom may be optionally quaternized. Heterocycloalkyl radicals are partially or completely saturated. Examples of heterocycloalkyl radicals include, but are not limited to, dioxolanil, thienyl[1,3]dithianil, tetrahydroquinolyl, tetrahydroisoquinolyl, decahydroquinolyl, decahydroisoquinolyl, imidazolinyl, imidazolidinyl, isotiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, oxazolidinyl, piperidinyl, piperazinyl, 4-piperidonyl, pyrrolidinyl, pyrazolidinyl, quinuclidinyl, thiazolidinyl, tetrahydrofuryl, trithianil, tetrahydropyranyl, thiomorpholinyl, thiamorpholinyl, 1-oxo-thiomorpholinyl, and 1,1-dioxo-thiomorpholinyl. The term heterocycloalkyl includes all ring forms of carbohydrates, including but not limited to monosaccharides, disaccharides, and oligosaccharides. Unless otherwise specified, heterocycloalkyls have 2 to 12 carbon atoms in the ring. In some embodiments, heterocycloalkyls have 2 to 10 carbon atoms in the ring. In some embodiments, heterocycloalkyls have 2 to 10 carbon atoms and 1 or 2 nitrogen atoms in the ring. In some embodiments, heterocycloalkyls have 2 to 10 carbon atoms and 3 or 4 nitrogen atoms in the ring. In some embodiments, heterocycloalkyls have 2 to 12 carbon atoms, 0 to 2 nitrogen atoms, 0 to 2 oxygen atoms, 0 to 2 phosphorus atoms, and 0 to 1 sulfur atom in the ring.In some embodiments, the heterocycloalkyl has 2 to 12 carbon atoms, 1 to 3 N atoms, 0 to 1 O atom, and 0 to 1 S atom in the ring. When referring to the number of carbon atoms in a heterocycloalkyl, it should be understood that the number of carbon atoms in a heterocycloalkyl is not the same as the total number of atoms (including heteroatoms) that constitute the heterocycloalkyl (i.e., the skeletal atoms of the heterocycloalkyl ring). Unless otherwise specified herein, heterocycloalkyls are optionally substituted with, for example, oxo, halogen, amino, nitrile, nitro, hydroxyl, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, etc. In some embodiments, the heterocycloalkyl is optionally substituted with oxo, halogen, methyl, ethyl, -CN, -CF3, -OH, -OMe, -NH2, or -NO2. In some embodiments, the heterocycloalkyl is optionally substituted with oxo, halogen, methyl, ethyl, -CN, -CF3, -OH, or -OMe. In some embodiments, the heterocycloalkyl group is optionally substituted with a halogen.

[0057] A "heteroaryl" refers to a cyclic radical comprising one carbon atom, one or more cyclic heteroatoms selected from the group consisting of nitrogen, oxygen, phosphorus, and sulfur, and at least one aromatic ring. In some embodiments, heteroaryls are monocyclic, bicyclic, or polycyclic. Specific examples of monocyclic heteroaryls include pyridinyl, imidazolyl, pyrimidinyl, pyrazolyl, triazolyl, pyrazinyl, tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl, oxazolyl, isothiazolyl, pyrrolyl, pyridadinyl, triazinyl, oxadiazolyl, thiadiazolyl, flazanyl, indidine, indole, benzofuran, benzothiophene, indazole, benzimidazole, purine, quinolidine, quinoline, isoquinoline, cinnoline, phthalazine, quinazoline, quinoxaline, 1,8-naphthyridine, and pteridine. Specific examples of monocyclic heteroaryls include pyridinyl, imidazolyl, pyrimidinyl, pyrazolyl, triazolyl, pyrazinyl, tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl, oxazolyl, isothiazolyl, pyrrolyl, pyridazinyl, triazinyl, oxadiazolyl, thiadiazolyl, and flazanil. Specific examples of bicyclic heteroaryls include indidine, indole, benzofuran, benzothiophene, indazole, benzimidazole, purine, quinolidine, quinoline, isoquinoline, cinnoline, phthalazine, quinazoline, quinoxaline, 1,8-naphthyridine, and pteridine. In some embodiments, the heteroaryl is pyridinyl, pyrazinyl, pyrimidinyl, thiazolyl, thienyl, thiadiazolyl, or furyl. In some embodiments, the heteroaryl contains 0 to 6 nitrogen atoms in the ring. In some embodiments, the heteroaryl ring contains 1 to 4 N atoms. In some embodiments, the heteroaryl ring contains 4 to 6 N atoms. In some embodiments, the heteroaryl ring contains 0 to 4 N atoms, 0 to 1 O atom, 0 to 1 P atom, and 0 to 1 S atom. In some embodiments, the heteroaryl ring contains 1 to 4 N atoms, 0 to 1 O atom, and 0 to 1 S atom.In some embodiments, the heteroaryl is a C1-C9 heteroaryl. In some embodiments, the monocyclic heteroaryl is a C1-C5 heteroaryl. In some embodiments, the monocyclic heteroaryl is a five-membered or six-membered heteroaryl. In some embodiments, the bicyclic heteroaryl is a C6-C9 heteroaryl. In some embodiments, the heteroaryl group comprises a partially reduced cycloalkyl group or heterocycloalkyl group as defined herein (e.g., 7,8-dihydroquinoline). In some embodiments, the heteroaryl group comprises a fully reduced cycloalkyl group or heterocycloalkyl group as defined herein (e.g., 5,6,7,8-tetrahydroquinoline). When the heteroaryl comprises a cycloalkyl group or heterocycloalkyl group, the heteroaryl is bonded to the rest of the molecule via carbon atoms or heteroatoms of the heteroaromatic ring. The heteroaryl radical may be a monocyclic or polycyclic (e.g., bicyclic, tricyclic, or tetracyclic) ring system, which may include condensed, spiro, or bridging ring systems. Unless otherwise specified herein, heteroaryls are optionally substituted with, for example, halogens, aminos, nitriles, nitros, hydroxyls, alkyls, alkenyls, alkynyls, haloalkyls, alkoxys, aryls, cycloalkyls, heterocycloalkyls, heteroaryls, etc. In some embodiments, heteroaryls are optionally substituted with halogens, methyls, ethyls, -CN, -CF3, -OH, -OMe, -NH2, or -NO2. In some embodiments, heteroaryls are optionally substituted with halogens, methyls, ethyls, -CN, -CF3, -OH, or -OMe. In some embodiments, heteroaryls are optionally substituted with halogens.

[0058] The term "part" refers to a specific segment or functional group of a molecule. Chemical parts are often perceived as chemical entities embedded in or attached to a molecule.

[0059] The terms “treat,” “prevent,” “improve,” and “inhibit” as used herein, and terms derived therefrom, do not necessarily imply 100% or complete treatment, prevention, improvement, or inhibition. Rather, there are varying degrees of treatment, prevention, improvement, and inhibition that a person skilled in the art would recognize as having a potential benefit or therapeutic effect. In this regard, the disclosed methods can provide treatment, prevention, improvement, or inhibition of any amount or level of a disorder in a mammal. For example, a disorder (including its symptoms or condition) may be reduced by, for example, about 100%, about 90%, about 80%, about 70%, about 60%, about 50%, about 40%, about 30%, about 20%, or about 10%. Furthermore, the treatment, prevention, improvement, or inhibition provided by the methods disclosed herein may include treatment, prevention, improvement, or inhibition of one or more conditions or symptoms of a disorder, such as cancer or an inflammatory disease. As used herein, “to treat” includes the concept of “to alleviate,” which means reducing the frequency or severity of any symptom or other adverse effect associated with the disorder, and / or any associated side effects. The term “to treat” also includes the concept of “to manage,” which means reducing the severity of a patient’s particular disease or disorder, or delaying its relapse, for example, extending the period of remission in a patient who has suffered from the disease.

[0060] In certain embodiments, the terms “prevent” or “prevent” used in relation to a disease or disorder may refer to a compound that, in a statistical sample, reduces the incidence of the disorder or condition in a treated sample compared to an untreated control sample, or delays the onset or reduces the severity of one or more symptoms of the disorder or condition compared to an untreated control sample.

[0061] As used herein, the term “therapeutic dose” refers to the effective amount in the dosage and duration necessary to achieve the desired therapeutic outcome. The therapeutic dose of a composition may vary depending on factors such as the individual’s condition, age, sex, weight, and the protein’s ability to elicit the desired response from the individual. The therapeutic dose may also be an amount that exceeds the toxicity or adverse effects of the composition that would have a beneficial therapeutic effect.

[0062] The terms "optional" or "optionally" mean that the event or situation described thereafter may or may not occur, and that the description includes both the cases in which the event or situation occurs and the cases in which it does not occur. For example, "optionally substituted alkyl" means either "alkyl" or "substituted alkyl" as defined above. Furthermore, an optionally substituted group may be unsubstituted (e.g., -CH2CH3), fully substituted (e.g., -CF2CF3), monosubstituted (e.g., -CH2CH2F), or substituted at some level between fully substituted and monosubstituted (e.g., -CH2CHF2, -CH2CF3, -CF2CH3, -CFHCHF2, etc.).

[0063] As used herein, the term “substituent” means an atomic position variable of a core molecule that is substituted at a specified atomic position, replacing one or more hydrogen atoms on the specified atom, insofar as the substitution does not exceed the normal valence of the specified atom and the substitution results in a stable compound. A combination of substituents and / or variables is permitted only if the combination results in a stable compound. Those skilled in the art should note that any carbon and heteroatoms with valences that appear not to be satisfied as described or illustrated herein are assumed to have a sufficient number of hydrogen atoms to satisfy the described or illustrated valences. In certain cases, one or more substituents having a double bond (e.g., “oxo” or “=O”) as a bonding site may be described, indicated or enumerated herein within a group of substituents, but their structure may show only a single bond as a connection point to the core structure. Those skilled in the art will understand that even if only a single bond is shown, a double bond is intended for those substituents.

[0064] The terms "optionally substituted" or "substituted" mean that the referenced group is optionally substituted with one or more additional groups selected individually and independently from D, halogens, -CN, -NH2, -NH(alkyl), -N(alkyl)2, -OH, -CO2H, -CO2alkyl, -C(=O)NH2, -C(=O)NH(alkyl), -C(=O)N(alkyl)2, -S(=O)2NH2, -S(=O)2NH(alkyl), -S(=O)2N(alkyl)2, alkyl, cycloalkyl, fluoroalkyl, heteroalkyl, alkoxy, fluoroalkoxy, heterocycloalkyl, aryl, heteroaryl, aryloxy, alkylthio, arylthio, alkylsulfoxide, arylsulfoxide, alkylsulfone, and arylsulfone. In some other embodiments, the optional substituent is independently selected from D, halogen, -CN, -NH2, -NH(CH3), -N(CH3)2, -OH, -CO2H, -CO2(C1~C4 alkyl), -C(=O)NH2, -C(=O)NH(C1~C4 alkyl), -C(=O)N(C1~C4 alkyl)2, -S(=O)2NH2, -S(=O)2NH(C1~C4 alkyl), -S(=O)2N(C1~C4 alkyl)2, C1~C4 alkyl, C3~C6 cycloalkyl, C1~C4 fluoroalkyl, C1~C4 heteroalkyl, C1~C4 alkoxy, C1~C4 fluoroalkoxy, -SC1~C4 alkyl, -S(=O)C1~C4 alkyl, and -S(=O)2C1~C4 alkyl. In some embodiments, the optional substituent is independently selected from D, halogen, -CN, -NH2, -OH, -NH(CH3), -N(CH3)2, -NH(cyclopropyl), -CH3, -CH2CH3, -CF3, -OCH3, and -OCF3. In some embodiments, the substituted group is substituted with one or two of the aforementioned groups. In some embodiments, the optional substituent on the (acyclic or cyclic) aliphatic carbon atom includes oxo (=O). When indicating the number of substituents, the term "one or more" means from one substituent to the maximum possible number of substitutions, i.e., from the substitution of one hydrogen to the substitution of all hydrogens by substituents.

[0065] The term "unsubstituted" means that a particular group does not have substituents.

[0066] Certain compounds described herein may exist in tautomeristic forms, and all such tautomeristic forms of compounds are within the scope of this disclosure.

[0067] Unless otherwise specified, the structures shown herein also include all stereochemical forms of the structure, namely the R and S configurations of each chiral center. Accordingly, single stereoisomers, as well as enantiomer mixtures and diastereomer mixtures of the compounds of the present invention, are within the scope of this disclosure.

[0068] As used herein, the term "peptide" refers to a compound comprising two or more amino acids. Peptides described herein may contain one or more non-natural amino acids. The term "peptide" also encompasses peptidomimetic compounds. In this invention, the term "amino acid" is used in its broadest sense and includes not only natural amino acids but also their derivatives and synthetic amino acids. For example, the term "amino acid" encompasses non-natural amino acids.

[0069] As used herein, the term "non-natural amino acid" refers to amino acids other than the 20 naturally occurring amino acids in proteins.

[0070] As used herein, the term “protein” refers to a polypeptide (i.e., a sequence of at least three amino acids linked together by peptide bonds). Proteins may contain non-amino acid portions (e.g., glycoproteins, proteoglycans, etc.) and / or may be processed or modified in other ways. Proteins may be complete polypeptides (with or without signal sequences) that are produced by and / or active within cells. In some embodiments, a protein is or contains a characteristic portion, such as a polypeptide produced by and / or active within cells. Proteins may contain multiple polypeptide chains. For example, polypeptide chains may be linked by one or more disulfide bonds or by other means.

[0071] The terms “peptidomimetic” or “mimetic” refer to biologically active compounds that mimic the biological activity of peptides or proteins but are no longer peptides as a whole in terms of chemical properties, for example, they may contain non-peptide bonds (i.e., bonds other than amide bonds between amino acids). As used herein, the term peptidomimetic is used in a broad sense to include molecules that are no longer entirely peptides in terms of properties, such as pseudopeptides, semipeptides, and peptoids. Whether completely or partially non-peptide, the peptidomimetic compounds described herein can provide a spatial arrangement of reactive chemical moieties that is very similar to the three-dimensional arrangement of active groups in the target amino acid sequence or target molecule that underlies the peptidomimetic. As a result of this similar geometric arrangement of active sites, peptidomimetic compounds can exert an effect on biological systems similar to the biological activity of the target entity.

[0072] In some embodiments, peptidomimetic molecules are substantially similar to the target amino acid sequence or molecule on which the peptidomimetic molecule is based, both in terms of three-dimensional shape and biological activity. Examples of methods for constructing peptidomimetic molecules by structurally modifying peptides include inversion of the chiral center of the backbone, which results in a D-amino acid residue structure that can improve proteolytic stability without adversely affecting activity, particularly at the N-terminus. One example is described in the paper “Tritiated D-ala1-Peptide T Binding”, Smith CSet al., Drug Development Res., 15, pp.371-379 (1988). A second method involves modifying the cyclic structure for stability, such as N-to-C interchain imides and lactams (Ede et al. in Smith and Rivier (Eds.) “Peptides: Chemistry and Biology”, Escom, Leiden (1991), pp.268-270). One example of this is provided in a stereochemically restricted thymopentin-like compound, such as the one disclosed in U.S. Patent No. 4,457,489. A third method involves replacing peptide bonds in the target entity with pseudo-peptide bonds that provide resistance to proteolysis.

[0073] The ranges provided herein are understood to be abbreviations of all values ​​within that range. For example, the range 1 to 50 is understood to include any number, combination of numbers, or subrange from the group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50, and all decimal values ​​between the aforementioned integers, such as 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, etc. With regard to subranges, "nested subranges" extending from any endpoint of the range are given particular consideration. For example, nested subranges of the exemplary range 1-50 could include 1-10, 1-20, 1-30, and 1-40 in one direction, or 50-40, 50-30, 50-20, and 50-10 in the opposite direction.

[0074] When used in this specification, C1 to C x (or C 1~x ) includes C1~C2, C1~C3...C1~C x This includes the following. As an example, a group indicated as "C1~C4" has 1 to 4 carbon atoms in that part, that is, a group containing 1 carbon atom, 2 carbon atoms, 3 carbon atoms, or 4 carbon atoms. Therefore, as an example, "C1~C4 alkyl" indicates that the alkyl group has 1 to 4 carbon atoms, that is, the alkyl group is selected from methyl, ethyl, propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, and t-butyl. As another example, C0~C2 alkylenes include direct bonds, -CH2- bonds, and -CH2CH2- bonds.

[0075] As used herein, the terms "cyclized" or "cyclization" mean that two amino acids separated by at least one amino acid within a single peptide are directly or indirectly linked to each other to form a cyclic structure within the molecule. In some cases, the two amino acids are linked via a linker or the like.

[0076] The terms "subject" or "patient" include mammals. Examples of mammals include any member of the mammalian class, such as non-human primates such as humans, chimpanzees, and other apes and monkey species; livestock such as cows, horses, sheep, goats, pigs; household animals such as rabbits, dogs, cats; experimental animals including rodents such as rats, mice, and guinea pigs, but are not limited thereto. In one aspect, the mammal is a companion animal such as a dog or a cat. In one aspect, the mammal is a human.

[0077] As used herein, the term "therapeutically effective amount" refers to an amount effective at the dosage required to achieve the desired therapeutic result. The therapeutically effective amount of a composition can vary depending on factors such as the condition of the individual (e.g., age, sex, and weight), the radiopharmaceutical conjugate, and the method of administration (e.g., oral or parenteral).

[0078] II. Radiopharmaceutical Conjugates As used herein, radiopharmaceutical conjugates and pharmaceutical compositions containing the conjugates are provided. The conjugates and compositions can be useful for the treatment of cancer. The conjugates and compositions can also be useful for the imaging and diagnosis of diseases.

[0079] In one embodiment, a conjugate comprising a peptide and a metal chelating agent configured to bind to a radionuclide is described herein. The peptide may be cyclic or acyclic, and may be monocyclic, bicyclic, or polycyclic. In one embodiment, a conjugate comprising a cyclic peptide and a metal chelating agent configured to bind to a radionuclide is described herein. In some embodiments, the peptide (such as a cyclic peptide) is configured to bind to a target. The conjugates described herein may further include a linker that covalently bonds the peptide to the metal chelating agent. In some embodiments, the conjugate is bonded to the metal chelating agent. 225 Contains radioactive nuclides such as Ac.

[0080] In some embodiments, a conjugate comprising (a) a target moiety comprising a monocyclic peptide and (b) a metal chelating agent configured to bind to a radionuclide is described herein. In some embodiments, a conjugate comprising (a) a monocyclic peptide and (b) a metal chelating agent configured to bind to a radionuclide is described herein. In some embodiments, a conjugate comprising (a) a target moiety comprising a monocyclic peptide and (b) a metal chelating agent configured to bind to a radionuclide is described herein. In some embodiments, a conjugate comprising (a) a monocyclic peptide and (b) a metal chelating agent configured to bind to a radionuclide is described herein. In some embodiments, the monocyclic peptide is cyclized by a non-disulfide bond. In some embodiments, the monocyclic peptide does not contain a disulfide bond. In some embodiments, the monocyclic peptide comprises 7 to 40 amino acid residues. In some embodiments, conjugates comprising (a) a cyclic binding peptide that binds to a cell surface protein or protein conjugate, and (b) a metal chelating agent configured to bind to a radionuclide are described herein. In some embodiments, the cyclic binding peptide is cyclized by a non-disulfide bond and consists of 7 to 40 amino acid residues. In some embodiments, conjugates comprising (a) a binding peptide that binds to a cell surface protein, (b) a metal chelating agent configured to bind to a radionuclide, and (c) a linker that covalently binds the binding peptide to the metal chelating agent are described herein. In some embodiments, the cell surface protein is a carcinoembryonic antigen, a tight junction protein, an adhesion protein, a transporter receptor, or a tyrosine kinase receptor (TKR). The conjugates described herein may further comprise a linker that covalently binds the cyclic peptide to the metal chelating agent. In some embodiments, the conjugate is bound to the metal chelating agent. 225 It contains radionuclides such as Ac. Exemplary configurations of the conjugates described herein are shown in Figures 1A to 1D.

[0081] In some embodiments, the conjugate described herein comprises two or more peptides (i.e., a first peptide, a second peptide, etc.). For example, the conjugate may comprise two different peptides, both configured to bind to the same target, either at the same or different binding sites. In another example, the conjugate may comprise two different peptides, the two peptides configured to bind to different targets. In yet another example, the conjugate may comprise two identical peptides.

[0082] In some embodiments, the conjugates described herein are designed to have a predetermined efflux profile. The efflux profile can be designed by adjusting the sequence and length of the peptide, the characteristics of the linker, the type of radionuclide, etc. In some embodiments, the efflux half-life of the conjugate is about 30 minutes to 120 hours. In some embodiments, the conjugate has an efflux half-life of about 1 to 120 hours. In some embodiments, the conjugate has an efflux half-life of at least 15 minutes, 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 7 hours, 10 hours, 11 hours, 12 hours, 13 hours, 14 hours, 15 hours, 16 hours, 17 hours, 18 hours, 19 hours, 20 hours, 21 hours, 22 hours, 23 hours, or 24 hours. In some embodiments, the conjugate has an elimination half-life of up to 120 hours, 80 hours, 70 hours, 60 hours, 50 hours, 40 hours, 30 hours, 24 hours, 12 hours, 10 hours, or 5 hours. In some embodiments, the conjugate has an elimination half-life of approximately 2 to 24 hours. In some embodiments, the conjugate has an elimination half-life of approximately 3 to 9 hours. In some embodiments, the conjugate has an elimination half-life of approximately 2 to 12 hours. In some embodiments, the conjugate has an elimination half-life of approximately 2 to 8 hours. In some embodiments, the conjugate has an elimination half-life of approximately 2 to 5 hours. In some embodiments, the conjugate has an elimination half-life of approximately 3 to 4 hours. In some embodiments, the elimination half-life is measured in rats. In some embodiments, the elimination half-life is measured in humans.

[0083] The conjugates described herein may have elimination half-lives in the tumor and non-tumor tissues of interest. The elimination half-life in tumors may be the same as, or different from, the elimination half-life in non-tumor issue (it may be longer or shorter). In some embodiments, the elimination half-life of the conjugate in tumors is about 3 hours to 14 days, about 2 to 10 days, about 7 to 10 days, or about 4 to 7 days. In some embodiments, the elimination half-life of the conjugate in tumors is greater than 14 days. In some embodiments, the elimination half-life of the conjugate in non-tumor tissues is about 1 hour to 14 days, about 12 hours to 2 days, about 1 to 3 days, about 2 to 10 days, about 7 to 10 days, or about 4 to 7 days. In some embodiments, the elimination half-life of the conjugate in the tumor is at least 1.1, 1.2, 1.3, 1.4, 1.5, 2.0, 2.5, 3.0, 4.0, or 5.0 times the elimination half-life of the conjugate in the non-tumor tissue of interest.

[0084] As used herein, “elimination half-life” may refer to the time it takes for a drug to decrease from its maximum concentration after administration to half of its maximum concentration. In some embodiments, the elimination half-life is determined after intravenous administration. In some embodiments, the elimination half-life is measured as the biological half-life, which is the half-life of a non-radioactive drug in a biological system. In some embodiments, the elimination half-life is measured as the effective half-life, which is the half-life of a radiopharmaceutical in a biological system, taking into account the half-life of the radionuclide.

[0085] The conjugate described herein is the time-integrated activity coefficient described in the tumor tissue or non-tumor tissue (i.e.,

[0086]

number

[0087]

number

[0088]

Number

[0089]

Number

[0090]

Number

[0091]

Number

[0092]

Number

[0093]

Number

[0094]

Number

[0095]

number

[0096]

number

[0097]

number

[0098]

number

[0099]

number

[0100]

number

[0101]

number

[0102]

number

[0103]

number

[0104]

number

[0105]

number

[0106]

number

[0107]

number

[0108] The conjugates described herein are used in the target organ.

[0109]

number

[0110]

number

[0111]

number

[0112]

number

[0113]

number

[0114]

number

[0115]

number

[0116]

number

[0117]

number

[0118]

number

[0119]

number

[0120] In some cases, the efflux profile of the conjugate can be regulated by reversible binding between the conjugate and plasma proteins such as albumin. Due to favorable affinity between the conjugate and plasma proteins, the plasma proteins can be used as a reservoir for the conjugate, improving the efflux profile by allowing the conjugate to bind and be stored at high concentrations and released at lower concentrations. In some embodiments, the dissociation constant (Kd) between the conjugate and human serum albumin is up to 500 μM, measured under human serum conditions at room temperature. In some embodiments, Kd is approximately 0.1 nM to approximately 1000 μM. In some embodiments, Kd is up to 100 μM. In some embodiments, Kd is up to 15 μM. In some embodiments, Kd is approximately 1 nM to approximately 10 μM. In some embodiments, Kd is approximately 10 nM to approximately 10 μM. In some embodiments, Kd is approximately 50 nM to approximately 1 μM. In some embodiments, Kd is approximately 100 nM to approximately 10 μM.

[0121] Peptide ligands In one embodiment, the conjugate described herein comprises a peptide (e.g., a conjugated peptide). In some embodiments, the conjugate comprises two or more peptides, which may be the same or different. The peptides may be linear or cyclic. In some embodiments, the peptides are monocyclic. The peptides may contain any preferred number of amino acid residues. In some embodiments, the peptides contain 5-50, 6-40, 7-30, 8-25, 12-25, or 9-20 amino acid residues. In some embodiments, the peptides consist of 7-14 amino acid residues. In some embodiments, the peptides contain 9-16 amino acid residues. In some embodiments, the peptides contain 11-14 amino acid residues. In some embodiments, the peptides contain 10-15 amino acid residues. In some embodiments, the peptides contain 10-20 amino acid residues. In some embodiments, the peptides contain 12-15 amino acid residues. In some embodiments, the peptides contain 13-14 amino acid residues. In some embodiments, the peptides contain 9 amino acid residues. In some embodiments, the peptide contains 10 amino acid residues. In some embodiments, the peptide contains 11 amino acid residues. In some embodiments, the peptide contains 12 amino acid residues. In some embodiments, the peptide contains 13 amino acid residues. In some embodiments, the peptide contains 14 amino acid residues. In some embodiments, the peptide contains 15 amino acid residues. In some embodiments, the peptide contains 16 amino acid residues. In some embodiments, the peptide contains 9 amino acid residues. In some embodiments, the peptide consists of 10 amino acid residues. In some embodiments, the peptide consists of 11 amino acid residues. In some embodiments, the peptide consists of 12 amino acid residues. In some embodiments, the peptide consists of 13 amino acid residues. In some embodiments, the peptide consists of 14 amino acid residues. In some embodiments, the peptide consists of 15 amino acid residues. In some embodiments, the peptide consists of 16 amino acid residues.In some embodiments, the conjugate comprises a monocyclic peptide of 10, 11, 12, 13, 14, or 15 amino acid residues. The peptides described herein may be binding peptides that bind to a target. In some embodiments, the binding peptide consists of 6 to 40 amino acid residues. In some embodiments, the binding peptide consists of 9 to 20 amino acid residues. In some embodiments, the binding peptide consists of 10 to 15 amino acid residues. In some embodiments, the binding peptide consists of 6 to 12 amino acid residues. In some embodiments, the binding peptide consists of 6 to 10 amino acid residues. In some embodiments, the binding peptide consists of 6 to 8 amino acid residues. In some embodiments, the binding peptide is monocyclic.

[0122] The molecular weights of the peptides described may vary. In some embodiments, the peptides have molecular weights ranging from about 0.1 to about 25 kDa. In some embodiments, the peptides have molecular weights ranging from about 0.2 to about 20 kDa, about 0.5 to about 15 kDa, about 0.75 to about 10 kDa, about 0.5 to about 10 kDa, about 0.5 to about 5 kDa, about 0.5 to about 2.5 kDa, about 0.5 to about 2 kDa, about 0.5 to about 1.5 kDa, about 0.5 to about 1 kDa, about 1 to about 10 kDa, about 1 to about 5 kDa, about 1 to about 2.5 kDa, about 1 to about 2 kDa, about 1 to about 1.5 kDa, about 1 to about 1.25 kDa, or about 0.5 to about 1.25 kDa. In some embodiments, the peptides have molecular weights ranging from about 0.5 to about 5 kDa. In some embodiments, the peptide has a molecular weight of about 0.5 to 2 kDa. In some embodiments, the peptide has a molecular weight of about 0.75 to 1.75 kDa. In some embodiments, the peptide has a molecular weight of about 1 to 1.5 kDa. In some embodiments, the peptide is monocyclic.

[0123] The peptides described herein can be cyclized (i.e., macrocyclic). Cyclization can be achieved, though less ideally, via a single disulfide bond, and more ideally, via peptide bonds, alkyl bonds, alkenyl bonds, ester bonds, thioester bonds, ether bonds, thioether bonds, phosphate ether bonds, azo bonds, CSC bonds, CNC bonds, C=NC bonds, C=NO bonds, amide bonds, lactam crosslinks, carbamoyl bonds, urea bonds, thiourea bonds, amine bonds, thioamide bonds, and the like. In some embodiments, the peptide is a cyclic peptide cyclized by peptide bonds, alkyl bonds, alkenyl bonds, ester bonds, thioester bonds, ether bonds, thioether bonds, phosphate ether bonds, azo bonds, CNC bonds, C=NC bonds, C=NO bonds, amide bonds, lactam crosslinks, carbamoyl bonds, urea bonds, thiourea bonds, amine bonds, or thioamide bonds. In some embodiments, the cyclic peptide is cyclized by a thioether bond. In some embodiments, cyclic peptides are cyclized via oxime cyclization. Cyclization of a peptide can stabilize its structure, thereby increasing its affinity for a target. Cyclization may occur between the N-terminus and the C-terminus, or between a terminal amino acid and a non-terminal amino acid. In some embodiments, cyclization occurs between two non-terminal amino acids. In some embodiments, the peptide is cyclized via oxime cyclization. In some embodiments, the peptide is cyclized between cysteine ​​and a haloacyl. In some embodiments, the peptide contains a haloacetyl group (e.g., chloroacetyl or bromoacetyl) at the N-terminus. In some embodiments, the peptide contains a haloacetyl group (e.g., chloroacetyl or bromoacetyl) at the C-terminus. In some embodiments, the peptide contains Cys at the C-terminus. In some embodiments, the peptide contains Cys at the N-terminus. In some embodiments, cyclization occurs via a thioether bond between Cys and the haloacetyl group. In some embodiments, cyclization occurs between the N-terminus and the C-terminus of the peptide.

[0124] For macrocyclic formation, for example, amino acids having functional group A and the corresponding amino acids having functional group B can be used (see Table 1). Either functional group A or functional group B may be located at the N-terminus. The amino acids having functional group A and the amino acids having functional group B may be N-terminal amino acids, C-terminal amino acids, or non-terminal amino acids, respectively. In some embodiments, the amino acid having functional group A is located at the N-terminus. In some embodiments, the amino acid having functional group A is located at the C-terminus. In some embodiments, the amino acid having functional group A is located at a non-terminal amino acid. In some embodiments, the amino acid having functional group B is located at the N-terminus. In some embodiments, the amino acid having functional group B is located at the C-terminus. In some embodiments, the amino acid having functional group B is located at a non-terminal amino acid.

[0125] [Table 1]

[0126] In some embodiments, chloroacetylated amino acids can be used as amino acids (IA). Examples of chloroacetylated amino acids include N-chloroacetyl-L-alanine, N-chloroacetyl-L-phenylalanine, N-chloroacetyl-L-tyrosine, N-chloroacetyl-L-tryptophan, N-3-(2-chloroacetamide)benzoyl-L-phenylalanine, N-3-(2-chloroacetamide)benzoyl-L-tyrosine, N-3-(2-chloroacetamide)benzoyl-L-tryptophan, β-N-chloroacetyl-L-diaminopropanoic acid, γ Examples include N-chloroacetyl-L-diaminobutyric acid, σ-N-chloroacetyl-L-ornithine, ε-N-chloroacetyl-L-lysine, N-3-chloromethylbenzoyl-L-tyrosine, and N-3-chloromethylbenzoyl-L-tryptophan, as well as their corresponding D-amino acid derivatives (e.g., N-chloroacetyl-D-alanine, N-chloroacetyl-D-phenylalanine, N-chloroacetyl-D-tyrosine, N-chloroacetyl-D-tryptophan).

[0127] Examples of amino acids (IB) include, but are not limited to, cysteine, homocysteine, mercaptonorvaline, mercaptonorleucine, 2-amino-7-mercaptoheptanoic acid, 2-amino-8-mercaptooctanoic acid, amino acids obtained by protecting the SH group of these amino acids and then removing the protecting group, and corresponding D-amino acid derivatives.

[0128] The cyclization method can be carried out, for example, by Kawakami, T. et al., Nature Chemical Biology 5, 888-890 (2009); Yamagishi, Y. et al., ChemBioChem 10, 1469-1472 (2009); Sako, Y. et al., Journal of American Chemical Society 130, 7932-7934 (2008); or by the method described in International Publication No. 2008 / 117833.

[0129] In some embodiments, for example, amino acid (II-A) can be selected from and used from propargylglycine, homopropargylglycine, 2-amino-6-heptic acid, 2-amino-7-octic acid, and 2-amino-8-nonic acid. Furthermore, 4-pentinoylated or 5-hexinoylated amino acids can also be used. Examples of 4-pentinoylated amino acids include N-(4-pentenoyl)-L-alanine, N-(4-pentenoyl)-L-phenylalanine, N-(4-pentenoyl)-L-tyrosine, N-(4-pentenoyl)-L-tryptophan, N-3-(4-pentinoylamide)benzoyl-L-phenylalanine, N-3-(4-pentinoylamide)benzoyl-L-tyrosine, N-3-(4-pentinoylamide)benzoyl-L-tryptophan, β-N-(4-pentenoyl)-L-diaminopropanoic acid, γ-N-(4-pentenoyl)-L-diaminobutyric acid, σ-N-(4-pentenoyl)-L-ornithine, and ε-N-(4-pentenoyl)-L-lysine, as well as their corresponding D-amino acid derivatives.

[0130] In some embodiments, for example, amino acid (II-B) can be selected from and used from azidoalanine, 2-amino-4-azidobutanoic acid, azidoptonorvaline, azidonorleucine, 2-amino-7-azidoheptanoic acid, and 2-amino-8-azidooctanoic acid. Furthermore, azidoacetylated or 3-azidopentanoylated amino acids can also be used. Examples of azidoacetylated amino acids include N-azidoacetyl-L-alanine, N-azidoacetyl-L-phenylalanine, N-azidoacetyl-L-tyrosine, N-azidoacetyl-L-tryptophan, N-3-(4-pentinoylamide)benzoyl-L-phenylalanine, N-3-(4-pentinoylamide)benzoyl-L-tyrosine, N-3-(4-pentinoylamide)benzoyl-L-tryptophan, β-N-azidoacetyl-L-diaminopropanoic acid, γ-N-azidoacetyl-L-diaminobutyric acid, α-N-azidoacetyl-L-ornithine, and ε-N-azidoacetyl-L-lysine, as well as their corresponding D-amino acid derivatives.

[0131] The cyclization method can be carried out, for example, according to the method described in Sako, Y. et al., Journal of American Chemical Society 130, 7932-7934 (2008) or International Publication No. 2008 / 117833.

[0132] Examples of amino acids (III-A) include, but are not limited to, N-(4-aminomethyl-benzoyl)-phenylalanine (AMBF) and 4-3-aminomethyltyrosine.

[0133] Examples of amino acids (III-B) include, but are not limited to, 5-hydroxytryptophan (WoH). Cyclization methods can be carried out, for example, according to the method described in Yamagishi, Y. et al., ChemBioChem 10, 1469-1472 (2009) or International Publication No. 2008 / 117833.

[0134] Examples of amino acids (IV-A) include, but are not limited to, 2-amino-6-chlorohexic acid, 2-amino-7-chloroheptic acid, and 2-amino-8-chlorooctic acid.

[0135] Examples of amino acids (IV-B) include, but are not limited to, cysteine, homocysteine, mercaptonorvaline, mercaptonorleucine, 2-amino-7-mercaptoheptanoic acid, and 2-amino-8-mercaptooctanoic acid, amino acids obtained by protecting the SH group of these amino acids and then removing the protecting group, and corresponding D-amino acid derivatives. The cyclization method can be carried out, for example, according to the method described in International Publication No. 2012 / 074129.

[0136] Examples of amino acids (VAs) include, but are not limited to, N-3-chloromethylbenzoyl-L-phenylalanine, N-3-chloromethylbenzoyl-L-tyrosine, and N-3-chloromethylbenzoyl-L-tryptophan.

[0137] Examples of amino acids (VB) include, but are not limited to, cysteine, homocysteine, mercaptonorvaline, mercaptonorleucine, 2-amino-7-mercaptoheptanoic acid, and 2-amino-8-mercaptooctanoic acid, as well as amino acids obtained by protecting the SH group of these amino acids and then removing the protecting group, and their corresponding D-amino acid derivatives.

[0138] The amino acids IA-VA and IB-VB can be introduced into the peptide by known methods, such as chemical synthesis or translation and synthesis, as described herein. In some embodiments, the cyclization reaction involves forming a thioether bond using amino acids containing a sulfanyl group, such as cysteine, homocysteine, mercaptonorvaline, mercaptovaline, mercaptonorleucine, 2-amino-7-mercaptoheptanoic acid, and 2-amino-8-mercaptooctanoic acid.

[0139] The peptides described herein may contain one or more negatively charged amino acids and / or one or more positively charged amino acids. Positively charged amino acids include, for example, lysine, arginine, histidine, and amino acids containing an additional amine group. Positively charged amino acids may include heteroaryl substitutions such as pyridine, imidazole, pyrazole, or triazole, which have one or more ring nitrogen atoms. Negatively charged amino acids include, for example, amino acids containing an additional carboxylic acid group, such as glutamic acid.

[0140] For example, the peptides described herein are of formula (I): Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7-Xaa8-Xaa9-Xaa10-Xaa11-Xaa12-Xaa13-Xaa14 (Sequence number 12) Equation (I) (In the formula, Xaa1 is F, Xaa2 is either I or T. Xaa3 is D, Xaa4 is D, Xaa5 is Y, Xaa6 is G, Xaa7 is I, Xaa8 is T, Xaa9 is D, Xaa10 is Y, Xaa11 is D, Xaa12 is either A or E. Xaa13 is A, D, V, or G. Xaa14 is C, and each of Xaa1 to Xaa14 is independently represented by the amino acid residues or derivatives thereof specified above, and may contain a macrocyclic peptide.

[0141] In one embodiment, equation (II), XaaN-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7-Xaa8-Xaa9-Xaa10-Xaa11-Xaa12-Xaa13-XaaC Formula (II) (In the formula, each of XaaN, Xaa2, Xaa3, Xaa4, Xaa5, and Xaa6 is independently an amino acid residue.) Cyclic peptides having the structure (each of Xaa7, Xaa8, Xaa9, Xaa10, Xaa11, Xaa12, Xaa13, and XaaC is either absent or an amino acid residue) are provided herein.

[0142] In some embodiments, formula (II), XaaN-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7-Xaa8-Xaa9-Xaa10-Xaa11-Xaa12-Xaa13-XaaC Formula (II) (wherein each of XaaN, Xaa2, Xaa3, Xaa4, Xaa5, and Xaa6 is independently an amino acid residue, each of Xaa7, Xaa8, Xaa9, Xaa10, Xaa11, Xaa12, Xaa13, and XaaC either does not exist independently or is an amino acid residue, the cyclic peptide is -(CH2) m -C(=O)-CH2-S-(CH2) n -, -C(=O)-CH2-S-CH2-CH2-, -(CH2) m -NH-CO-(CH2) n -, -(CH2) m -CO-NH-(CH2) n -, -(CH2) m -S-(CH2) n -, -(CH2) m -CH=CH-(CH2) n -, -(CH2) m -NH-(CH2) n [[ID=З4]]-, -(CH2) m -S-CH2-benzene-CH2-S-(CH2) n -, -(CH2) m -triazine-(CH2) n -, -(CH2) m -succinimide-S-(CH2) n -, -C(=O)-CH2-NH-CH2-, and -C(=O)-CH2-O-CH2-, and m and n are each independently 0 or an integer from 1 to 6), are provided herein.

[0143] In some embodiments, m is 0. In some embodiments, m is 1. In some embodiments, m is 2. In some embodiments, m is 3. In some embodiments, m is 4. In some embodiments, m is 5. In some embodiments, m is 6. In some embodiments, n is 0. In some embodiments, n is 1. In some embodiments, n is 2. In some embodiments, n is 3. In some embodiments, n is 4. In some embodiments, n is 5. In some embodiments, n is 6.

[0144] In some embodiments, the ring-closing group is formed by cyclization of the cyclic peptide. The ring-closing group can be formed by forming a bond between XaaN and XaaC. The ring-closing group can be formed by forming a bond between the N-terminus and C-terminus of the peptide. In some embodiments, the cyclic peptide of formula (II) contains a ring-closing group of -C(=O)-CH2-S-. In some embodiments, the ring-closing group -C(=O)-CH2-S- is formed between XaaN and cysteine, and XaaN is chloroacetylated. In some embodiments, cysteine ​​is located at the C-terminus of the cyclic peptide. In some embodiments, cysteine ​​is located within 3 amino acids from the C-terminus of the cyclic peptide.

[0145] In one embodiment, equation (III):

[0146] [ka] (In the formula, Each of XaaN, Xaa2, Xaa3, Xaa4, Xaa0, Xaa13, and XaaC is an amino acid residue, p is 0, 1, 2, 3, 4, 5, 6, 7, or 8. Each amino acid residue in the cyclic peptide is joined by a peptide bond, except that XaaN and XaaC are -L N -L cyc -Lc - is connected via L N and L C These are, independently and selectively, C1-C6 alkylenes, selectively substituted C1-C6 heteroalkylenes, or bonds. L cyc It is a ring-closing group, Cyclic peptides having a monocyclic structure are provided herein.

[0147] In some embodiments of formula (III), -L N -L cyc -L c - is formed by reacting the functional groups of XaaN and XaaC. For example, if XaaN is functionalized with -C(=O)-CH2Cl and XaaC is cysteine,

[0148] [ka] teeth,

[0149] [ka] It is possible.

[0150] As shown in formula (III), only the cyclic portion of the peptide sequence is included. In some embodiments, the conjugate containing the peptide of formula (III) may further include amino acid residues at the N-terminus and / or C-terminus of the peptide, which are not part of the cyclic structure. In some embodiments, the conjugate containing the peptide of formula (III) may further include one or more amino acid residues bound to XaaN, which are not part of the cyclic structure. In some embodiments, the conjugate containing the peptide of formula (III) may further include one or more amino acid residues bound to XaaC, which are not part of the cyclic structure.

[0151] In some embodiments of formula (III), -(Xaa0)p- is -Xaa5-Xaa6-Xaa7-Xaa8-Xaa9-Xaa10-Xaa11-Xaa12-, where each of Xaa5, Xaa6, Xaa7, Xaa8, Xaa9, Xaa10, Xaa11, and Xaa12 is independently absent or an amino acid residue.

[0152] In some embodiments of formula (III), L N is a combination. In some embodiments of equation (III), L N is an optionally substituted C1-C6 alkylene, which is optionally substituted with one or more substituents selected from halogen, -OH, amino, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, and C1-C6 heteroalkyl. In some embodiments of formula (III), L N L is an unsubstituted C1-C6 alkylene. In some embodiments of formula (III), L N This is unsubstituted C1~C 63 It is an alkylene. In some embodiments of formula (III), L N is an unsubstituted C1-C4 alkylene. In some embodiments of formula (III), L N These are -CH2-, -CH2-CH2-, -CH2-CH2-CH2-, or -CH2-CH2-CH2-CH2-.

[0153] In some embodiments of formula (III), L C is a combination. In some embodiments of equation (III), L C is an optionally substituted C1-C6 alkylene, which is optionally substituted with one or more substituents selected from halogen, -OH, amino, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, and C1-C6 heteroalkyl. In some embodiments of formula (III), L C is an unsubstituted C1-C6 alkylene. In some embodiments of the cyclic peptide of formula (III), LC These are C1-C3 alkylenes. In some embodiments of formula (III), L C is an unsubstituted C1-C4 alkylene. In some embodiments of formula (III), L C These are -CH2-, -CH2-CH2-, -CH2-CH2-CH2-, or -CH2-CH2-CH2-CH2-.

[0154] In some embodiments of formula (III), L N and L C Each of these is independently an arbitrarily substituted C1-C6 alkylene, an arbitrarily substituted C1-C6 heteroalkylene, or a bond, and each C1-C6 alkylene and C1-C6 heteroalkylene is one or more R 10 It is optionally replaced by, Each R 10 These are, independently, halogen, -CN, -NO2, -OH, -OR a -OC(=O)R a , -OC(=O)OR b -OC(=O)NR c R d -SH, -SR a -S(=O)R a -S(=O)2R a -S(=O)2NR c R d , -NR c R d , -NR b C(=O)NR c R d , -NR b C(=O)R a , -NR b C(=O)OR b , -NR b S(=O)2R a -C(=O)R a , -C(=O)OR b -C(=O)NR c R d , -Si(R a )3, -P(=O)(R b)2, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, wherein alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl are optionally and independently one or more R 10a It is replaced by, Alternatively, two R atoms on the same atom 10 Do they come together to form an oxo, Alternatively, two R atoms on the same atom 10 These combine to form a cycloalkyl or heterocycloalkyl group, each consisting of one or more R 10a Whether it is being replaced by an arbitrary choice, Or, two R atoms on different atoms 10 These combine to form a cycloalkyl, heterocycloalkyl, aryl, or heteroaryl molecule, each containing one or more R 10a It is optionally replaced by, Each R 10a These are, independently, halogen, -CN, -NO2, -OH, -OR a , -NR c R d -C(=O)R a , -C(=O)OR b -C(=O)NR c R d , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, Each R aThese are independently C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-C6 alkyl(cycloalkyl), C1-C6 alkyl(heterocycloalkyl), C1-C6 alkyl(aryl), or C1-C6 alkyl(heteroaryl), and the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl are independently optionally substituted with one or more R. Or, two R's a These, together with the atoms to which they are bonded, form heterocycloalkyl groups that are optionally substituted with one or more R atoms. Each R a These are independently hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-C6 alkyl(cycloalkyl), C1-C6 alkyl(heterocycloalkyl), C1-C6 alkyl(aryl), or C1-C6 alkyl(heteroaryl), and the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl are independently optionally substituted with one or more R. Or, two R's b These, together with the atoms to which they are bonded, form heterocycloalkyl groups that are optionally substituted with one or more R atoms. R c and R dEach of these is independently hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-C6 alkyl(cycloalkyl), C1-C6 alkyl(heterocycloalkyl), C1-C6 alkyl(aryl), or C1-C6 alkyl(heteroaryl), and each of the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more R. Or, R c and R d These, together with the atoms to which they are bonded, form heterocycloalkyl groups that are optionally substituted with one or more R atoms. Each R is independently a halogen, -CN, -OH, -OCH3, -S(=O)CH3, -S(=O)2CH3, -S(=O)2NH2, -S(=O)2NHCH3, -S(=O)2N(CH3)2, -NH2, -NHCH3, -N(CH3)2, -C(=O)CH3, -C(=O)OH, -C(=O)OCH3, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, and C1-C6 heteroalkyl. Alternatively, two R atoms on the same atom can form an oxo.

[0155] In some embodiments, XaaN of formula (II) or formula (III) is a natural or unnatural amino acid. In some embodiments, XaaN is a natural amino acid. In some embodiments, XaaN is an unnatural amino acid. In some embodiments, XaaN is an unnatural amino acid selected from Tables 4A to 4G. In some embodiments, XaaN is an unnatural amino acid selected from Table 4G. In some embodiments, XaaN is an aliphatic amino acid, such as alanine, glycine, isoleucine, leucine, proline, valine, or a derivative thereof. In some embodiments, XaaN is an aromatic amino acid, such as phenylalanine, tryptophan, tyrosine, or a derivative thereof. In some embodiments, XaaN is an acidic amino acid, such as aspartic acid, glutamic acid, or a derivative thereof. In some embodiments, XaaN is a basic amino acid, such as arginine, histidine, lysine, or a derivative thereof. In some embodiments, XaaN is a hydroxyl amino acid, such as serine, threonine, or a derivative thereof. In some embodiments, XaaN is a sulfur-containing amino acid, such as cysteine, methionine, or a derivative thereof. In some embodiments, XaaN is an amide (containing an amide group) amino acid, such as asparagine, glutamine, or a derivative thereof. In some embodiments, XaaN has no charge. In some embodiments, XaaN has a charge of -1, such as aspartic acid, glutamic acid, or a derivative thereof. In some embodiments, XaaN has a charge of +1, such as arginine, histidine, lysine, or a derivative thereof. In some embodiments, XaaN is lysine.

[0156] In some embodiments, Xaa2 of formula (II) or formula (III) is a natural or non-natural amino acid. In some embodiments, Xaa2 is a natural amino acid. In some embodiments, Xaa2 is a non-natural amino acid. In some embodiments, Xaa2 is a non-natural amino acid selected from Tables 4A to 4G. In some embodiments, Xaa2 is a non-natural amino acid selected from Table 4G. In some embodiments, Xaa2 is an aliphatic amino acid, such as alanine, glycine, isoleucine, leucine, proline, valine, or derivatives thereof. In some embodiments, Xaa2 is an aromatic amino acid, such as phenylalanine, tryptophan, tyrosine, or derivatives thereof. In some embodiments, Xaa2 is an acidic amino acid, such as aspartic acid, glutamic acid, or derivatives thereof. In some embodiments, Xaa2 is a basic amino acid, such as arginine, histidine, lysine, or derivatives thereof. In some embodiments, Xaa2 is a hydroxyl amino acid, such as serine, threonine, or a derivative thereof. In some embodiments, Xaa2 is a sulfur-containing amino acid, such as cysteine, methionine, or a derivative thereof. In some embodiments, Xaa2 is an amide (containing an amide group) amino acid, such as asparagine, glutamine, or a derivative thereof. In some embodiments, Xaa2 has no charge. In some embodiments, Xaa2 has a charge of -1, such as aspartic acid, glutamic acid, or a derivative thereof. In some embodiments, Xaa2 has a charge of +1, such as arginine, histidine, lysine, or a derivative thereof.

[0157] In some embodiments, Xaa3 of formula (II) or formula (III) is a natural or non-natural amino acid. In some embodiments, Xaa3 is a natural amino acid. In some embodiments, Xaa3 is a non-natural amino acid. In some embodiments, Xaa3 is a non-natural amino acid selected from Tables 4A to 4G. In some embodiments, Xaa3 is a non-natural amino acid selected from Table 4G. In some embodiments, Xaa3 is an aliphatic amino acid, such as alanine, glycine, isoleucine, leucine, proline, valine, or a derivative thereof. In some embodiments, Xaa3 is an aromatic amino acid, such as phenylalanine, tryptophan, tyrosine, or a derivative thereof. In some embodiments, Xaa3 is an acidic amino acid, such as aspartic acid, glutamic acid, or a derivative thereof. In some embodiments, Xaa3 is a basic amino acid, such as arginine, histidine, lysine, or a derivative thereof. In some embodiments, Xaa3 is a hydroxyl amino acid, such as serine, threonine, or a derivative thereof. In some embodiments, Xaa3 is a sulfur-containing amino acid, such as cysteine, methionine, or a derivative thereof. In some embodiments, Xaa3 is an amide (containing an amide group) amino acid, such as asparagine, glutamine, or a derivative thereof. In some embodiments, Xaa3 has no charge. In some embodiments, Xaa3 has a charge of -1, such as aspartic acid, glutamic acid, or a derivative thereof. In some embodiments, Xaa3 has a charge of +1, such as arginine, histidine, lysine, or a derivative thereof.

[0158] In some embodiments, Xaa4 of formula (II) or formula (III) is a natural or non-natural amino acid. In some embodiments, Xaa4 is a natural amino acid. In some embodiments, Xaa4 is a non-natural amino acid. In some embodiments, Xaa4 is a non-natural amino acid selected from Tables 4A to 4G. In some embodiments, Xaa4 is a non-natural amino acid selected from Table 4G. In some embodiments, Xaa4 is an aliphatic amino acid, such as alanine, glycine, isoleucine, leucine, proline, valine, or a derivative thereof. In some embodiments, Xaa4 is an aromatic amino acid, such as phenylalanine, tryptophan, tyrosine, or a derivative thereof. In some embodiments, Xaa4 is an acidic amino acid, such as aspartic acid, glutamic acid, or a derivative thereof. In some embodiments, Xaa4 is a basic amino acid, such as arginine, histidine, lysine, or a derivative thereof. In some embodiments, Xaa4 is a hydroxyl amino acid, such as serine, threonine, or a derivative thereof. In some embodiments, Xaa4 is a sulfur-containing amino acid, such as cysteine, methionine, or a derivative thereof. In some embodiments, Xaa4 is an amide (containing an amide group) amino acid, such as asparagine, glutamine, or a derivative thereof. In some embodiments, Xaa4 has no charge. In some embodiments, Xaa4 has a charge of -1, such as aspartic acid, glutamic acid, or a derivative thereof. In some embodiments, Xaa4 has a charge of +1, such as arginine, histidine, lysine, or a derivative thereof.

[0159] In some embodiments, Xaa5 of formula (II) or formula (III) is a natural or non-natural amino acid. In some embodiments, Xaa5 is a natural amino acid. In some embodiments, Xaa5 is a non-natural amino acid. In some embodiments, Xaa5 is a non-natural amino acid selected from Tables 4A to 4G. In some embodiments, Xaa5 is a non-natural amino acid selected from Table 4G. In some embodiments, Xaa5 is an aliphatic amino acid, such as alanine, glycine, isoleucine, leucine, proline, valine, or derivatives thereof. In some embodiments, Xaa5 is an aromatic amino acid, such as phenylalanine, tryptophan, tyrosine, or derivatives thereof. In some embodiments, Xaa5 is an acidic amino acid, such as aspartic acid, glutamic acid, or derivatives thereof. In some embodiments, Xaa5 is a basic amino acid, such as arginine, histidine, lysine, or derivatives thereof. In some embodiments, Xaa5 is a hydroxyl amino acid, such as serine, threonine, or a derivative thereof. In some embodiments, Xaa5 is a sulfur-containing amino acid, such as cysteine, methionine, or a derivative thereof. In some embodiments, Xaa5 is an amide (containing an amide group) amino acid, such as asparagine, glutamine, or a derivative thereof. In some embodiments, Xaa5 has no charge. In some embodiments, Xaa5 has a charge of -1, such as aspartic acid, glutamic acid, or a derivative thereof. In some embodiments, Xaa5 has a charge of +1, such as arginine, histidine, lysine, or a derivative thereof. In some embodiments, Xaa5 is absent.

[0160] In some embodiments, Xaa6 of formula (II) or formula (III) is a natural or non-natural amino acid. In some embodiments, Xaa6 is a natural amino acid. In some embodiments, Xaa6 is a non-natural amino acid. In some embodiments, Xaa6 is a non-natural amino acid selected from Tables 4A to 4G. In some embodiments, Xaa6 is a non-natural amino acid selected from Table 4G. In some embodiments, Xaa6 is an aliphatic amino acid, such as alanine, glycine, isoleucine, leucine, proline, valine, or a derivative thereof. In some embodiments, Xaa6 is an aromatic amino acid, such as phenylalanine, tryptophan, tyrosine, or a derivative thereof. In some embodiments, Xaa6 is an acidic amino acid, such as aspartic acid, glutamic acid, or a derivative thereof. In some embodiments, Xaa6 is a basic amino acid, such as arginine, histidine, lysine, or a derivative thereof. In some embodiments, Xaa6 is a hydroxyl amino acid, such as serine, threonine, or a derivative thereof. In some embodiments, Xaa6 is a sulfur-containing amino acid, such as cysteine, methionine, or a derivative thereof. In some embodiments, Xaa6 is an amide (containing an amide group) amino acid, such as asparagine, glutamine, or a derivative thereof. In some embodiments, Xaa6 has no charge. In some embodiments, Xaa6 has a charge of -1, such as aspartic acid, glutamic acid, or a derivative thereof. In some embodiments, Xaa6 has a charge of +1, such as arginine, histidine, lysine, or a derivative thereof. In some embodiments, Xaa6 is absent.

[0161] In some embodiments, Xaa7 of formula (II) or formula (III) is a natural or non-natural amino acid. In some embodiments, Xaa7 is a natural amino acid. In some embodiments, Xaa7 is a non-natural amino acid. In some embodiments, Xaa7 is a non-natural amino acid selected from Tables 4A to 4G. In some embodiments, Xaa7 is a non-natural amino acid selected from Table 4G. In some embodiments, Xaa7 is an aliphatic amino acid, such as alanine, glycine, isoleucine, leucine, proline, valine, or a derivative thereof. In some embodiments, Xaa7 is an aromatic amino acid, such as phenylalanine, tryptophan, tyrosine, or a derivative thereof. In some embodiments, Xaa7 is an acidic amino acid, such as aspartic acid, glutamic acid, or a derivative thereof. In some embodiments, Xaa7 is a basic amino acid, such as arginine, histidine, lysine, or a derivative thereof. In some embodiments, Xaa7 is a hydroxyl amino acid, such as serine, threonine, or a derivative thereof. In some embodiments, Xaa7 is a sulfur-containing amino acid, such as cysteine, methionine, or a derivative thereof. In some embodiments, Xaa7 is an amide (containing an amide group) amino acid, such as asparagine, glutamine, or a derivative thereof. In some embodiments, Xaa7 has no charge. In some embodiments, Xaa7 has a charge of -1, such as aspartic acid, glutamic acid, or a derivative thereof. In some embodiments, Xaa7 has a charge of +1, such as arginine, histidine, lysine, or a derivative thereof. In some embodiments, Xaa7 is absent.

[0162] In some embodiments, Xaa8 of formula (II) or formula (III) is a natural or non-natural amino acid. In some embodiments, Xaa8 is a natural amino acid. In some embodiments, Xaa8 is a non-natural amino acid. In some embodiments, Xaa8 is a non-natural amino acid selected from Tables 4A to 4G. In some embodiments, Xaa8 is a non-natural amino acid selected from Table 4G. In some embodiments, Xaa8 is an aliphatic amino acid, such as alanine, glycine, isoleucine, leucine, proline, valine, or a derivative thereof. In some embodiments, Xaa8 is an aromatic amino acid, such as phenylalanine, tryptophan, tyrosine, or a derivative thereof. In some embodiments, Xaa8 is an acidic amino acid, such as aspartic acid, glutamic acid, or a derivative thereof. In some embodiments, Xaa8 is a basic amino acid, such as arginine, histidine, lysine, or a derivative thereof. In some embodiments, Xaa8 is a hydroxyl amino acid, such as serine, threonine, or a derivative thereof. In some embodiments, Xaa8 is a sulfur-containing amino acid, such as cysteine, methionine, or a derivative thereof. In some embodiments, Xaa8 is an amide (containing an amide group) amino acid, such as asparagine, glutamine, or a derivative thereof. In some embodiments, Xaa8 has no charge. In some embodiments, Xaa8 has a charge of -1, such as aspartic acid, glutamic acid, or a derivative thereof. In some embodiments, Xaa8 has a charge of +1, such as arginine, histidine, lysine, or a derivative thereof. In some embodiments, Xaa8 is absent.

[0163] In some embodiments, Xaa9 of formula (II) or formula (III) is a natural or non-natural amino acid. In some embodiments, Xaa9 is a natural amino acid. In some embodiments, Xaa9 is a non-natural amino acid. In some embodiments, Xaa9 is a non-natural amino acid selected from Tables 4A to 4G. In some embodiments, Xaa9 is a non-natural amino acid selected from Table 4G. In some embodiments, Xaa9 is an aliphatic amino acid, such as alanine, glycine, isoleucine, leucine, proline, valine, or derivatives thereof. In some embodiments, Xaa9 is an aromatic amino acid, such as phenylalanine, tryptophan, tyrosine, or derivatives thereof. In some embodiments, Xaa9 is an acidic amino acid, such as aspartic acid, glutamic acid, or derivatives thereof. In some embodiments, Xaa9 is a basic amino acid, such as arginine, histidine, lysine, or derivatives thereof. In some embodiments, Xaa9 is a hydroxyl amino acid, such as serine, threonine, or a derivative thereof. In some embodiments, Xaa9 is a sulfur-containing amino acid, such as cysteine, methionine, or a derivative thereof. In some embodiments, Xaa9 is an amide (containing an amide group) amino acid, such as asparagine, glutamine, or a derivative thereof. In some embodiments, Xaa9 has no charge. In some embodiments, Xaa9 has a charge of -1, such as aspartic acid, glutamic acid, or a derivative thereof. In some embodiments, Xaa9 has a charge of +1, such as arginine, histidine, lysine, or a derivative thereof. In some embodiments, Xaa9 is absent.

[0164] In some embodiments, Xaa10 of formula (II) or formula (III) is a natural or non-natural amino acid. In some embodiments, Xaa10 is a natural amino acid. In some embodiments, Xaa10 is a non-natural amino acid. In some embodiments, Xaa10 is a non-natural amino acid selected from Tables 4A to 4G. In some embodiments, Xaa10 is a non-natural amino acid selected from Table 4G. In some embodiments, Xaa10 is an aliphatic amino acid, such as alanine, glycine, isoleucine, leucine, proline, valine, or derivatives thereof. In some embodiments, Xaa10 is an aromatic amino acid, such as phenylalanine, tryptophan, tyrosine, or derivatives thereof. In some embodiments, Xaa10 is an acidic amino acid, such as aspartic acid, glutamic acid, or derivatives thereof. In some embodiments, Xaa10 is a basic amino acid, such as arginine, histidine, lysine, or derivatives thereof. In some embodiments, Xaa10 is a hydroxyl amino acid, such as serine, threonine, or a derivative thereof. In some embodiments, Xaa10 is a sulfur-containing amino acid, such as cysteine, methionine, or a derivative thereof. In some embodiments, Xaa10 is an amide (containing an amide group) amino acid, such as asparagine, glutamine, or a derivative thereof. In some embodiments, Xaa10 has no charge. In some embodiments, Xaa10 has a charge of -1, such as aspartic acid, glutamic acid, or a derivative thereof. In some embodiments, Xaa10 has a charge of +1, such as arginine, histidine, lysine, or a derivative thereof. In some embodiments, Xaa10 is absent.

[0165] In some embodiments, Xaa11 of formula (II) or formula (III) is a natural or non-natural amino acid. In some embodiments, Xaa11 is a natural amino acid. In some embodiments, Xaa11 is a non-natural amino acid. In some embodiments, Xaa11 is a non-natural amino acid selected from Tables 4A to 4G. In some embodiments, Xaa11 is a non-natural amino acid selected from Table 4G. In some embodiments, Xaa11 is an aliphatic amino acid, such as alanine, glycine, isoleucine, leucine, proline, valine, or derivatives thereof. In some embodiments, Xaa11 is an aromatic amino acid, such as phenylalanine, tryptophan, tyrosine, or derivatives thereof. In some embodiments, Xaa11 is an acidic amino acid, such as aspartic acid, glutamic acid, or derivatives thereof. In some embodiments, Xaa11 is a basic amino acid, such as arginine, histidine, lysine, or derivatives thereof. In some embodiments, Xaa11 is a hydroxyl amino acid, such as serine, threonine, or a derivative thereof. In some embodiments, Xaa11 is a sulfur-containing amino acid, such as cysteine, methionine, or a derivative thereof. In some embodiments, Xaa11 is an amide (containing an amide group) amino acid, such as asparagine, glutamine, or a derivative thereof. In some embodiments, Xaa11 has no charge. In some embodiments, Xaa11 has a charge of -1, such as aspartic acid, glutamic acid, or a derivative thereof. In some embodiments, Xaa11 has a charge of +1, such as arginine, histidine, lysine, or a derivative thereof. In some embodiments, Xaa11 is absent.

[0166] In some embodiments, Xaa12 of formula (II) or formula (III) is a natural or non-natural amino acid. In some embodiments, Xaa12 is a natural amino acid. In some embodiments, Xaa12 is a non-natural amino acid. In some embodiments, Xaa12 is a non-natural amino acid selected from Table 4G. In some embodiments, XaaC is a non-natural amino acid selected from Tables 4A to 4G. In some embodiments, Xaa12 is an aliphatic amino acid, such as alanine, glycine, isoleucine, leucine, proline, valine, or a derivative thereof. In some embodiments, Xaa12 is an aromatic amino acid, such as phenylalanine, tryptophan, tyrosine, or a derivative thereof. In some embodiments, Xaa12 is an acidic amino acid, such as aspartic acid, glutamic acid, or a derivative thereof. In some embodiments, Xaa12 is a basic amino acid, such as arginine, histidine, lysine, or a derivative thereof. In some embodiments, Xaa12 is a hydroxyl amino acid, such as serine, threonine, or a derivative thereof. In some embodiments, Xaa12 is a sulfur-containing amino acid, such as cysteine, methionine, or a derivative thereof. In some embodiments, Xaa12 is an amide (containing an amide group) amino acid, such as asparagine, glutamine, or a derivative thereof. In some embodiments, Xaa12 has no charge. In some embodiments, Xaa12 has a charge of -1, such as aspartic acid, glutamic acid, or a derivative thereof. In some embodiments, Xaa12 has a charge of +1, such as arginine, histidine, lysine, or a derivative thereof. In some embodiments, Xaa12 is absent.

[0167] In some embodiments, Xaa13 of formula (II) or formula (III) is a natural or non-natural amino acid. In some embodiments, Xaa13 is a natural amino acid. In some embodiments, Xaa13 is a non-natural amino acid. In some embodiments, Xaa13 is a non-natural amino acid selected from Tables 4A to 4G. In some embodiments, Xaa13 is a non-natural amino acid selected from Table 4G. In some embodiments, Xaa13 is an aliphatic amino acid, such as alanine, glycine, isoleucine, leucine, proline, valine, or derivatives thereof. In some embodiments, Xaa13 is an aromatic amino acid, such as phenylalanine, tryptophan, tyrosine, or derivatives thereof. In some embodiments, Xaa13 is an acidic amino acid, such as aspartic acid, glutamic acid, or derivatives thereof. In some embodiments, Xaa13 is a basic amino acid, such as arginine, histidine, lysine, or derivatives thereof. In some embodiments, Xaa13 is a hydroxyl amino acid, such as serine, threonine, or a derivative thereof. In some embodiments, Xaa13 is a sulfur-containing amino acid, such as cysteine, methionine, or a derivative thereof. In some embodiments, Xaa13 is an amide (containing an amide group) amino acid, such as asparagine, glutamine, or a derivative thereof. In some embodiments, Xaa13 has no charge. In some embodiments, Xaa13 has a charge of -1, such as aspartic acid, glutamic acid, or a derivative thereof. In some embodiments, Xaa13 has a charge of +1, such as arginine, histidine, lysine, or a derivative thereof. In some embodiments of formula (II), Xaa13 is absent.

[0168] In some embodiments, XaaC of formula (II) or formula (III) is a natural or non-natural amino acid. In some embodiments, XaaC is a natural amino acid. In some embodiments, XaaC is a non-natural amino acid. In some embodiments, XaaC is a non-natural amino acid selected from Tables 4A to 4G. In some embodiments, XaaC is a non-natural amino acid selected from Table 4G. In some embodiments, XaaC is an aliphatic amino acid, such as alanine, glycine, isoleucine, leucine, proline, valine, or derivatives thereof. In some embodiments, XaaC is an aromatic amino acid, such as phenylalanine, tryptophan, tyrosine, or derivatives thereof. In some embodiments, XaaC is an acidic amino acid, such as aspartic acid, glutamic acid, or derivatives thereof. In some embodiments, XaaC is a basic amino acid, such as arginine, histidine, lysine, or derivatives thereof. In some embodiments, XaaC is a hydroxyl amino acid, such as serine, threonine, or a derivative thereof. In some embodiments, XaaC is a sulfur-containing amino acid, such as cysteine, methionine, or a derivative thereof. In some embodiments, XaaC is an amide (containing an amide group) amino acid, such as asparagine, glutamine, or a derivative thereof. In some embodiments, XaaC has no charge. In some embodiments, XaaC has a charge of -1, such as aspartic acid, glutamic acid, or a derivative thereof. In some embodiments, XaaC has a charge of +1, such as arginine, histidine, lysine, or a derivative thereof. In some embodiments, XaaC is Cys. In some embodiments, XaaC is homocysteine. In some embodiments of formula (II), XaaC is absent.

[0169] In some embodiments, each of Xaa0 in formula (III) is independently a natural amino acid or a non-natural amino acid. In some embodiments, Xaa0 is a natural amino acid. In some embodiments, Xaa0 is a non-natural amino acid. In some embodiments, Xaa0 is a non-natural amino acid selected from Tables 4A to 4G. In some embodiments, Xaa0 is a non-natural amino acid selected from Table 4G. In some embodiments, Xaa0 is an aliphatic amino acid, such as alanine, glycine, isoleucine, leucine, proline, valine, or a derivative thereof. In some embodiments, Xaa0 is an aromatic amino acid, such as phenylalanine, tryptophan, tyrosine, or a derivative thereof. In some embodiments, Xaa0 is an acidic amino acid, such as aspartic acid, glutamic acid, or a derivative thereof. In some embodiments, Xaa0 is a basic amino acid, such as arginine, histidine, lysine, or a derivative thereof. In some embodiments, Xaa0 is a hydroxyl amino acid, such as serine, threonine, or a derivative thereof. In some embodiments, Xaa0 is a sulfur-containing amino acid, such as cysteine, methionine, or a derivative thereof. In some embodiments, Xaa0 is an amide (containing an amide group) amino acid, such as asparagine, glutamine, or a derivative thereof. In some embodiments, Xaa0 has no charge. In some embodiments, Xaa0 has a charge of -1, such as aspartic acid, glutamic acid, or a derivative thereof. In some embodiments, Xaa0 has a charge of +1, such as arginine, histidine, lysine, or a derivative thereof.

[0170] In some embodiments of formula (III), p is 0, 1, 2, 3, 4, 5, 6, 7, or 8. In some embodiments, p is 0. In some embodiments, p is 1. In some embodiments, p is 2. In some embodiments, p is 3. In some embodiments, p is 4. In some embodiments, p is 5. In some embodiments, p is 6. In some embodiments, p is 7. In some embodiments, p is 8.

[0171] In some embodiments, the cyclic peptide of formula (I), formula (II), or formula (III) has an effective charge of -3 to +1. In some embodiments, the cyclic peptide has an effective charge of -3. In some embodiments, the cyclic peptide has an effective charge of -2. In some embodiments, the cyclic peptide has an effective charge of -1. In some embodiments, the cyclic peptide has an effective charge of 0. In some embodiments, the cyclic peptide has an effective charge of +1. In some embodiments, the cyclic peptide of formula (I), formula (II), or formula (III) has an effective charge of up to -4. In some embodiments, the cyclic peptide has an effective charge of -4. In some embodiments, the cyclic peptide of formula (I), formula (II), or formula (III) has an effective charge of at least +2. In some embodiments, the cyclic peptide has an effective charge of +2. In some embodiments, the cyclic peptide has an effective charge of +3. The effective charge can be determined by summing the charges of each of the Xaa1-Xaa14 amino acids (or each amino acid within a peptide). For example, aspartic acid (D) and glutamic acid (E) each have a charge of -1, lysine (K), arginine (R), and histidine (H) each have a charge of +1, and the remaining standard amino acids each have a charge of 0.

[0172] In some embodiments, the cyclic peptide of formula (III) has an effective charge of -3 to +1. In some embodiments, the cyclic peptide has an effective charge of -3. In some embodiments, the cyclic peptide has an effective charge of -2. In some embodiments, the cyclic peptide has an effective charge of -1. In some embodiments, the cyclic peptide has an effective charge of 0. In some embodiments, the cyclic peptide has an effective charge of +1. The effective charge can be determined by summing the charges of each amino acid in the cyclic peptide.

[0173] In some embodiments, the cyclic peptides described herein (e.g., cyclic peptides of formula (I), formula (II), or formula (III)) are configured to bind to plasma proteins with a predetermined affinity, measured, for example, as a plasma protein-albumin binding (PPB) percentage. The above binding percentage can be determined by HSA-HPLC (measurement of drug-protein binding by immobilized human serum albumin-HPLC). PPB can be measured in vitro by HPLC (e.g., Example B3) or other suitable means known in the art. In some embodiments, when measured by HPLC according to the conditions described in Example B3, 1% to 99% of the cyclic peptide binds to human serum albumin (HSA) in vitro. In some embodiments, when measured by HPLC, approximately 2% to 99%, 5% to 99%, 10% to 99%, 20% to 99%, 30% to 99%, 40% to 99%, 50% to 99%, 60% to 99%, 70% to 99%, or 80% to 99% of the cyclic peptide binds to HSA in vitro. In some embodiments, approximately 10% to 95% of the cyclic peptide binds to HSA in vitro (i.e., approximately 10% to 95% of PPB). In some embodiments, approximately 20% to 90% of the cyclic peptide binds to HSA in vitro. In some embodiments, approximately 20% to 60% of the cyclic peptide binds to HSA in vitro. In some embodiments, approximately 40% to 95% of the cyclic peptide binds to HSA in vitro. In some embodiments, approximately 40% to 80% of the cyclic peptide binds to HSA in vitro. In some embodiments, approximately 40% to 60% of the cyclic peptide binds to HSA in vitro. In some embodiments, approximately 60% to 99% of the cyclic peptide binds to HSA in vitro. In some embodiments, approximately 60% to 95% of the cyclic peptide binds to HSA in vitro. In some embodiments, approximately 60% to 80% of the cyclic peptide binds to HSA in vitro. In some embodiments, approximately 60% to 70% of the cyclic peptide binds to HSA in vitro. In some embodiments, approximately 40% to 50% of the cyclic peptide binds to HSA in vitro.In some embodiments, approximately 50% to 60% of the cyclic peptide binds to HSA in vitro. In some embodiments, approximately 70% to 80% of the cyclic peptide binds to HSA in vitro. In some embodiments, approximately 80% to 99% of the cyclic peptide binds to HSA in vitro. In some embodiments, approximately 80% to 85% of the cyclic peptide binds to HSA in vitro.

[0174] In some embodiments, the conjugates described herein (e.g., conjugates comprising the cyclic peptide of formula (I), formula (II), or formula (III)) are configured to bind to plasma proteins with a predetermined affinity, for example, as the plasma protein-albumin binding (PPB) percentage. PPB can be measured in vitro by HPLC (e.g., Example B3) or other suitable means known in the art. In some embodiments, when measured by HPLC according to the conditions described in Example B3, 1% to 99% of the conjugate binds to human serum albumin (HSA) in vitro. In some embodiments, when measured by HPLC, approximately 2% to 99%, 5% to 99%, 10% to 99%, 20% to 99%, 30% to 99%, 40% to 99%, 50% to 99%, 60% to 99%, 70% to 99%, or 80% to 99% of the conjugate binds to HSA in vitro. In some embodiments, approximately 10% to 95% of the conjugate binds to HSA in vitro (i.e., approximately 10% to 95% PPB). In some embodiments, approximately 20% to 90% of the conjugate binds to HSA in vitro. In some embodiments, approximately 20% to 60% of the conjugate binds to HSA in vitro. In some embodiments, approximately 40% to 95% of the conjugate binds to HSA in vitro. In some embodiments, approximately 40% to 80% of the conjugate binds to the HSA in vitro. In some embodiments, approximately 40% to 60% of the conjugate binds to the HSA in vitro. In some embodiments, approximately 60% to 99% of the conjugate binds to the HSA in vitro. In some embodiments, approximately 60% to 95% of the conjugate binds to the HSA in vitro. In some embodiments, approximately 60% to 80% of the conjugate binds to the HSA in vitro. In some embodiments, approximately 60% to 70% of the conjugate binds to the HSA in vitro. In some embodiments, approximately 40% to 50% of the conjugate binds to the HSA in vitro.In some embodiments, approximately 50% to 60% of the conjugate binds to the HSA in vitro. In some embodiments, approximately 70% to 80% of the conjugate binds to the HSA in vitro. In some embodiments, approximately 80% to 99% of the conjugate binds to the HSA in vitro. In some embodiments, approximately 80% to 85% of the conjugate binds to the HSA in vitro.

[0175] In some embodiments, the cyclic peptide of formula (I), formula (II), or formula (III) contains no disulfide bonds at all.

[0176] In some embodiments of the cyclic peptide of formula (III), L cyc This is formed by reacting functional group A and the corresponding functional group B in Table 1. Functional group A may be part of amino acid XaaN, or XaaN can be functionalized with functional group A. Functional group B may be part of amino acid XaaC, or XaaC can be functionalized with functional group B. In some embodiments, L cyc This is a group formed by reacting functional group (IA) and functional group (IB) shown in Table 1. In some embodiments, L cyc This is a group formed by reacting functional group (II-A) and functional group (II-B) shown in Table 1. In some embodiments, L cyc This is a group formed by reacting functional group (III-A) and functional group (III-B) shown in Table 1. In some embodiments, L cyc This is a group formed by reacting functional group (IV-A) and functional group (IV-B) shown in Table 1. In some embodiments, L cycは These are groups formed by reacting functional groups (VA) and (VB) as shown in Table 1.

[0177] In some embodiments of the cyclic peptide of formula (III), L cycは, -C(=O)-CH2-S-. In some embodiments of the cyclic peptide of formula (III), XaaC is cysteine ​​and XaaN is chloroacetylated, L N and L C It does not exist, L cyc This is formed by reacting the -C(=O)-CH2Cl on XaaN with the -SH group on cysteine.

[0178] In some embodiments of the cyclic peptide of formula (III), XaaC is cysteine, homocysteine, lysine, homolysine, ornithine, diaminobutric acid, serine, homoserine, threonine, or homothreonine, and XaaN is chloroacetylated, L cyc These are -C(=O)-CH2-S-, -C(=O)-CH2-NH-, or -C(=O)-CH2-O- formed by reacting -C(=O)-CH2Cl on XaaN with a functional group of XaaC (-SH, -NH2, -OH, -COOH, etc.). In some embodiments, L N and L C It does not exist (i.e., it is not combined).

[0179] In some embodiments of the cyclic peptide of formula (III), XaaC is aspartic acid, glutamic acid, or homoglutamic acid, and XaaN contains or is functionalized with -NH2. cyc This is an amide formed by reacting the -NH2 group on XaaN with the -COOH functional group on XaaC.

[0180] In some embodiments of the cyclic peptide of formula (III), XaaC is lysine, homolysine, ornithine, or diaminobutrine, and XaaN contains or is functionalized with -COOH. cyc This is an amide formed by reacting the -COOH group on XaaN with the functional group -NH2 on XaaC.

[0181] In some embodiments of the cyclic peptide of formula (III), XaaC is cysteine ​​or homocysteine, and XaaN contains a halogen such as -Br or is functionalized with a halogen, L cyc This is an -S- formed by reacting -Br on XaaN with the functional group -SH on -XaaC.

[0182] In some embodiments of the cyclic peptide of formula (III), XaaC is allyl-glycine or homoallyl-glycine, and XaaN contains or is functionalized with -CH=CH2. cyc This is a -CH=CH2- formed by reacting the -CH=CH2 on XaaN with the functional group -CH=CH2 on XaaC.

[0183] In some embodiments of the cyclic peptide of formula (III), XaaC is aspartic acid-4-semialdehyde or glutamic acid-5-semialdehyde, and XaaN contains or is functionalized with -NH2. cyc This is an -NH- formed by reacting the -NH2 on XaaN with the functional group -C(=O) of XaaC.

[0184] In some embodiments of the cyclic peptide of formula (III), XaaC is cysteine ​​or homocysteine ​​conjugated with 1,2- or 1,3- or 1,4-bis-(bromomethyl)benzene, and XaaN contains or is functionalized with -SH. cyc This is -S-CH2-benzene-CH2-S- formed by reacting the -SH on XaaN with the functional group of XaaC.

[0185] In some embodiments of the cyclic peptide of formula (III), XaaC is functionalized with an azide, XaaN is functionalized with an alkyne, and L cycXaaC is a triazole formed by a click reaction between an azide and an alkyne. In some embodiments of the cyclic peptide of formula (III), XaaC is functionalized with an alkyne, XaaN is functionalized with an azide, and L cyc It is a triazole formed by a click reaction between an azide and an alkyne.

[0186] In some embodiments of the cyclic peptide of formula (III), XaaC is functionalized with an azide, XaaN is functionalized with an alkene, and L cyc XaaN is a triazoline formed by a cycloaddition reaction between an azide and an alkene. In some embodiments of the cyclic peptide of formula (III), XaaC is functionalized with an alkene (e.g., XaaC is alkynylglycine, homoalkynylglycine), XaaN is functionalized with an azide, and L cyc It is a triazoline formed by a cycloaddition reaction between an azide and an alkene.

[0187] In some embodiments of the cyclic peptide of formula (III), XaaC is cysteine ​​or homocysteine, and XaaN contains or is functionalized with maleimide, L cyc This is a succinimide-S- formed by reacting a maleimide on XaaN with the SH group-CH=CH2 of XaaC.

[0188] In some embodiments of the cyclic peptide of formula (III), L cyc The structure is shown in Table 2A, where n is 0 and m is 0. In some embodiments of the cyclic peptide of formula (II), the ring-closing group has the structure shown in Table 2A.

[0189] For example, the cyclic peptide of formula (III) has a structure

[0190] [ka] The formula may have the following characteristics (wherein XaaC is cysteine):

[0191] In some embodiments, the cyclic peptide of formula (III) has a structure

[0192] [ka] It can have.

[0193] In some embodiments, the cyclic peptide of formula (III) has a structure

[0194] [ka] It can have.

[0195] In some embodiments, a conjugate comprising a cyclic peptide of formula (III) has a structure

[0196] [ka] It has.

[0197] In some embodiments of the cyclic peptide of formula (III), L N -L cyc -L C -C(=O)-CH2-S-, -C(=O)-CH2-S-CH2-, -C(=O)-CH2-S-CH2-CH2-, -(CH2) m -NH-CO-(CH2) n -,-(CH2) m -CO-NH-(CH2) n -,-(CH2) m -S-(CH2) n -,-(CH2) m -CH=CH-(CH2) n -,-(CH2) m -NH-(CH2) n -,-(CH2) m -S-CH2-benzene-CH2-S-(CH2) n -,-(CH2)m-triazine-(CH2) n -,-(CH2)m -Succinimide-S-(CH2) n -, -C(=O)-CH2-NH-CH2-, or -C(=O)-CH2-O-CH2-, where m and n are independently 0 or integers from 1 to 6. In some embodiments of the cyclic peptide of formula (III), L cyc This is the basis for Table 2A.

[0198] In some embodiments of the cyclic peptide of formula (III), L cyc These are formed by reacting the functional groups of XaaN shown in Table 2B with XaaC, or with the functional groups of XaaC.

[0199] In some embodiments, a conjugate comprising a cyclic peptide of formula (III) has a structure

[0200] [ka] (In the formula, the side chain of XaaN is conjugated to the side chain of XaaC.)

[0201] [Table 2]

[0202] In some embodiments of formula (III), L cyc This is the structure shown in Table 2A, where m is 0 and n is 0. In some embodiments of equation (III), L cyc This includes the structure shown in Table 2A, where m is 0 and n is 0.

[0203] In some embodiments, m is 0. In some embodiments, m is 1. In some embodiments, m is 2. In some embodiments, m is 3. In some embodiments, m is 4. In some embodiments, m is 5. In some embodiments, m is 6. In some embodiments, n is 0. In some embodiments, n is 1. In some embodiments, n is 2. In some embodiments, n is 3. In some embodiments, n is 4. In some embodiments, n is 5. In some embodiments, n is 6.

[0204] [Table 3]

[0205] In some embodiments, the cyclic peptide of formula (III) can be represented by the compounds in Table 3. In some embodiments, the conjugate further comprises a metal chelating agent and optionally a linker. In some embodiments, the conjugate further comprises a radionuclide such as Ac-225 or lutetium-177.

[0206] [Table 4]

[0207] As shown in Table 3, only the cyclic portion of the peptide sequence is included. In some embodiments, a conjugate containing any one of the peptides in Table 3 may further include amino acid residues at the N-terminus and / or C-terminus of the peptide, which are not part of the cyclic structure.

[0208] As shown in Table 3, the abbreviations have the following meanings.

[0209] The lowercase letter 'd' stands for D-amino acid; for example, dF refers to d-phenylalanine.

[0210] Me refers to a methyl group; for example, MeG represents N-methylglycine.

[0211] Ahp refers to 2-aminoheptanoic acid.

[0212] Nal1 refers to 1-naphthylalanine.

[0213] Chg refers to cyclohexylglycine.

[0214] F3C refers to 3-chlorophenylalanine.

[0215] mBph refers to 3-phenylphenylalanine.

[0216] Cba refers to cyclobutylalanine.

[0217] Hph refers to homophenylalanine.

[0218] W6C refers to 6-chlorotryptaphan.

[0219] The peptides described herein may be peptidomimetic. For example, peptides may contain non-peptide bonds, and peptides may contain one or more non-natural amino acids. Unless otherwise specified, each amino acid in the peptides described herein (except the natural amino acid glycine) may independently be D-type or L-type. Both D-type and L-type peptides are encompassed in this disclosure.

[0220] In this disclosure, the term amino acid encompasses derivatives of amino acids. Examples of derivatives include amino acids obtained by modifying natural amino acids that constitute proteins produced by biomolecules encoded in the DNA of cells. Examples of such non-natural amino acids include hydroxyproline and hydroxylysine, which are amino acids into which a hydroxyl group has been introduced, and diaminopropionic acid, which is an amino acid into which an amino group has been introduced.

[0221] The peptides described herein may contain N-substituted amino acids. In some embodiments, the N-substituted amino acid is a derivative of tryptophan, phenylalanine, tyrosine, arginine, histidine, isoleucine, leucine, lysine, or valine. In some embodiments, the N-substitution is an N-alkyl such as N-methyl and N-ethyl. In some embodiments, the N-substitution is an N-aryl such as N-phenyl or N-biphenyl. In some embodiments, the N-substitution is an N-heteroaryl such as N-pyridyl. In some embodiments, the N-substituted amino acid is at the N-terminus of the peptide. In some embodiments, the N-substituted amino acid is a non-terminal amino acid.

[0222] In some embodiments, the peptides described herein include one or more amino acids from Tables 4A to 4G.

[0223] [Table 5]

[0224] [Table 6]

[0225] [Table 7]

[0226] [Table 8]

[0227] Examples of alkyl groups in Table 1D include methyl, ethyl, and propyl groups.

[0228] [Table 9]

[0229] Table 10

[0230] Table 11-1

[0231] Table 11-2

[0232] Table 11-3

[0233] Table 11-4

[0234] Table 11-5

[0235] Table 11-6

[0236] Table 11-7

[0237] Table 11-8

[0238] Table 11-9

[0239] Table 11-10

[0240] Table 11-11

[0241] Table 11-12

[0242] Table 11-13

[0243] Table 11-14

[0244] Table 11-15

[0245] Table 11-16

[0246] Table 11-17

[0247] Table 11-18

[0248] Table 11-19

[0249] Table 11-20

[0250] Table 11-21

[0251] Table 11-22

[0252] Table 11-23

[0253] Table 11-24

[0254] Table 11-25

[0255] Table 11-26

[0256] Table 11-27

[0257] Table 11-28

[0258] Table 11-29

[0259] Examples of amino acids include L-amino acids from natural proteins, non-natural amino acids, and chemically synthesized compounds that possess properties known in the art as characteristics of amino acids. Examples of non-natural amino acids include, but are not limited to, α,α-disubstituted amino acids (such as α-methylalanine), N-alkyl-α-amino acids, D-amino acids, β-amino acids, and α-hydroxy acids, each having a main chain structure different from that of natural amino acids; amino acids having a side chain structure different from that of natural amino acids (such as norleucine and homohistidine); amino acids having an additional methylene group in their side chain ("homo" amino acids, such as homophenylalanine and homohistidine); and amino acids obtained by substituting the carboxylic acid-functional amino group in their side chain with a sulfonic acid group (such as cysteic acid).

[0260] The peptides described herein may contain one or more non-natural amino acids. Non-natural amino acids include, but are not limited to, (1) amino acids corresponding to amino acid residues on polypeptides that have been modified after expression (e.g., phosphorylated tyrosine, acetylated lysine, or farnesylated cysteine), (2) naturally occurring amino acids that cannot be used for expression on ribosomes, and (3) artificial amino acids that do not exist naturally (non-natural amino acids). Non-limiting examples of non-natural amino acids include p-acetyl-L-phenylalanine, p-iodo-L-phenylalanine, p-methoxyphenylalanine, O-methyl-L-tyrosine, p-propargyloxyphenylalanine, p-propargyl-phenylalanine, L-3-(2-naphthyl)alanine, 3-methyl-phenylalanine, O-4-allyl-L-tyrosine, 4-propyl-L-tyrosine, tri-O-acetyl-GlcNAcp-serine, L-DOPA, and fluoride. Examples include phenylalanine, isopropyl-L-phenylalanine, p-azido-L-phenylalanine, p-acyl-L-phenylalanine, p-benzoyl-L-phenylalanine, boronophenylalanine, O-propargyltyrosine, L-phosphoserine, phosphonoserine, phosphonotyrosine, p-bromophenylalanine, selenocysteine, p-amino-L-phenylalanine, isopropyl-L-phenylalanine, and azido-lysine (AzK). In some embodiments, the unnatural amino acids are unnatural analogs of tyrosine amino acids, glutamine amino acids, phenylalanine amino acids, alanine amino acids, serine amino acids, threonine amino acids, alkyl, aryl, acyl, azide, cyano, halo, hydrazine, hydrazide, hydroxyl, alkenyl, alkyn, ether, thiol, sulfonyl, selen, ester, thio acid, borate, boronic acid ester, phospho, phosphono, phosphine, heterocyclic, enone, imine, aldehyde, hydroxylamine, keto, or amino-substituted amino acids, or combinations thereof.In some embodiments, non-natural amino acids are amino acids having a photoactivatable crosslinking agent, spin-labeled amino acids, fluorescent amino acids, metal-linked amino acids, metal-containing amino acids, radioactive amino acids, photocaged amino acids and / or photoisomerizable amino acids, amino acid-containing biotin or biotin analogs, keto-containing amino acids, amino acids containing polyethylene glycol or polyether, heavy atom-substituted amino acids, chemically cleavable or photocleavable amino acids, amino acids with extended side chains, amino acids containing toxic groups, sugar-substituted amino acids, carbon-bonded sugar-containing amino acids, redox-active amino acids, α-hydroxy-containing acids, aminothio acids, α,α-disubstituted amino acids, β-amino acids, cyclic amino acids other than proline or histidine, or aromatic amino acids other than phenylalanine, tyrosine, or tryptophan.

[0261] In some embodiments, the non-natural amino acids incorporated into the peptide may include: 1) ketone functional groups (such as those found in para- or metaacetyl-phenylalanine) that can react specifically with hydrazine, hydroxylamine, and their derivatives (addition of ketone functional groups to the genetic code of E. coli. Wang L, Zhang Z, Brock A, Schultz P G. Proc Natl Acad Sci USA. 2003 Jan. 7;100(1):56-61; Bioorg Med Chem Lett. 2006 Oct. 15;16(20):5356-9. Genetic introduction of diketone-containing amino acids into proteins. Zeng H, Xie J, Schultz PG); 2) azides (such as those found in p-azide-phenylalanine) that can react with alkynes via copper-catalyzed "click chemistry" or strain-promoting (3+2) cycloaddition to form the corresponding triazoles (addition of p-azide-L-phenylalanine to the genetic code of E. coli. Chin JW, Santoro SW, Martin AB, King DS, Wang L, Schultz P GJ Am Chem Soc. 2002 Aug. 7;124(31):9026-7; Addition of novel reactive amino acids to the genetic code of budding yeast. Deiters A, Cropp TA, Mukherji M, Chin JW, Anderson JC, Schultz P GJ Am Chem Soc. 2003 Oct. 1;125(39):11782-3), or it can react with arylphosphine via Staudinger ligation (selective Staudinger modification of proteins containing p-azidophenylalanine), Tsao ML, Tian F, Schultz P G. Chembiochem. 2005 December;6(12):2147-9), azides that can form the corresponding amide, 3) alkynes that can react with azides to form the corresponding triazole (in vivo uptake of alkynes into proteins in E. coli).Examples include one or more of the following: 4) Boronic acids (boronic acid esters) (Angew Chem Int Ed Engl. 2008; 47(43): 8220-3. Genetically encoded boronic acid ester-containing amino acids, Brustad E, Bushey ML, Lee JW, Groff D, Liu W, Schultz PG) that can specifically react with compounds containing two or more hydroxyl groups arranged at appropriate intervals, or that can undergo palladium-mediated coupling with halogenated compounds; and 5) Metal chelate-forming amino acids, including bipyridyl amino acids that can specifically coordinate to metal ions (Angew Chem Int Ed Engl. 2007; 46(48): 9239-42. Genetically encoded bidentate metal-binding amino acids, Xie J, Liu W, Schultz PG).

[0262] The peptides of the present invention include a variety of derivatives thereof. Examples of derivatives include those having an amide group, an ester group, or a carboxyl group at the C-terminus and / or N-terminus. Additional examples of peptide derivatives include peptides obtained by modifications such as phosphorylation, methylation, acetylation, adenylylation, ADP-ribosylation, or glycosylation, or fusion proteins obtained by fusing with other peptides or proteins. These derivatives can be prepared by methods known to those skilled in the art or by methods similar thereto.

[0263] In some embodiments, the peptides described herein include basic amino acids. Examples of basic amino acids include arginine, lysine, citrulline, ornithine, creatine, histidine, diaminobutanoic acid, and diaminopropionic acid.

[0264] In some embodiments, peptides having 90% or more sequence identity with any of the sequences disclosed herein are provided herein. In some embodiments, the sequence identity is at least 95% or 99%.

[0265] The sequence identity percentage can be calculated using a computer program or direct sequence comparison. Preferred computer programming methods for determining the identity between two sequences include, but are not limited to, the GCG program package, FASTA, BLASTP, and TBLASTN (see, for example, DWMount, 2001, Bioinformatics: Sequence and Genome Analysis, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY). The BLASTP and TBLASTN programs are publicly available from NCBI and other sources. The Smith-Waterman algorithm can also be used to determine the identity percentage. Examples of parameters for amino acid sequence comparison include: 1) Needleman and Wunsch's algorithm (J.Mol.Biol.,48:443-453(1970)); 2) Hentikoff and BLOSSUM62 comparison matrix from Hentikoff (Proc.Nat.Acad.Sci.USA.,89:10915-10919(1992)); 3) Gap penalty = 12; and 4) Gap length penalty = 4. A program useful for using these parameters is publicly available as the "gap" program (Genetics Computer Group (Madison, Wis.)). The aforementioned parameters are the default parameters for polypeptide comparison (no penalty for end gaps). Alternatively, polypeptide sequence identity can be calculated using the following equation: Percent identity: (Number of identical residues) / (Alignment length of amino acid residues) × 100. In this calculation, the alignment length includes internal gaps but not terminal gaps.

[0266] In some embodiments, the peptides are bicyclic or polycyclic. In some embodiments, the conjugates described herein include bicyclic peptides. Exemplary bicyclic peptides include the bicyclic targeted peptides BT5528, BT1718, and BT8009. Exemplary bicyclic peptides are described in U.S. Patent Publication No. 20180200378, U.S. Patent No. 10441663, U.S. Patent No. 8680022(B2), U.S. Patent Publication No. 20180280525, and U.S. Patent Publication No. 20200215199, each incorporated herein by reference in its entirety.

[0267] In some embodiments, the peptide is a lasso peptide. Lasso peptides can be synthetic or naturally occurring by bacteria and possess a unique lasso-like fold through which the chain passes, providing a functional 3D sequence for engaging biological targets. This lasso structure enables beneficial properties such as affinity, stability, and potent biological activity. A suitable lasso structure can be designed by algorithm. Exemplary lasso peptides are Hegemann, JD, et al., Lasso Peptides: An Intriguing Class of Bacterial Natural Products, Acc. Chem. Res., 2015, 48, 1909-1919; Tietz, JI, et al., A new genome-mining tool redefines the lasso peptide biosynthetic landscape, Nature Chem Bio,2017,13,470-478;DiCaprio,AJ,et al.,Enzymatic Reconstitution and Biosynthetic Investigation of the Lasso Peptide Fusilassin,J.Am.Chem.Soc.,2019,141,290-297;Al Toma,RS,et al.,Site-Directed and Global Incorporation of Orthogonal and Isostructural Noncanonical Amino Acids into the Ribosomal Lasso Peptide Capistruin is available in ChemBioChem, 2015, 16, 503-509.

[0268] Further exemplary peptides include BMS-753493, somatostatin, octreotide, octreotate, lanreotide, pasireotide, JR-11, L-779,976, BIM-23120, satreotide, depreotide, 18F-KYNDRLPLYISNP (SEQ ID NO: 10), CaIX-P1, and FAP-2286.

[0269] The peptides of the present invention also include salts thereof. As the peptide salts, salts of physiologically acceptable bases or acids are used. Examples include addition salts with inorganic acids (hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, phosphoric acid, etc.), organic acids (p-toluenesulfonic acid, methanesulfonic acid, oxalic acid, p-bromophenylsulfonic acid, carboxylic acids, succinic acid, citric acid, benzoic acid, or acetic acid), inorganic bases (ammonium hydroxide, alkali metal or alkaline earth metal hydroxides, carbonates, or bicarbonates, etc.), and addition salts with amino acids.

[0270] The peptides of the present invention can be prepared by known peptide preparation methods, such as chemical synthesis methods including liquid-phase methods, solid-phase methods, or hybrid methods combining liquid-phase and solid-phase methods, or by genetic engineering methods.

[0271] In the solid-phase method, for example, an esterification reaction can be carried out between the hydroxyl group of a hydroxyl group-containing resin and the carboxyl group of a first amino acid (usually the C-terminal amino acid of the target peptide) having an α-amino group protected by a protecting group. As an esterification catalyst, dehydration condensation agents such as 1-mesitylenesulfonyl-3-nitro-1,2,4-triazole (MSNT), dicyclohexylcarbodiimide (DCC), and diisopropylcarbodiimide (DIPCDI) may be used. Next, the protecting group of the α-amino group of the first amino acid is removed, and a second amino acid is added in which all functional groups except the carboxyl group of the main chain are protected, thereby activating the carboxyl group and bonding the first and second amino acids to each other. Next, the α-amino group of the second amino acid is deprotected, and a third amino acid is added in which all functional groups except the carboxyl group of the main chain are protected, thereby activating the carboxyl group and bonding the second and third amino acids to each other. By repeating the above reaction, a peptide of the desired length is synthesized. Next, all functional groups are deprotected. Examples of resins for solid-phase synthesis include Merrifield resin, MBHA resin, CI-Trt resin, SASRIN resin, Wang resin, Rink amide resin, HMFS resin, Amino-PEGA resin (Merck), and HMPA-PEGA resin (Merck). These resins may be washed with a solvent (such as dimethylformamide (DMF), 2-propanol, or methylene chloride) before use. The peptide chain can be cleaved from the resin by treatment with an acid such as TFA or hydrogen fluoride (HF).

[0272] Examples of protecting groups for the α-amino group include the benzyloxycarbonyl (Cbz or Z) group, the tert-butoxycarbonyl (Boc) group, the fluorenylmethoxycarbonyl (Fmoc) group, the benzyl group, the allyl group, and the allyloxycarbonyl (Alloc) group. The Cbz group can be deprotected using hydrofluoric acid or hydrogenation. The Boc group can be deprotected using trifluoroacetic acid (TFA). The Fmoc group can be deprotected by treatment with piperidine. For protecting the α-carboxyl group, methyl esters, ethyl esters, benzyl esters, tert-butyl esters, cyclohexyl esters, etc. Other functional groups of amino acids include the hydroxyl group of serine or threonine, which can be protected with a benzyl group or a tert-butyl group, and the hydroxyl group of tyrosine, which can be protected with a 2-bromobenzyloxycarbonyl group or a tert-butyl group. The amino group of the lysine side chain or the carboxyl group of glutamic acid or aspartic acid can be protected in the same manner as the α-amino group or α-carboxyl group.

[0273] The carboxyl group can be activated with a coupling agent. Examples of coupling agents include dicyclohexylcarbodiimide (DCC), diisopropylcarbodiimide (DIPCDI), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC or WSC), (1H-benzotriazole-1-yloxy)tris(dimethylamino)phosphonium=hexafluorophosphate (BOP), and 1-[bis(dimethylamino)methyl]-1H-benzotriazolium-3-oxide=hexafluorophosphate (HBTU).

[0274] The preparation of peptides by recombinant methods (translation and synthesis systems) can be carried out using nucleic acids encoding the peptides of this disclosure. The nucleic acids encoding the peptides may be either DNA or RNA. The nucleic acids encoding the peptides can be prepared by known methods. For example, the nucleic acids can be synthesized using an automated synthesizer. The DNA thus obtained may have restriction enzyme recognition sites for insertion into a vector, and may have a nucleotide sequence encoding an amino acid sequence for enzymatic cleavage of the resulting peptide chain. The obtained peptides may be converted from free peptides to their salts, or from their salts to free peptides, by known or based methods.

[0275] To suppress degradation by host-derived proteases, a chimeric protein expression method can be used, in which the target peptide is expressed as a chimeric peptide with another peptide. In this case, nucleic acids encoding the target peptide and the peptide that binds to it are used as nucleic acids. Next, an expression vector is prepared using the nucleic acids encoding the peptide of the present invention. The nucleic acid can be inserted downstream of the promoter of the expression vector either as is or after adding a linker digested with restriction enzymes. Examples of vectors include plasmids derived from Escherichia coli (pBR322, pBR325, pUC12, pUC13, pUC18, pUC19, pUC118, and pBluescript II, etc.), plasmids derived from Bacillus subtilis (pUB110, pTP5, pC1912, pTP4, pE194, and pC194, etc.), plasmids derived from yeast (pSH19, pSH15, YEp, YRp, Ylp, and YAC, etc.), bacteriophages (e-phage and M13 phage, etc.), viruses (retroviruses, vaccinia virus, adenovirus, adeno-associated virus (AAV), cauliflower mosaic virus, tobacco mosaic virus, baculovirus), and cosmids. Promoters can be appropriately selected depending on the type of host. When the host is an animal cell, for example, promoters derived from SV40 (Simian virus 40) or CMV (cytomegalovirus) can be used. When the host is E. coli, the trp promoter, T7 promoter, lac promoter, etc., can be used. The expression vector may also incorporate nucleic acids encoding DNA origins (ori), selection markers (antibiotic resistance, nutritional requirements, etc.), enhancers, splicing signals, polyadenylation signals, tags (FLAG, HA, GST, GFP, etc.).

[0276] Next, appropriate host cells are transformed using the above vector. The host can be appropriately selected depending on its relationship with the vector, and for example, Escherichia coli, Bacillus subtilis, Bacillus bacteria, yeast, insects or insect cells, or animal cells can be used. Examples of animal cells include HEK293T cells, CHO cells, COS cells, myeloma cells, HeLa cells, and Vero cells. Transformation can be carried out by known methods such as lipofection, calcium phosphate, electroporation, microinjection, or particle gun technology, depending on the type of host. The target peptide is expressed by culturing the transformed cells according to conventional methods. The peptide from the culture of the transformed cells can be purified as follows: Cultured cells are collected, suspended in an appropriate buffer, and then disrupted by sonication, freeze-thaw cycles, etc. The resulting lysates are centrifuged or filtered to obtain a crude extract. If peptides are secreted into the culture medium, the supernatant is collected. Purification of the crude extract or culture supernatant can also be carried out by known methods or methods based thereon (e.g., salting out, dialysis, ultrafiltration, gel filtration, SDS-PAGE, ion exchange chromatography, affinity chromatography, reverse-phase high-performance liquid chromatography).

[0277] The translation and synthesis system may be a cell-free translation system. Examples of cell-free translation systems include ribosomal proteins, aminoacyl-tRNA synthetase (ARS), ribosomal RNA, amino acids, rRNA, GTP, ATP, translation initiation factor (IF), elongation factor (EF), termination factor (RF), ribosomal regeneration factor (RRF), and other factors necessary for translation. To increase expression efficiency, E. coli extract or wheat bran extract may be added. Furthermore, rabbit red blood cell extract or insect cell extract may be added. By continuously supplying energy to the system containing these by dialysis, it is possible to produce several hundred μg to several mg / mL of protein. This system may also contain RNA polymerase for transcription from DNA. Commercially available cell-free translation systems include E. coli-derived systems such as Roche Diagnostics' "RTS-100™" or PGI's PURESYSTEM™, or systems using wheat germ extract from ZOEGENE or Cell-free Science. By using a cell-free translation system, high-purity peptides can be obtained without purifying the expression product.

[0278] In cell-free translation systems, artificial aminoacyl-tRNAs obtained by acyl-linking (acylation) a desired amino acid or hydroxy acid to tRNA can be used instead of aminoacyl-tRNAs synthesized by natural aminoacyl-tRNA synthetases. Such aminoacyl-tRNAs can be synthesized using artificial ribozymes. Examples of such ribozymes include flexizymes (see H. Murakami, A. Ohta, H. Ashigai, H. Suga (2006) Nature Methods 3, 357-359 “The flexizyme system: a highly flexible tRNA aminoacylation tool for the synthesis of nonnatural peptides”; International Publication No. 2007 / 066627, etc.). In addition to the original form of flexizyme (Fx), modified versions such as dinitrobenzyl flexizyme (dFx), enhanced flexizyme (eFx), and aminoflexizyme (aFx) are also known. By using tRNA conjugated with a desired amino acid or hydroxy acid, prepared using Flexizyme, the desired codon can be translated while associating it with the desired amino acid or hydroxy acid. Non-standard amino acids may be used as the desired amino acid. For example, non-natural amino acids necessary for the above cyclization can be introduced into the peptide by this method. For example, an in vitro system can be used in which nonsense mutations are suppressed using chemically aminoacylated suppressor tRNA. Transcription and translation of plasmids containing nonsense mutations can be carried out in a cell-free system, for example, using an E. coli S30 extract and commercially available enzymes and other reagents. The peptide can be purified by chromatography. As another example, translation can be performed in African clawed frog oocytes by microinjection of mutant mRNA and chemically aminoacylated suppressor tRNA.As yet another example, *E. coli* cells can be cultured in the absence of the native amino acid to be substituted (e.g., phenylalanine) and in the presence of a desired non-native amino acid(s) (e.g., 2-azaphenylalanine, 3-azaphenylalanine, 4-azaphenylalanine, or 4-fluorophenylalanine). The non-native amino acid can be incorporated into the peptide in place of the corresponding native amino acid. Native amino acid residues can also be converted to non-native species by in vitro chemical modification. Chemical modification can be combined with site-directed mutagenesis to further expand the range of substitutions.

[0279] The peptides described herein can also be produced by chemical synthesis (for example, by the method described in Solid Phase Peptide Synthesis, 2nd Edition, The Pierce Chemical Co., Rockford, Ill. (1984)). Modification of proteins can also be carried out by chemical synthesis.

[0280] target In some embodiments, the peptides described herein or conjugates containing the peptides bind to structures on cells, such as cell surface proteins. These structures may be proteins, peptides, or glycans that are overexpressed or selectively expressed on affected cells, such as cancer cells. In some embodiments, the structure may be an isoform or splicing variant of the protein or peptide. In some embodiments, the structure may be a protein or peptide that is post-translationally modified. In some embodiments, the structure may be a protein or peptide derived from a variant sequence of the gene from which the protein or peptide originates. In some embodiments, the structure may be a fragment or cleaved form of the protein or peptide. This structure may be a glycan expressed on affected cells, such as cancer cells. The glycan may be an O-glycan, N-glycan, GSL-glycan, glycolipid, etc. In some embodiments, the peptide binds to a glycan containing a cancer glycan epitope. In some embodiments, the peptide binds to cancer cells. In some embodiments, the peptide binds to non-cancer cells within the tumor environment. In some embodiments, the peptide binds to a fetal carcinogen, tight junction protein, adhesion protein, EPH-related tyrosine kinase receptor (TKR), and / or transporter protein. In some embodiments, the cell surface protein is a fetal carcinogen. In some embodiments, the fetal carcinogen is fetal carcinogen (CEA) or α-fetal protein (AFP). In some embodiments, the fetal carcinogen is fetal carcinogen-associated cell adhesion molecule 5 (CEACAM5). In some embodiments, the fetal carcinogen is tumor-associated calcium signaling transducer 2 (Trop-2). In some embodiments, the cell surface protein is an EPH-related tight junction protein. In some embodiments, the tight junction protein is a claudin (e.g., claudin 2, 3, 4, 7, 8, 12, 15, or 18), occludin, oligodendrocyte-specific protein (OSP), peripheral myelin protein (PMP), or junction adhesion molecule.In some embodiments, the cell surface protein is an adhesion protein. In some embodiments, the adhesion protein is nectin cell adhesion molecule 4 (nectin-4), carcinoembryonic antigen-associated cell adhesion molecule 5 (CEACAM5), mesothelin, or ephrin receptor. In some embodiments, the adhesion protein is selected from integrins, cadherins, selectins, and immunoglobulin-like cell adhesion molecules. In some embodiments, the cell surface protein is a tyrosine kinase receptor (TKR). In some embodiments, the tyrosine kinase receptor is an eph-related tyrosine kinase receptor. In some embodiments, the eph-related tyrosine kinase receptor is an ephrin A receptor or an ephrin B receptor. In some embodiments, the Eph receptor is an EPH receptor A2 (EPHA2). In some embodiments, the tyrosine kinase receptor is an epidermal growth factor receptor (EGFR), fibroblast growth factor receptor (FGFR), vascular endothelial growth factor receptor (VEGFR), ErbB receptor, RET receptor, or discoidin domain receptor (DDR). In some embodiments, the ErbB receptor is the Her2 receptor. In some embodiments, the cell surface protein is the transport receptor. In some embodiments, the transport receptor is the folate receptor 1 (FOLR1) or NaPi2b.

[0281] In some embodiments, the peptides described herein or conjugates containing the peptides bind to transmembrane glycoproteins. In some embodiments, the transmembrane glycoprotein is prostate-specific membrane antigen (PSMA), tumor-associated calcium signaling transducer 2 (Trop-2), somatostatin receptor type 2 (SSTR2), or carbonic anhydrase IX (CAIX). In some embodiments, the peptide binds to prostate-specific membrane antigen (PSMA). In some embodiments, the peptide binds to tumor-associated calcium signaling transducer 2 (Trop-2). In some embodiments, the peptide binds to folate receptor 1 (FOLR1). In some embodiments, the peptide binds to nectin cell adhesion molecule 4 (nectin-4). In some embodiments, the peptide binds to carcinoembryonic antigen-associated cell adhesion molecule 5 (CEACAM5). In some embodiments, the peptide binds to EPH receptor A2 (EPHA2). In some embodiments, the peptide binds to mesothelin, EPH receptor A2 (EPHA2), tumor-associated calcium signaling transducer 2 (Trop-2), somatostatin receptor type 2 (SSTR2), carbonic anhydrase IX (CAIX), delta-like 3 (DLL3), fibroblast-activating protein alpha (FAP-alpha), B7-H4, tumor endothelial marker 8 (TEM8), NaPi2b, claudin 18.2, tumor-associated glycoprotein 72 (TAG72), or CD70.

[0282] The peptides described herein or conjugates containing the peptides can bind to fetal carcinogens. In some embodiments, the peptides bind to fetal carcinogens encoded by genes selected from CEACAM1 (CEA), CEACAM5, CEACAM6, 5T4 (TPBG), ALPPL2, DLK1, PLAC1, SPA17, and AKAP4. In some embodiments, the peptides bind to fetal carcinogens, which are fetal carcinogen-associated cell adhesion molecule 1, fetal carcinogen-associated cell adhesion molecule 5, fetal carcinogen-associated cell adhesion molecule 6, trophoblast glycoprotein, alkaline phosphatase (germ cell type), protein delta homolog 1, placenta-specific protein 1, sperm surface protein Sp17, or A-kinase anchor protein 4.

[0283] Peptides or conjugates containing the peptides described herein can bind to tumor surface markers. In some embodiments, the peptides bind to tumor surface markers encoded by genes selected from ANKRD30A(NY-BR-1), C4.4A, CSPG4, CTA16.88, GD2, GPC3, GPNMB, KAAG1, LAMP-1, PSCA, PSMA, TAG-72, TROP2, and CD248(TEM1). In some embodiments, the peptides bind to tumor surface markers selected from ankyrin repeat domain-containing protein 30A, a homolog of the urokinase receptor, chondroitin sulfate proteoglycan 4, tumor-associated antigen 16.88, ganglioside GD2, glypican-3, transmembrane glycoprotein NMB, kidney-associated antigen 1, lysosome-associated membrane glycoprotein 1, prostate stem cell antigen, glutamate carboxypeptidase 2, tumor-associated glycoprotein 72, tumor-associated calcium signal transducer 2, and endosialin.

[0284] The peptides described herein or conjugates containing such peptides can bind to receptors or ligands. In some embodiments, the peptide binds to a receptor or ligand encoded by a gene selected from AMHR2, AXL, c-MET, CD123(IL3Ra), CD142(TF), KIT, MET, TDGF1(CRIPTO), CS1(SLAMF7), DLL3, DLL4, DR5(TRAILR2), EDNRB, EFNA4, EGFR, EGFRvlll, EPHA2, HER2(ERBB2), ETBR, FGFR2, FGFR2b, FGFR3, FLT3, FOLR1, GCC(GUCY2C), GFRA1, GRPR, HER3(ERBB3), IGF1R, IL13RA2, IL1RAP, IL3RA, KDR(VEGFR2), LIF, NOTCH3, NTSR1, PRLR, PTK7, ROR1, ROR2, SORT1, TENB2(TMEFF2), TFR1, and TMEFF1.In some embodiments, the peptide is anti-Müllerian hormone type 2 receptor, tyrosine protein kinase receptor UFO, hepatocyte growth factor receptor, interleukin 3 receptor subunit α, tissue factor, mast / stem cell growth factor receptor, hepatocyte growth factor receptor, teratocyte-derived growth factor 1, SLAM family member 7, delta-like protein 3, delta-like protein 4, TNF-related apoptosis-inducing ligand receptor 2, endothelin receptor type B, ephrin A4, epidermal growth factor receptor, epidermal growth factor receptor variant III, ephrin type A receptor 2, receptor tyrosine protein kinase erbB-2, endothelin B receptor, fibroblast growth factor receptor 2, fibroblast growth factor receptor 2 subtype b, fibroblast growth factor receptor 3, receptor tyrosine protein kinase FLT3, folate receptor α, It binds to receptors or ligands selected from guanylyl cyclase C, GDNF family receptor α-1, gastrin-releasing peptide receptor GRP-R, receptor tyrosine protein kinase erbB-3, insulin-like growth factor 1 receptor, interleukin 13 receptor subunit α-2, interleukin 1 receptor accessory protein, interleukin 3 receptor subunit α, vascular endothelial growth factor receptor 2, leukemia suppressor, neurogenic locus Notch homolog protein 3, neurotensin receptor type 1, prolactin receptor, inactive tyrosine protein kinase 7, inactive tyrosine protein kinase transmembrane receptor ROR1, tyrosine protein kinase transmembrane receptor ROR2, sorbitol, tomoregulin-2, transferrin receptor protein 1, and tomoregulin-1.

[0285] The peptides described herein or conjugates containing the peptides can bind to cell adhesion proteins and matrix proteins. In some embodiments, the peptides bind to cell adhesion proteins and matrix proteins encoded by genes selected from ADAM9, ALCAM, CDH6, CD105(ENG), CD138(SDC1), CD44, CD44v6, CD52, CD56(NCAM-1), Claudin 18.2, EPCAM(TROP1), ITGAV, see below, L1CAM, LRRC15, LYPD3, MSLN(mesoserine), MUC1, MUC16, MUC5AC, NCAM, Nectin-4, NRXN1, CDH3(P-cadherin), TEM8, and TNC. In some embodiments, the peptide binds to cell adhesion proteins and matrix proteins selected from disintegrin and metalloproteinase domain-containing protein 9, activated leukocyte adhesion molecule, cadherin-6, endoglin, syndecan-1, CD44 antigen, CD44 antigen variant 6, CAMPATH-1 antigen, nerve cell adhesion molecule 1, claudin-18 splice 2, epithelial cell adhesion molecule, integrin α-V, integrin, nerve cell adhesion molecule L1, leucine-rich repeat-containing protein 15, Ly6 / PLAUR domain-containing protein 3, mesothelin, mucin-1, mucin-16, mucin-5AC, nerve cell adhesion molecule, nectin-4, neurexin-1, cadherin-3, anthrax toxin receptor 1, and tenascin.

[0286] The peptides described herein or conjugates containing such peptides can be bound to immunomodulatory proteins. In some embodiments, the peptide binds to an immunomodulatory protein encoded by a gene selected from B7H4(VTCN), BCMA(TNFRSF17), CD19, CD205(LY75), CD206(MRC1), CD22(Siglec2), CD25(IL2RA), CD274(PD-L1), CD27L, CD3, CD30(TNFRSF8), CD32a, CD33(SIGLEC3), CD37(TSPAN26), CD46(MCP), CD70, CD74, CD79b, FCRL5, ICOS, LILRB4, LY6E, CD20(MS4A1), NKG2D, TIM-1(HAVCR1), CD137(4-1BB,TNFRSF9), ULBP1, ULBP2, and CD276(B7-H3). In some embodiments, the peptides include V-set domain-containing T cell activation inhibitor 1, tumor necrosis factor receptor superfamily member 17, B lymphocyte antigen CD19, lymphocyte antigen 75, macrophage mannose receptor 1, B cell receptor CD22, interleukin 2 receptor subunit α, programmed cell death 1 ligand 1, tumor necrosis factor receptor superfamily member 7, T cell surface glycoprotein CD3, tumor necrosis factor receptor superfamily member 8, low affinity immunoglobulin γFc region receptor Iia, myeloid cell surface antigen CD33, leukocyte antigen CD37, It binds to immunomodulatory proteins selected from membrane cofactor proteins, CD70 antigen, HLA class II histocompatibility antigen γ chain, B cell antigen receptor conjugate-associated protein β chain, Fc receptor-like protein 5, inducible T cell costimulatory factor, leukocyte immunoglobulin-like receptor subfamily B member 4, lymphocyte antigen 6E, B lymphocyte antigen CD20, NKG2-D type II membrane endogenous protein, T cell immunoglobulin and mucin domain 1, tumor necrosis factor receptor superfamily member 9, UL16-binding protein 1, UL16-binding protein 2, and CD276 antigen.

[0287] The peptides described herein or conjugates containing the peptides can bind to transporter proteins. In some embodiments, the peptides bind to transporter proteins encoded by genes selected from ASCT2(SLC1A5), LIV1(SLC39A6), NaPi2b, and SLC44A4. In some embodiments, the peptides bind to transporter proteins selected from neutral amino acid transporter B, zinc transporter ZIP6, sodium-dependent phosphate transporter protein 2B, and choline transporter-like protein 4.

[0288] The peptides described herein or conjugates containing the peptides can bind to membrane enzymes. In some embodiments, the peptides bind to membrane enzymes encoded by genes selected from ASPH, CA6, CA9 (CAIX), CD174 (FUT1), CD38, CDS, ENPP3, FAP, and MMP14 (MT1-MMP). In some embodiments, the peptides bind to membrane enzymes selected from aspartyl / asparaginyl β-hydroxylase, carbonic anhydrase 6, carbonic anhydrase 9, galactoside α-(1,2)-fucosyltransferase 1, ADP-ribosylcyclase / cyclic ADP-ribose hydrolase 1, phosphatidic acid cytidylyltransferase 1, ectonucleotide pyrophosphatase / phosphodiesterase family member 3, prolyl endopeptidase FAP, and matrix metalloproteinase-14.

[0289] The peptides described herein or conjugates containing the peptides can bind to multispan proteins. In some embodiments, the peptides bind to multispan proteins encoded by genes selected from SSTR2, STEAP1, SEZ6, and SLITRK6. In some embodiments, the peptides bind to multispan proteins selected from somatostatin receptor type 2, metalloreductase STEAP1, seizure protein 6 homolog, and SLIT and NTRK-like proteins 6.

[0290] Linker The conjugates described herein may include one or more linkers. In some embodiments, the linker covalently binds the peptide to the metal chelating agent. In some embodiments, the peptide binds directly to the metal chelating agent without a linker.

[0291] The linker may contain one or more amino acid residues. In some embodiments, the linker may contain 1-3, 1-5, 1-10, 5-10, or 5-20 amino acid residues. In some embodiments, the linker may contain 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid residues. In some embodiments, the linker may contain 1-5 amino acid residues. For example, the linker may contain one or more lysine (K) residues, such as K, KK, or KKK sequences. In some embodiments, the linker may contain lysine or a derivative thereof. In some embodiments, the linker may contain lysine. In some embodiments, one or more amino acids in the linker may be non-natural amino acids.

[0292] The linkers described herein can be bound to the N-terminus, C-terminus, or non-terminal amino acids of a peptide, or through a combination of the above. In some embodiments, the linker is bound to the peptide via its N-terminus. In some embodiments, the linker is bound to the peptide via its C-terminus. In some embodiments, the linker is bound to the peptide via a non-terminal amino acid. The linker can be bound to the peptide, the metal chelating agent, or both, for example, via a chemically reactive group. Examples of chemically reactive groups include, but are not limited to, free amino, imino, hydroxyl, thiol, or carboxyl groups (e.g., N-terminus or C-terminus, ε-amino groups of one or more lysine residues, free carboxylic acid groups of one or more glutamic acid or aspartic acid residues, or sulfhydryl groups of one or more cysteinyl residues). The linker binding site on the peptide may be a native or non-native amino acid of the peptide, and / or may be introduced into the peptide by, for example, DNA recombination techniques (e.g., by introducing a cysteine ​​or protease cleavage site into the amino acid sequence) or by protein biochemistry (e.g., reduction, pH adjustment, or proteolysis). Exemplary methods for linking the linker include carbodiimide reactions, reactions using bifunctional reagents such as dialdehydes or imide esters, Schiff base reactions, Suzuki-Miyaura cross-coupling reactions, isothiocyanates as coupling agents, and click chemistry.

[0293] The linker can have a predetermined length, thereby allowing the metal chelating agent (and optionally a radionuclide) and the peptide to be linked while maintaining an appropriate distance between them. In some embodiments, the linker has a length of 1 to 100 atoms, 1 to 60 atoms, 1 to 30 atoms, 1 to 15 atoms, 1 to 10 atoms, 1 to 5 atoms, or 2 to 20 atoms. In some embodiments, the linker has a length of 1 to 10 atoms.

[0294] Linkers may include flexible and / or rigid regions. Exemplary flexible linker regions include those containing glycine and ser residues ("GS" linkers), glycine residues, alkylene chains, and PEG chains. Exemplary rigid linker regions include α-helix-forming sequences (e.g., EAAAK (SEQ ID NO: 11)), proline-rich sequences, and double and / or triple bond-rich regions.

[0295] The linker may be cleavable, for example, under physiological conditions, such as intracellular conditions, such as when the linker is cleaved, so that the chelating agent and radionuclide are released into the intracellular environment. The linker may be a peptidyl linker that is cleaved by an intracellular peptidase or protease enzyme, such as, but not limited to, lysosomal proteases or endosomal proteases. In some embodiments, the peptidyl linker is at least 2 amino acid long, or at least 3 amino acid long. Examples of cleaving agents include cathepsins B and D, and plasmin. In other embodiments, the linker is not cleavable. In some embodiments, the linker is pH sensitive, i.e., sensitive to hydrolysis at a specific pH value. For example, a pH-sensitive linker may be hydrolyzable under acidic conditions. For example, the linker may be an acid-unstable linker that is hydrolyzable in lysosomes (e.g., hydrazone, semicarbazone, thiosemicarbazone, cis-aconitate amide, orthoester, acetal, ketal, etc.). Such linkers are relatively stable under neutral pH conditions, such as in blood, but become unstable at pH 5.5 or below 5.0, which is the approximate pH of lysosomes. In some embodiments, the hydrolyzable linker is a thioether linker.

[0296] In some embodiments, the linker comprises one or more of the following: substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl. In some embodiments, the linker comprises substituted or unsubstituted C1-C 30 Contains alkylene. In some embodiments, the linker is (-CH2-CH2-O-) 1~10 It contains polyethylene glycol, etc. In some embodiments, the linker is

[0297] [ka] Includes structures selected from and structures derived from any one of them.

[0298] In some embodiments, the linker includes click chemistry residues. In some embodiments, the linker is bound to the peptide, the metal chelating agent, or both via click chemistry, thereby forming click chemistry residues. For example, the peptide may contain an azide group (at the N-terminus, C-terminus, or non-terminal amino acid) that reacts with the alkyne moiety of the linker. In another example, the peptide may contain an alkyne group (at the N-terminus, C-terminus, or non-terminal amino acid) that reacts with the azide of the linker. The metal chelating agent and the linker can be bound together in a similar manner. In some embodiments, the linker includes an azide moiety, an alkyne moiety, or both. In some embodiments, the linker includes a triazole. In some embodiments, the click chemistry residues are

[0299] [ka] In some embodiments, the click chemistry residue is a DIBO-azide residue, a BARAC-azide residue, a DBCO-azide residue, a DIFO-azide residue, a COMBO-azide residue, a BCN-azide residue, or a DIMAC-azide residue. In some embodiments, the linker includes a nitron bipolar cycloaddition residue. In some embodiments, the linker includes a tetrazine ligation residue. In some embodiments, the linker includes a quadriclan ligation residue. Exemplary click chemistry residues are shown in Hein et al., “Click Chemistry, A Powerful Tool for Pharmaceutical Sciences,” Pharmaceutical Research volume 25, pages 2216-2230 (2008); Thirumurugan et al., “Click Chemistry for Drug Development and Diverse Chemical-Biology Applications,” Chem. Rev. 2013, 113, 7, 4905-4979; U.S. Patent Application Publication No. 20160107999(A1); U.S. Patent No. 10266502(B2); and U.S. Patent Application Publication No. 20190204330(A1), each of which is incorporated herein by reference in its entirety.

[0300] In some embodiments, the linkers described herein include two or more motifs. In some embodiments, one or more motifs are linked via click chemistry and can be added to / out of the linker by click. Each motif within the linker can have an independent function. For example, the linker may include a motif that functions to regulate the plasma half-life and / or a motif that functions as a spacer between the peptide and the metal chelator.

[0301] In some embodiments, the linker is structure

[0302] [ka] (In the formula, each L is independently -O-, -NR) L -, -N(R L )2 + -, -OP(=O)(OR L )O-, -S-, -S(=O)-, -S(=O)2-, =CH-, -C(=O)-, -C(=O)O-, -OC(=O)-, -OC(=O)O-, -C(=O)NR L -, -NR L C(=O)-, -OC(=O)NR L -, -NR L C(=O)O-, -NR L C(=O)NR L -, -NR L C(=S)NR L -, -CR L =N-, -N=CR L , -NR L S(=O)2-, -S(=O)2NR L -, -C(=O)NR L S(=O)2-, -S(=O)2NR L C(=O)-, substitution or non-substitution of C3~C 15 Cycloalkyl, substituted or unsubstituted C1-C 12 Heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted C1-C 30 Alkylene, substituted or unsubstituted C2-C 30 Alkenylenes, substituted or unsubstituted C2-C2 30 Alkynylene, substituted or unsubstituted C1-C 30 Heteroalkylene, -(C1~C 30 Alkylene)-O-, -O-(C1~C 30 Alkylene)-,-(C1~C 30 Alkylene)-NR L -, -NR L -(C1~C 30 Alkylene)-,-(C1~C 30 Alkylene)-N(R L )2 + -, -N(R L )2 + -(C1~C30 Alkylene)-, or click chemistry residue, Each R L These are independently hydrogen, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted C1-C4 heteroalkyl, substituted or unsubstituted C2-C6 alkenyl, substituted or unsubstituted C2-C5 alkynyl, substituted or unsubstituted C3-C8 cycloalkyl, substituted or unsubstituted C2-C7 heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl. n has 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15.

[0303] In some embodiments, the linker is structure

[0304] [ka] (wherein L is independently -O-, -NR) L -, -N(R L )2 + -, -OP(=O)(OR L )O-, -S-, -S(=O)-, -S(=O)2-, -CH=CH-, =CH-, -C≡C-, -C(=O)-, -C(=O)O-, -OC(=O)-, -OC(=O)O-, -C(=O)NR L -, -NR L C(=O)-, -OC(=O)NR L -, -NR L C(=O)O-, -NR L C(=O)NR L -, -NR L S(=O)2-, -S(=O)2NR L -, -C(=O)NR L S(=O)2-, or -S(=O)2NR L C(=O)-)

[0305] In some embodiments, the linker is substituted or unsubstituted C1-C 30 Alkylene, C1~C 12The linker contains alkylene, C1-C8 alkylene, C1-C6 alkylene, or C2-C6 alkylene. In some embodiments, the linker contains C2-C6 alkylene. In some embodiments, the linker contains C4-C6 alkylene.

[0306] In some embodiments, the linker is structure

[0307] [ka] (In the formula, each L 1 , L 2 , and L 3 These are independently -O- and -NR L -, -N(R L )2 + -, -OP(=O)(OR L )O-, -S-, -S(=O)-, -S(=O)2-, =CH-, -C(=O)-, -C(=O)O-, -OC(=O)-, -OC(=O)O-, -C(=O)NR L -, -NR L C(=O)-, -OC(=O)NR L -, -NR L C(=O)O-, -NR L C(=O)NR L -, -NR L C(=S)NR L -, -CR L =N-, -N=CR L , -NR L S(=O)2-, -S(=O)2NR L -, -C(=O)NR L S(=O)2-, -S(=O)2NR L C(=O)-, substitution or non-substitution of C3~C 15 Cycloalkyl, substituted or unsubstituted C1-C 12 Heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted C1-C 30 Alkylene, substituted or unsubstituted C2-C 30 Alkenylenes, substituted or unsubstituted C2-C2 30 Alkynylene, substituted or unsubstituted C1-C30 Heteroalkylenes, substituted or unsubstituted C1-C 15 Arirene, -(C1~C 30 Alkylene)-O-, -O-(C1~C 30 Alkylene)-,-(C1~C 30 Alkylene)-NR L -, -NR L -(C1~C 30 Alkylene)-,-(C1~C 30 Alkylene)-N(R L )2 + -, -N(R L )2 + -(C1~C 30 Alkylene)-, or click chemistry residue, R is hydrogen, azide, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted C1-C4 heteroalkyl, substituted or unsubstituted C2-C6 alkenyl, substituted or unsubstituted C2-C5 alkynyl, substituted or unsubstituted cycloalkynyl, substituted or unsubstituted C3-C 30 Cycloalkyl, substituted or unsubstituted C2-C 30 A heterocycloalkyl, a substituted or unsubstituted aryl, or a substituted or unsubstituted heteroaryl, R L This includes hydrogen, substituted or unsubstituted C1-C4 alkyl groups, substituted or unsubstituted C1-C4 heteroalkyl groups, substituted or unsubstituted C2-C6 alkenyl groups, substituted or unsubstituted C2-C5 alkynyl groups, and substituted or unsubstituted C3-C6 groups. 30 Cycloalkyl, substituted or unsubstituted C2-C 30 A heterocycloalkyl, a substituted or unsubstituted aryl, or a substituted or unsubstituted heteroaryl, X is N or CR L And, m, p, and q each independently have (0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15).

[0308] In some embodiments, the linker is structured

[0309] [ka] (In the formula, each L 1 and L 2 These are independently -O- and -NR L -, -N(R L )2 + -, -OP(=O)(OR L )O-, -S-, -S(=O)-, -S(=O)2-, -CH=CH-, =CH-, -C≡C-, -C(=O)-, -C(=O)O-, -OC(=O)-, -OC(=O)O-, -C(=O)NR L -, -NR L C(=O)-, -OC(=O)NR L -, -NR L C(=O)O-, -NR L C(=O)NR L -, -NR L S(=O)2-, -S(=O)2NR L -, -C(=O)NR L S(=O)2-, -S(=O)2NR L C(=O)-, substitute or non-substitute C1~C 20 Alkylene, or -(CHR L -CHR L -O) 1~10 -and, R L These are hydrogen, substituted or unsubstituted C1-C4 alkyl groups, substituted or unsubstituted C1-C4 heteroalkyl groups, substituted or unsubstituted C2-C6 alkenyl groups, substituted or unsubstituted C2-C5 alkynyl groups, substituted or unsubstituted C3-C8 cycloalkyl groups, or substituted or unsubstituted C2-C7 heterocycloalkyl groups. R is hydrogen, azide, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted C1-C4 heteroalkyl, substituted or unsubstituted C2-C6 alkenyl, substituted or unsubstituted C2-C5 alkynyl, substituted or unsubstituted cycloalkynyl, substituted or unsubstituted C3-C8 cycloalkyl, substituted or unsubstituted C2-C7 heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl. m is between 1 and 10, and p is between 0 and 3.

[0310] In some embodiments, L 2 -O-, -NR L -, -N(R L )2 + -, -OP(=O)(OR L )O-, -S-, -S(=O)-, -S(=O)2-, -C(=O)-, -C(=O)O-, -OC(=O)-, -OC(=O)O-, -C(=O)NR L -, -NR L C(=O)-, -OC(=O)NR L -, -NR L C(=O)O-, -NR L C(=O)NR L -, -NR L S(=O)2-, -S(=O)2NR L -, -C(=O)NR L S(=O)2-, -S(=O)2NR L C(=O)-, substituted or unsubstituted C1-C6 alkylene, or -(CH2-CH2-O) 1~6 -and, L 1 -O-, -NR L -, -N(R L )2 + -, -OP(=O)(OR L )O-, -S-, -S(=O)-, -S(=O)2-, -CH=CH-, =CH-, -C≡C-, -C(=O)-, -C(=O)O-, -OC(=O)-, -OC(=O)O-, -C(=O)NR L -, -NR L C(=O)-, -OC(=O)NR L -, -NR L C(=O)O-, -NR L C(=O)NR L -, -NR L S(=O)2-, -S(=O)2NR L -, -C(=O)NR L S(=O)2-, -S(=O)2NR L C(=O)-, substitute or non-substitute C1~C 20 Alkylene, or -(CH2-CH2-O)1~6 -and, R L is hydrogen, or a substituted or unsubstituted C1-C4 alkyl group. R is hydrogen, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted C3-C 30 Cycloalkyl, substituted or unsubstituted C2-C 30 A heterocycloalkyl, a substituted or unsubstituted aryl, or a substituted or unsubstituted heteroaryl, m ranges from 1 to 10, and p ranges from 0 to 3.

[0311] In some embodiments, the linker is structure

[0312] [ka] (In the formula, L 2 -O-, -NR L -, -N(R L )2 + -, -OP(=O)(OR L )O-, -S-, -S(=O)-, -S(=O)2-, -C(=O)-, -C(=O)O-, -OC(=O)-, -OC(=O)O-, -C(=O)NR L -, -NR L C(=O)-, -OC(=O)NR L -, -NR L C(=O)O-, -NR L C(=O)NR L -, -NR L S(=O)2-, -S(=O)2NR L -, -C(=O)NR L S(=O)2-, -S(=O)2NR L C(=O)-, substituted or unsubstituted C1-C6 alkylene, or -(CH2-CH2-O) 1~6 -and, L 1 -O-, -NR L -, -N(R L )2 + -, -OP(=O)(OR L)O-, -S-, -S(=O)-, -S(=O)2-, -CH=CH-, =CH-, -C≡C-, -C(=O)-, -C(=O)O-, -OC(=O)-, -OC(=O)O-, -C(=O)NR L -, -NR L C(=O)-, -OC(=O)NR L -, -NR L C(=O)O-, -NR L C(=O)NR L -, -NR L S(=O)2-, -S(=O)2NR L -, -C(=O)NR L S(=O)2-, -S(=O)2NR L C(=O)-, substitute or non-substitute C1~C 20 Alkylene, or -(CH2-CH2-O) 1~6 -and, R L is hydrogen, or a substituted or unsubstituted C1-C4 alkyl group. R is hydrogen, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted C3-C 30 Cycloalkyl, substituted or unsubstituted C2-C 30 Heterocycloalkyl, substituted or unsubstituted C6-C 10 An aryl, or a substituted or unsubstituted C5-C9 heteroaryl, m is between 1 and 4, and p is between 0 and 3.

[0313] In some embodiments, R is hydrogen, substituted or unsubstituted C6-C 10 These are aryls, substituted or unsubstituted C5-C9 heteroaryls, or sterols.

[0314] In some embodiments, at least one L 1 This is unsubstituted C3~C 20 It is alkylene.

[0315] In some embodiments, the linker is substituted or unsubstituted C6-C 10Aryls, substituted or unsubstituted C5-C9 heteroaryls, sterols, sulfonamides, phosphate esters, polyethylene glycols, or C3-C 20 It contains alkylene or one or more amino acid residues.

[0316] In some embodiments, the linker is

[0317] [ka] In some embodiments, the linker is ricin or contains ricin. In some embodiments, the linker is C1-C 12 It contains alkylene. In some embodiments, the linker contains C3-C9 alkylene. In some embodiments, the linker contains C2-C8 alkylene. In some embodiments, the linker contains 1-10 repeating ethylene glycol units. In some embodiments, the linker contains 2-4 repeating ethylene glycol units. In some embodiments, the linker contains 5-8 repeating ethylene glycol units. In some embodiments, the linker contains NH2-(CH2)n-COOH, where n is 1-12. In some embodiments, the linker contains NH2-(CH2)2-COOH. In some embodiments, the linker contains NH2-(CH2)3-COOH. In some embodiments, the linker contains NH2-(CH2)4-COOH. In some embodiments, the linker contains NH2-(CH2)5-COOH. In some embodiments, the linker contains NH2-(CH2)6-COOH. In some embodiments, the linker contains NH2-(CH2)7-COOH. In some embodiments, the linker contains NH2-(CH2)8-COOH. In some embodiments, the linker contains NH2-(CH2) 10 -Contains COOH. In some embodiments, the linker is absent.

[0318] In some embodiments, the linker is configured to reversibly bind to plasma proteins such as albumin. In some embodiments, the dissociation constant (Kd) between the linker and human serum albumin is up to 15 μM, measured at room temperature under human serum conditions. In some embodiments, Kd is about 0.1 nM to about 10 μM. In some embodiments, Kd is about 10 nM to about 10 μM. In some embodiments, Kd is about 50 nM to about 1 μM. In some embodiments, Kd is about 100 nM to about 10 μM.

[0319] Metal chelating agents In one embodiment, a conjugate comprising a metal chelating agent configured to bind to a radionuclide is described herein. The metal chelating agent may refer to a portion of the conjugate configured to bind to a radionuclide. In some embodiments, the conjugate described herein comprises two or more independent metal chelating agents, e.g., two, three, four, five or more metal chelating agents. In some embodiments, the conjugate described herein comprises two metal chelating agents, which may be the same or different. The metal chelating agents can be bound to a linker or peptide via any preferred group / atom of the chelating agent.

[0320] In some embodiments, the metal chelating agent can bond to a radioactive atom. The bond may be direct; for example, the metal chelating agent may form a hydrogen bond or electrostatic interaction with the radioactive atom. The bond may be indirect; for example, the metal chelating agent may bond to a molecule containing the radioactive atom. In some embodiments, the metal chelating agent includes or is a macrocyclic molecule. In some embodiments, the metal chelating agent includes or is 2,2',2",2'"-(1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrayl)tetraacetic acid (DOTA) or 1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA). In some embodiments, the metal chelating agent includes a macrocyclic compound, which may include, for example, O and / or N, DOTA, NOTA, one or more amines, one or more ethers, one or more carboxylic acids, EDTA, DTPA, TETA, DO3A, PCTA, or desferrioxamine.

[0321] In some embodiments, the metal chelating agent comprises multiple amines. In some embodiments, the metal chelating agent comprises four or more N atoms, or four or more carboxylic acid groups, or a combination thereof. In some embodiments, the metal chelating agent does not contain S. In some embodiments, the metal chelating agent comprises a ring. In some embodiments, the ring comprises O and / or N. In some embodiments, the metal chelating agent is a ring comprising three or more N atoms, or three or more carboxylic acid groups, or a combination thereof. In some embodiments, the metal chelating agent is polydentate.

[0322] In some embodiments, the metal chelating agents described herein include cyclic chelating agents. Exemplary cyclic chelating agents include AAZTA, BAT, BAT-TM, Crown, Cyclen, DO2A, CB-DO2A, DO3A, H3HP-DO3A, Oxo-DO3A, p-NH2-Bn-Oxo-DO3A, DOTA, DOTA-3py, DOTA-PA, DOTA-GA, DOTA-4AMP, DOTA-2py, DOTA-1py, p-SCN-Bn-DOTA, CHX-A”-EDTA, and MeO-DOTA-NCS. EDTA, DOTAMAP, DOTAGA, DOTAGA-anhydride, DOTMA, DOTASA, DOTAM, DOTP, CB-Cyclam, TE2A, CB-TE2A, CB-TE2P, DM-TE2A , MM-TE2A, NOTA, NOTP, HEHA, HEHA-NCS, p-SCN-Bn-HEHA, DTPA, CHX-A”-DTPA, p-NH2-Bn-CHX-A”-DTPA, p-SCN-DTP A, p-SCN-Bz-Mx-DTPA, 1B4M-DTPA, p-SCN-Bn1B-DTPA, p-SCN-Bn-1B4M-DTPA, p-SCN-Bn-CHX-A”-DTPA, PEPA, p-SCN-Bn-PEPA, TETPA, DOTPA, DOTMP, DOTPM, t-Bu-calix[4]arene-tetracarboxylic acid, macropa, macropa-NCS, macropid, H3L 1 H3L 4 ,H2azapa,H5decapa,bispa 2 , H4pypa, H4octapa, H4CHXoctapa, p-SCN-Bn-H4octapa, p-SCN-Bn-H4octapa, TTHA, p-NO2-Bn-neunpa, H4octox, H2macropa, H2bispa 2H4phospa, H6phospa, p-SCN-Bn-H6phospa, TETA, p-NO2-Bn-TETA, TRAP, TPA, H BED, SHBED, HBED-CC, (HBED-CC), TFP, DMSA, DMPS, DHLA, TGA, BAL, and BALバゾン, p-SCN-NOTE, nNOTE, NODAGA, CB-TE1A1P, 3P-C-NETA-NCS, 3p-C-DEPA, 3P-C- DEPA-NCS, TCMC, PCTA, NODIA-Me, TACN, pycup1A1B, pycup2A, THP, DEDPA, H2DEDP A, p-SCN-Bn-H2DEDPA, p-SCN-Bn-TCMC, NTA, NOC, 3p-C-NETA, p-NH2-B n-TE3A, SarAr, DiAmSar, SarAr-NCS, AmBaSar, BaBaSar, TACN-TM, CP256, C-NE3T A, C-NE3TA-NCS, NODASA, NETA-モノアド, C-NETA, NOPO, BPCA, p-SCN-Bn-DFO, DFO-C hX-Mal、DFO、DFO-IAC、DFO-BAC、DiP-LICAM、EC、SBAD、BAPEN、TACHPYR、NEC-SP、L pyExamples include, but are not limited to, L1, L2, L3, and EuK-106. In some embodiments, the metal chelating agent is DOTA, TRITA, TETA, DOTA-MA, DO3A-HP, DOTMA, DOTA-pNB, DOTP, DOTMP, DOTEP, DOTMPE, F-DOTPME, DOTPP, DOTBzP, DOTA-monoamide, p-NCS-DOTA, p-NCS-PADOTA, BAT, DO3TMP-monoamide, p-NCS-TRITA, NOTA, or CHX-A”-DTPA. In some embodiments, the metal chelating agents described herein include acyclic chelating agents. Exemplary acyclic chelating agents include DTA, CyEDTA, EDTMP, DTPMP, DTPA, CyD Examples of metal chelating agents described herein include, but are not limited to, TPA, Cy2DTPA, DTPA-MA, DTPA-BA, and BOPA. In some embodiments, the metal chelating agents described herein include DOTA, DOTP, DOTMA, DOTAM, DTPA, NTA, EDTA, DO3A, DO2A, NOC, NOTA, TETA, TACN, DiAmSar, CB-Cyclam, CB-TE2A, DOTA-4AMP, or NOTP. In some embodiments, the metal chelating agents described herein include H4pypa, H4octox, H4octapa, p-NO2-Bn-neunpa, p-SCN-Bn-H4neunpa, TTHA, t Bu4pypa-C7-NHS, H4neunpa, H2macropa, HP-DO3A, BT-DO3A, DO3A-Nprop, DO3AP, DO2A2P, DOA3P, DOTP, DOTPMB, DOTAMAE, DOTAMAP, DO3AM Bu , DOTMA, TCE-DOTA, DEPA, PCTA, p-NO2-Bn-PCTA, p-NO2-Bn-DOTA, symPC2APA, symPCA2PA, asymPC2APA, asymPCA2PA, TRAP, AAZTA, DATA m Includes THP, HEHA, or HBED.

[0323] In some embodiments, the metal chelating agent is DO3A. In some embodiments, the metal chelating agent is PEPA. In some embodiments, the metal chelating agent is EDTA. In some embodiments, the metal chelating agent is CHX-A”-DTPA. In some embodiments, the metal chelating agent is HEHA. In some embodiments, the metal chelating agent is DOTMP. In some embodiments, the metal chelating agent is t-Bu-calix[4]arene-tetracarboxylic acid. In some embodiments, the metal chelating agent is macropa. In some embodiments, the metal chelating agent is macropa-NCS. In some embodiments, the metal chelating agent is H4pypa. In some embodiments, the metal chelating agent is H4octapa. In some embodiments, the metal chelating agent is H4CHXoctapa. In some embodiments, the metal chelating agent is DOTP. In some embodiments, the metal chelating agent is crown.

[0324] In some embodiments, the metal chelating agent is DOTA. In some embodiments, the metal chelating agent is a chiral derivative of DOTA. Exemplary chiral DOTA chelating agents are described in Dai et al., Nature Communications (2018) 9:857. In some embodiments, the metal chelating agent is 2,2',2",2'"-((2S,5S,8S,11S)-2,5,8,11-tetramethyl-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrayl)tetraacetic acid. In some embodiments, the metal chelating agent is structural

[0325] [ka] It has. In some embodiments, the metal chelating agent is 2,2',2",2'"-((2S,5S,8S,11S)-2,5,8,11-tetraethyl-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrayl)tetraacetic acid. In some embodiments, the metal chelating agent has structure

[0326] [ka] It has.

[0327] In some embodiments, the metal chelating agent is structure

[0328] [ka] The formula has a structure in which each R is independently selected from hydrogen, alkyl, haloalkyl, hydroxyalkyl, aminoalkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkylcycloalkyl, alkylheterocycloalkyl, alkylaryl, alkylheteroaryl, or amino acid side chains. In some embodiments, the metal chelating agent is structure

[0329] [ka] The formula comprises, where each R is independently selected from hydrogen, alkyl, haloalkyl, hydroxyalkyl, aminoalkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkylcycloalkyl, alkylheterocycloalkyl, alkylaryl, alkylheteroaryl, or an amino acid side chain.

[0330] In some embodiments, the conjugate includes DOTA. In some embodiments, the conjugate includes DOTA derivatives such as p-SCN-Bn-DOTA and MeO-DOTA-NCS. In some embodiments, the conjugate includes two independent metal chelating agents, at least one or both of which are DOTA. Structures of some exemplary metal chelating agents are shown in Figures 2 to 16 (bonding points are not shown). Exemplary metal chelating agents are further described in International Publication No. 2012 / 174136; U.S. Patent Application Nos. 20130183235(A1) and 20120219495(A1); Ramogida et al., EJNMMI radiopharm.chem. 4, 21 (2019); Thiele et al., Cancer Biotherapy and Radiopharmaceuticals 2018; Li et al., Bioconjugate Chem. 2019, 30, 5, 1539-1553; and Baranyai et al., Eur.J.Inorg.Chem. 36-56 (2020), each of which is incorporated herein by reference in its entirety.

[0331] Radioactive nuclides In one embodiment, a conjugate containing a radionuclide is described herein. Generally, the type of radionuclide used in therapeutic radiopharmaceuticals can be adapted to the specific type of cancer, the type of target portion (e.g., binding peptide), etc. Radionuclides that undergo alpha decay produce a particle consisting of two neutrons and two protons, while radionuclides that undergo beta decay emit high-energy electrons from their nucleus. Some radionuclides may also emit Augers. In some embodiments, the conjugate includes an alpha-emitting radionuclide. Alpha rays can cause direct and irreparable double-strand DNA breaks, compared to gamma and beta rays, which cause single-strand breaks through indirect DNA damage. In the design of radiopharmaceutical conjugates, the range of these particles in tissue and the half-life of the radionuclide may also be considered. Tables 5A and 5B below show some characteristics of exemplary radionuclides.

[0332] [Table 12]

[0333] [Table 13]

[0334] In some embodiments, the conjugate described herein comprises one or more independent radionuclides. In some embodiments, the conjugate comprises two radionuclides. In some embodiments, each of the one or more radionuclides is bound to the metal chelating agent of the conjugate. In some embodiments, the two radionuclides of the conjugate are bound to the same metal chelating agent. In some embodiments, the two radionuclides of the conjugate are bound to two independent metal chelating agents. In some embodiments, each of the one or more radionuclides is an alpha-emitting radionuclide.

[0335] In some embodiments, the conjugate described herein includes an alpha-emitting radionuclide. In some embodiments, the alpha-emitting radionuclide is actinium-225( 225 Ac), Astatine-211 ( 211 At), Radium-223 ( 223 Ra), Radium-224 224 Ra), Bismuth-213 213 Bi), Terbium-149( 149 Tb), or Thorium-227( 227 Th) is the alpha particle-emitting radionuclide. In some embodiments, the alpha particle-emitting radionuclide is 225 It is Ac. In some embodiments, the alpha particle-emitting radionuclide is 213 It is Bi. In some embodiments, the alpha particle-emitting radionuclide is 212 It is Bi. In some embodiments, the alpha particle-emitting radionuclide is 212It is Pb. In some embodiments, the alpha particle-emitting radionuclide is 224 It is Ra. In some embodiments, the alpha particle-emitting radionuclide is 223 It is Ra. In some embodiments, the alpha particle-emitting radionuclide is 227 Th is used. In some embodiments, the alpha particle-emitting radionuclide is 211 At. In some embodiments, alpha particle-emitting radionuclides are 149 Tb. In some embodiments, the radioactive nuclide is zirconium-89( 89 Zr) is the radioactive nuclide. In some embodiments, the radioactive nuclide is zirconium-89( 89 Zr). In some embodiments, the conjugate described herein is 67 Cu, 64 Cu, 89 Zr, 90 Y, 109 Pd, 111 Ag, 149 PM, 153 Sm, 166 Ho, 99m Tc, 67 Ga, 68 Ga, 111 In, 90 Y, 177 Lu, 186 Re, 188 Re, 197 Au, 198 Au, 199 Au, 105 Rh, 165 Ho, 161 Tb, 149 PM, 44 Sc, 47 Sc, 70 As, 71 As, 72 As, 73 As, 74 As, 76 As, 77 As, 212 Pb, 212 Bi, 213 Bi, 225 Ac, 117m Sn, 67 Ga, 201Tl, 123 I, 131 I, 160 Gd, 148 Nd, 89 Sr, and 211 It includes radionuclides selected from At. In some embodiments, the radionuclides are 225 It is Ac. In some embodiments, the radionuclide is 221 Fr, 217 At, 213 Bi, 213 Po, 209 Tl, 209 Pb, or 209 Bi, etc. 225 It is a decay product of Ac. In some embodiments, the conjugate consists of two 225 It contains Ac radionuclides. In some embodiments, the radionuclides are 177 Lu. In some embodiments, the conjugate consists of two 177 Contains Lu radioactive nuclide.

[0336] In some embodiments, the conjugate comprises an alpha-emitting radionuclide bound to a metal chelating agent. In some embodiments, the alpha-emitting radionuclide is actinium-225, astatine-211, thorium-227, or radium-223. In some embodiments, the alpha-emitting radionuclide is actinium-225.

[0337] In some embodiments, the conjugate comprises a beta-particle emitting radionuclide bound to a metal chelating agent. In some embodiments, the beta-particle emitting radionuclide is zirconium-89, yttrium-90, iodine-131, samarium-153, lutetium-177, or lead-212.

[0338] In some embodiments, the conjugate includes a gamma-emitting radionuclide. In some embodiments, the gamma-emitting radionuclide is indium-111.

[0339] In some embodiments, the conjugates described herein do not contain any radionuclides, i.e., they are non-radioactive conjugates. For example, in some cases, for testing and experimental purposes, radionuclides may be replaced with substitutes (e.g., 225 (AC can be replaced with lantern.) Conjugates containing non-radioactive drugs

[0340] In one embodiment, a conjugate comprising a peptide, a non-radioactive drug, and optionally a linker is described herein. In some embodiments, the conjugate further comprises a metal chelating agent and optionally a radionuclide bound to the metal chelating agent. The peptide may be cyclic or acyclic, and may be monocyclic, bicyclic, or polycyclic. In one embodiment, a conjugate comprising a cyclic peptide and a non-radioactive drug is described herein. In some embodiments, the peptide (such as a cyclic peptide) is configured to bind to a target. The conjugates described herein may further comprise a linker.

[0341] Non-radioactive drugs can be toxins. In some embodiments, the toxin is selected from Pseudomonas exotoxin (PE), debuganin, bougain, diphtheria toxin (DT), and ricin. Non-radioactive drugs can be chemotherapeutic agents.

[0342] Non-radioactive drugs can be cytotoxic drugs. Examples of cytotoxic drugs include apridin, azalibine, anastrozole, azacitidine, bleomycin, bortezomib, bryostatin-1, busulfan, calitiamycin, camptothecin, 10-hydroxycamptothecin, carmustine, Celebrex, chlorambucil, cisplatin, irinotecan (CPT-11), SN-38, carboplatin, cladribine, cyclophosphoamide, cytarabine, dacarbazine, docetaxel, and dactinophosphate. Mycin, daunomiysingl clonide, daunorubicin, dexamethasone, diethylstilbestrol, doxorubicin, 2-pyrrolinodoxorubicin (2P-DOX), cyanomorpholinodoxorubicin, doxorubisingl clonide, epirubicingl clonide, ethinylestradiol, estramustine, etoposide, etoposide glucuronide, etoposide phosphate, floxuridine (FUdR), 3',5'-O-dioleoyl-FudR FUdR-dO), fludarabine, flutamide, fluorouracil, fluoxymesterone, gemcitabine, hydroxyprogesterone caproate, hydroxyurea, idarubicin, ifosphamide, L-asparaginase, leucovorin, lomustine, mechloretamine, medroprogesterone acetate, megestrol acetate, melphalan, mercaptopurine, 6-mercaptopurine, methotrexate, mitoxantrone, mitramycin, mitomycin Examples include mitotane, phenyl butyrate, prednisone, procarbazine, paclitaxel, pentostatin, PSI-341, semustine streptozocin, tamoxifen, taxane, taxol, testosterone propionate, thalidomide, thioguanine, thiotepa, teniposide, topotecan, uracil mustard, velcade, vinblastine, vinorelbine, vincristine, lysine, abrin, ribonuclease, onconase, rapLR1, DNase I, staphylococcal enterotoxin A, pokeweed antiviral protein, geronin, diphtheria toxin, Pseudomonas exotoxin, Pseudomonas endotoxin, or combinations thereof.

[0343] In some embodiments, the non-radioactive drug is duocalmycin and its analogues, dorastatin, combretastatin, calicheamicin, N-acetyl--calicheamicin (CMC), calicheamicin derivatives, meitansine and its analogues, DM-I, auristatin E, auristatin EB (AEB), auristatin EFP (AEFP), monomethyl auristatin E (MMAE), monomethyl auristatin F (MMAF), tubulicine, disorazole, epotilon, paclitaxel, docetaxel, topotecan, echinomycin, estramustine, semadin, eleuterobin, metopterin The following are selected: phosphorus, actinomycin, daunorubicin, daunorubicin conjugate, mitomycin C, mitomycin A, vincristine, retinoic acid, camptothecin, camptothecin derivatives, SN38, meitansine, meitansinoid derivatives, DM1, DM4, TK1, amanitin, pyrrolobenzodiazepine, pyrrolobenzodiazepine dimer, methotrexate, ilomedine, aspirin, IMID, lenalidomide, and pomalidomide.

[0344] Isomers / stereoisomers In some embodiments, the compounds described herein exist as geometric isomers. In some embodiments, the compounds described herein have one or more double bonds. The compounds presented herein include cis, trans, syn, anti, entgegen (E), and tuzamen (Z) isomers, as well as their corresponding mixtures. In some cases, the compounds described herein have one or more chiral centers, each center existing in either an R or S configuration. The compounds described herein include diastereomers, enantiomers, and epimers, as well as their corresponding mixtures. In further embodiments of the compounds and methods provided herein, mixtures of enantiomers and / or diastereoisomers obtained from a single preparation step, combination, or interconversion are useful for the applications described herein. In some embodiments, the compounds described herein are prepared as their individual stereoisomers by reacting a racemic mixture of the compounds with an optically active resolving agent to form a pair of diastereoisomer compounds, separating the diastereomers, and recovering the optically pure enantiomers. In some embodiments, dissociable conjugates are preferred. In some embodiments, the diastereomers have different physical properties (e.g., melting point, boiling point, solubility, reactivity, etc.) and are separated by utilizing these differences. In some embodiments, the diastereomers are separated by chiral chromatography, or preferably by separation / resolution techniques based on differences in solubility. In some embodiments, the optically pure enantiomers are then recovered together with a resolving agent.

[0345] Tautomers A "tautomer" is a molecule in which protons can be transferred from one atom of a molecule to another atom of the same molecule. The compounds presented herein exist as tautomers in certain embodiments. When tautomerism is possible, a chemical equilibrium of tautomers exists. The exact ratio of tautomers varies depending on several factors, including physical state, temperature, solvent, and pH. Examples of tautomer equilibrium include:

[0346] [ka]

[0347] In some cases, the compounds disclosed herein exist in tautomerized forms. For clarity, the structures of the above compounds are shown in one tautomerized form. Another tautomerized form is expressly included in this disclosure.

[0348] labeled compound In some embodiments, the compounds described herein exist in isotopically labeled forms. In some embodiments, the methods disclosed herein include methods for treating a disease by administering such isotopically labeled compounds. In some embodiments, the methods disclosed herein include methods for treating a disease by administering such isotopically labeled compounds as a pharmaceutical composition. Thus, in some embodiments, the compounds disclosed herein include isotopically labeled compounds, which are identical to those described herein but in which one or more atoms are substituted with atoms having atomic masses or mass numbers different from those commonly found in nature. Examples of isotopes that can be incorporated into the compounds described herein, or their solvates, or their stereoisomers include: 2 H, 3 H, 13 C, 14 C, 15 N, 18 O, 17 O, 31 P, 32 P, 35 S, 18 F, and 36 Examples include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, and chloride ions, such as Cl. Compounds described herein, including the aforementioned isotopes and / or other isotopes of other atoms, and their pharmaceutically acceptable salts, solvates, or stereoisomers are within the scope of this disclosure. Specific isotope-labeled compounds, 3 H and 14Compounds incorporating radioactive isotopes such as 13C are useful in drug and / or substrate distribution assays within tissues. Tritium-labeled isotopes, i.e. 3 H isotopes, and carbon-14, i.e. 14 13C isotopes are noteworthy for their ease of preparation and detectability. Furthermore, deuterium, that is 2 Substitution with heavy isotopes such as 1H produces certain therapeutic benefits resulting from improved metabolic stability, such as increased in vivo half-life or reduced dose requirements. In some embodiments, isotope-labeled compounds or their pharmaceutically acceptable salts, solvates, or stereoisomers are prepared by any preferred method.

[0349] In some embodiments, the compounds described herein may be labeled by other means, including, but not limited to, the use of a chromophore or fluorescent moiety, bioluminescent labeling, or chemiluminescent labeling.

[0350] Pharmaceutically acceptable salts In some embodiments, the compounds described herein exist as pharmaceutically acceptable salts thereof. In some embodiments, the methods disclosed herein include methods for treating a disease by administering such pharmaceutically acceptable salts. In some embodiments, the methods disclosed herein include methods for treating a disease by administering such pharmaceutically acceptable salts as a pharmaceutical composition. As used herein, “pharmaceutically acceptable salt” means any salt of a compound useful for the therapeutic purpose of the subject.

[0351] In some embodiments, the compounds described herein have acidic or basic groups and therefore react with a number of inorganic or organic bases, as well as either inorganic or organic acids, to form pharmaceutically acceptable salts. In some embodiments, these salts are prepared in situ during the final isolation and purification of the compounds disclosed herein, or by reacting the free purified compounds individually with suitable acids or bases and isolating the salts thus formed.

[0352] Examples of pharmaceutically acceptable salts include salts prepared by the reaction of the compounds described herein with mineral acids, organic acids, or inorganic bases, such as acetates, acrylates, adipines, alginates, aspartates, benzoates, benzenesulfons, bisulfites, bromides, butyrates, butynate-1,4-diates, camphorates, camphorsulfons, capronates, caprylates, chlorobenzoates, chlorides, citrates, cyclopentanepropionates, decanoates, diglucons, dihydrogen phosphates, dinitrobenzoates, dodecyl sulfates, ethanesulfons, formates, fumarates, glucoheptanoates, glycerophosphates, glycolates, hemisulfates, heptanoates, hexanoates, hexine-1,6-diates, hydroxybenzoates, γ-hydroxybutyrates, and hydrochlorides. Examples include hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, iodide, isobutyrate, lactate, maleate, malonate, methanesulfonate, mandelate, metaphosphate, methanesulfonate, methoxybenzoate, methylbenzoate, monohydrogen phosphate, 1-naphthalenesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, palmitate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivaphosphate, propionate, pyrosulfate, pyrophosphate, propionate, phthalate, phenylacetate, phenylbutyrate, propanesulfonate, salicylate, succinate, sulfate, sulfite, succinate, suberinate, sebacinate, sulfonate, tartrate, thiocyanate, tosylate, undecanoate, and xylenesulfonate.

[0353] Furthermore, the compounds described herein can be prepared as pharmaceutically acceptable salts formed by reacting the compounds in their free base form with a pharmaceutically acceptable inorganic or organic acid. Examples of inorganic acids include hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and metaphosphoric acid. Examples of organic acids include acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, p-toluenesulfonic acid, tartaric acid, trifluoroacetic acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl)benzoic acid, and cinnamic acid. Examples include, but are not limited to, mandelic acid, aryl sulfonic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethanedisulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 2-naphthalenesulfonic acid, 4-methylbicyclo-[2.2.2]octa-2-ene-1-carboxylic acid, glucoheptonic acid, 4,4'-methylenebis-(3-hydroxy-2-ene-1-carboxylic acid), 3-phenylpropionic acid, trimethylacetic acid, tertiary butylacetic acid, lauryl sulfate, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, and muconic acid.

[0354] In some embodiments, the compounds described herein containing a free acid group react with suitable bases such as pharmaceutically acceptable metal cation hydroxides, carbonates, bicarbonates, or sulfates, or with ammonia, or with pharmaceutically acceptable organic primary, secondary, tertiary, or quaternary amines. Typical salts include alkali salts or alkaline earth salts such as lithium, sodium, potassium, calcium, and magnesium, as well as aluminum salts. Specific examples of bases include sodium hydroxide, potassium hydroxide, choline hydroxide, sodium carbonate, and N2. + (C 1~4 Examples include alkyl(4) and others.

[0355] Representative organic amines useful for the formation of base addition salts include ethylamine, diethylamine, ethylenediamine, ethanolamine, diethanolamine, and piperazine. It should be understood that the compounds described herein also include quaternization of the basic nitrogen-containing groups they contain. In some embodiments, water-soluble, oil-soluble, or dispersible products are obtained by such quaternization.

[0356] solvate In some embodiments, the compounds described herein exist as solvates. This disclosure provides a method for treating a disease by administering such solvates. This disclosure further provides a method for treating a disease by administering such solvates as a pharmaceutical composition.

[0357] Solvates contain either a stoichiometric or non-stoichiometric amount of solvent and, in some embodiments, are formed during a crystallization process using a pharmaceutically acceptable solvent such as water or ethanol. When the solvent is water, a hydrate is formed, and when the solvent is alcohol, an alcoholic dihydrate is formed. Conveniently, solvates of the compounds described herein can be prepared or formed during the processes described herein. Furthermore, the compounds provided herein can exist in both solvated and unsolvated forms. Generally, the solvated form is considered equivalent to the unsolvated form with respect to the purpose of the compounds and methods provided herein. Accordingly, one aspect of this disclosure belongs to hydrates and solvates of the compounds disclosed herein, and / or their pharmaceutically acceptable salts as described herein, which can be isolated and characterized by methods known in the art, such as thermogravimetric analysis (TGA), TGA-mass spectroscopy, TGA-infrared spectroscopy, powder X-ray diffraction (PXRD), Karl Fischer titration, and high-resolution X-ray diffraction.

[0358] Preparation of compounds The compounds used in the reactions described herein are prepared starting from commercially available chemicals and / or compounds described in the chemical literature, according to organic synthesis techniques known to those skilled in the art. "Commercially available chemicals" include, for example, Acros Organics (Pittsburgh, PA), Aldrich Chemical (Milwaukee, WI, including Sigma Chemical and Fluka), Apin Chemicals Ltd. (Milton Park, UK), Avocado Research (Lancashire, UK), BDH, Inc. (Toronto, Canada), Bionet (Cornwall, UK), Chem Service Inc. (West Chester, PA), Crescent Chemical Co. (Hauppauge, NY), Eastman Organic Chemicals, Eastman Kodak Company (Rochester, NY), Fisher Scientific Co. (Pittsburgh, PA), Fisons Chemicals (Leicestershire, UK), Frontier Scientific (Logan, UT), ICN Biomedicals, Inc. (Costa Mesa, CA), Key Organics (Cornwall, UK), Lancaster Synthesis (Windham, NH), Maybridge Chemical Co. It is available from standard commercial sources such as Ltd. (Cornwall, UK), Parish Chemical Co. (Orem, UT), Pfaltz & Bauer, Inc. (Waterbury, CN), Polyorganix (Houston, TX), Pierce Chemical Co. (Rockford, IL), Riedel de Haen AG (Hanover, Germany), Spectrum Quality Product, Inc. (New Brunswick, NJ), TCI America (Portland, OR), Trans World Chemicals, Inc. (Rockville, MD), and Wako Chemicals USA, Inc. (Richmond, VA).

[0359] Suitable reference books and papers that detail the synthesis of reactants useful for the preparation of the compounds described herein, or provide references to papers describing the preparations, include, for example, “Synthetic Organic Chemistry”, John Wiley & Sons, Inc., New York; SRSandler et al., “Organic Functional Group Preparations”, 2nd Ed., Academic Press, New York, 1983; HOHouse, “Modern Synthetic Reactions”, 2nd Ed., WABenjamin, Inc. Menlo Park, Calif. 1972; TLGilchrist, “Heterocyclic Chemistry”, 2nd Ed., John Wiley & Sons, New York, 1992; J. March, “Advanced Organic Chemistry: Reactions, Mechanisms and Structure”, 4th Ed., Wiley-Interscience, New York, 1992. Other suitable reference books and papers that detail the synthesis of reactants useful for the preparation of the compounds described herein, or provide references to papers describing the preparation, include, for example, Fuhrhop, J. and Penzlin G. "Organic Synthesis: Concepts, Methods, Starting Materials", Second, Revised and Enlarged Edition (1994) John Wiley & Sons ISBN:3-527-29074-5; Hoffman, RV "Organic Chemistry, An Intermediate Text" (1996) Oxford University Press, ISBN 0-19-509618-5; Larock, RC "Comprehensive Organic Transformations: A Guide to Functional Group Preparations" 2nd Edition (1999) Wiley-VCH, ISBN:0-471-19031-4; March, J."Advanced Organic Chemistry: Reactions, Mechanisms, and Structure" 4th Edition (1992), John Wiley & Sons, ISBN: 0-471-60180-2; Otera, J. (editor), "Modern Carbonyl Chemistry" (2000), Wiley-VCH, ISBN: 3-527-29871-1; Patai, S., "Patai's 1992 Guide to the Chemistry of Functional Groups" (1992), Interscience, ISBN: 0-471-93022-9; Solomons, T.W.G., "Organic Chemistry" 7th Edition (2000), John Wiley & Sons, ISBN: 0-471-19095-0; Stowell, J.C., "Intermediate Organic Chemistry" 2nd Edition (1993), Wiley-Interscience, ISBN: 0-471-57456-2; "Industrial Organic Chemicals: Starting Materials and Intermediates: An Ullmann's Encyclopedia" (1999), John Wiley & Sons, ISBN: 3-527-29645-X, in 8 volumes; "Organic Reactions" (1942 - 2000), John Wiley & Sons, in over 55 volumes; and "Chemistry of Functional Groups", John Wiley & Sons, in 73 volumes, etc. can be cited.

[0360] Specific reactants and similar reactants are selectively identified through an index of known chemicals created by the American Chemical Society's Chemical Abstract Service. This index is available in most public and university libraries, as well as online. Chemicals that are known but not commercially available in catalogs are selectively prepared by custom chemical synthesis companies. Many standard chemical suppliers (e.g., those listed above) offer custom synthesis services. A reference for the preparation and selection of pharmaceutical salts of the compounds described herein is PHStahl & CGWermuth, “Handbook of Pharmaceutical Salts”, Verlag Helvetica Chimica Acta, Zurich, 2002.

[0361] In one embodiment, a cyclic peptide, a metal chelating agent, optionally a linker, and optionally 177 Lu or 225Methods for producing conjugates containing radionuclides such as Ac are described herein. In some embodiments, the conjugate is prepared by one or more of the following steps: (a) synthesizing a peptide sequence by solid-phase peptide synthesis; (b) cyclizing the peptide by forming an intramolecular non-peptide bond; (c) attaching a metal chelating agent to the peptide; and (d) optionally labeling the conjugate with a radionuclide. In some embodiments, steps (a), (b), (c), and (d) are performed in the order described. In some embodiments, the step of synthesizing a peptide sequence includes synthesizing the peptide sequence in a protected form and performing a deprotection reaction. In some embodiments, the step of cyclizing the peptide includes forming a non-peptide bond between the N-terminus and C-terminus of the peptide. In some embodiments, the step of cyclizing the peptide includes forming a non-peptide bond between the N-terminus of the peptide and cysteine ​​or homocysteine. In some embodiments, the step of cyclizing the peptide includes forming a cyclizing group selected from -C(=O)-CH2-S-, -S-, -CH=CH-, -NH-, -maleimide-S-, -C(=O)-CH2-NH-, and -C(=O)-CH2-O-. In some embodiments, the step of cyclizing the peptide includes forming the cyclizing groups of Table 2A. In some embodiments, the step of cyclizing the peptide includes reacting a pair of functional groups or amino acids listed in Table 2B. In some embodiments, solid-phase peptide synthesis can be replaced by other suitable peptide synthesis methods known in the art.

[0362] Mai. Pharmaceutical composition For example, the radiopharmaceutical conjugates described herein, comprising a pharmaceutically acceptable salt or solvate, can be administered as pure chemicals themselves or as components of a pharmaceutically acceptable formulation. In some embodiments, the conjugates described herein are combined with a pharmaceutically suitable or acceptable carrier selected based on the choice of administration route and standard pharmaceutical practice, for example, Remington: The Science and Practice of Pharmacy (Gennaro, 21 st This is described in Ed. Mack Pub. Co., Easton, PA (2005). Provided herein are pharmaceutical compositions comprising at least one conjugate, or a stereoisomer thereof, a pharmaceutically acceptable salt, amide, ester, solvate, or N-oxide described herein, together with one or more pharmaceutically acceptable carriers. The carrier(s) (or excipient(s)) are acceptable or preferred if they are compatible with the other components of the composition and are not harmful to the recipient of the composition (i.e., subject or patient).

[0363] In one embodiment, the present disclosure provides a pharmaceutical composition comprising a conjugate described herein, or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable excipient or carrier. In certain embodiments, the described conjugate is substantially pure in that it contains less than about 10%, less than about 5%, less than about 1%, or less than about 0.1% of other small organic molecules, such as unreacted intermediates or synthetic by-products generated in one or more steps of the synthesis method.

[0364] Pharmaceutical compositions may contain pharmaceutically acceptable carriers, diluents, or excipients. Examples of pharmaceutically acceptable carriers include solvents (aqueous or nonaqueous), solutions, emulsions, dispersions, coatings, isotonic agents, and absorption enhancers or retarders suitable for the administration method of the drug. Such formulations may be in liquid form; emulsion, suspension, syrup or elixir; or solid form; tablets (coated or uncoated), capsules (hard or soft), powders, granules, crystals, or microbeads. Auxiliary components (e.g., preservatives, antibacterial agents, antiviral agents, and antifungal agents) may also be incorporated into the composition. Pharmaceutical compositions may be formulated to suit specific topical or systemic routes of administration. Therefore, pharmaceutical compositions may contain carriers, diluents, or excipients suitable for administration via a particular route.

[0365] The compounds and pharmaceutical compositions of this disclosure may be administered by any preferred means, including orally, topically (including oral and sublingual), rectally, vaginally, percutaneously, parenterally, subcutaneously, intraperitoneally, intrapulmonaryly, intradermally, subarachnoidally, epidurally, and intranasally, and intralesional administration may also be possible if local treatment is required. The term parenterally as used herein includes, for example, subcutaneously, intravenously, intramuscularly, intrasternally, intraperitoneally, and by infusion techniques. The term parenterally also includes injection into the eye, i.e., the eye, intravitreous, intracheek, percutaneously, intranasally, intracerebrally, intrabrain including intracranially and intradurally, injection into joints including the ankle, knee, hip, shoulder, elbow, wrist, etc., and infusion in the form of suppositories. In certain embodiments, the compounds and / or formulations are administered orally. In certain embodiments, the compounds and / or formulations are administered by systemic administration. In certain embodiments, the compounds and / or formulations are administered parenterally. In certain embodiments, the compound and / or formulation is administered topically to the target site.

[0366] In some embodiments, the conjugates described herein, or pharmaceutically acceptable salts or solvates thereof, and pharmaceutical compositions are administered by parenteral injection as solutions that may contain other chemical components such as carriers, stabilizers, diluents, dispersants, suspending agents, thickeners, preservatives, or excipients. Parenteral injections can be formulated for rapid, high-volume injection or continuous infusion. Pharmaceutical compositions can be in forms suitable for parenteral injection as sterile suspensions, solutions, or emulsions in oily or aqueous vehicles, and may contain formulation agents such as suspending agents, stabilizers, or dispersants. Pharmaceutical formulations for parenteral administration include aqueous solutions of the active compound in a water-soluble form. Solutions or suspensions used for parenteral, intradermal, or subcutaneous application may include: sterile diluents such as water for injection, physiological saline, fixative oil, polyethylene glycol, glycerin, propylene glycol, or other synthetic solvents; antimicrobial agents such as benzyl alcohol or methylparaben; antioxidants such as ascorbic acid, gentisic acid, or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates, or phosphates; surfactants such as polysorbate 80; and agents for adjusting osmotic pressure such as sodium chloride or glucose. pH can be adjusted with an acid or base such as hydrochloric acid or sodium hydroxide. In some embodiments, the pharmaceutical composition includes a reducing agent. The presence of a reducing agent helps minimize the possibility of radiolysis. In some embodiments, the reducing agent is ascorbic acid, gentisic acid, sodium thiosulfate, citric acid, tartaric acid, or a combination thereof.

[0367] Pharmaceutical compositions comprising the conjugate or a pharmaceutically acceptable salt or solvate thereof described herein can be prepared according to standard techniques and further include a pharmaceutically acceptable carrier. In some embodiments, physiological saline can be used as the pharmaceutically acceptable carrier. Other suitable carriers include, for example, water, buffer water, 0.9% isotonic saline, 0.4% saline, and 0.3% glycine, which include glycoproteins to enhance the stability of albumin, lipoproteins, globulins, etc. These compositions can be sterilized by conventional sterilization techniques. The resulting aqueous solutions may be packaged for use or filtered under sterile conditions and then lyophilized. In some embodiments, the lyophilized preparations are mixed with a sterile aqueous solution before administration. The compositions may contain pharmaceutically acceptable auxiliary substances as needed to approximate physiological conditions, such as pH adjusters and buffers, tonicity adjusters, etc., including sodium acetate, sodium lactate, sodium chloride, potassium chloride, calcium chloride, sodium lactate, sorbitan-monolauric acid, and triethanolamine-oleic acid. Pharmaceutical compositions can be selected according to physical properties including, but not limited to, fluid volume, viscosity, and other parameters, depending on the chosen specific mode of administration. The amount of conjugate administered may depend on the specific target portion used, the disease condition being treated, the therapeutic agent being delivered, and the clinician's judgment.

[0368] The concentration of the conjugate described herein or its pharmaceutically acceptable salt or solvate in a pharmaceutical formulation may vary. In some embodiments, the conjugate is present in the pharmaceutical composition in amounts of about 0.05% to about 1% by weight, about 1% to about 2% by weight, about 2% to about 5% by weight, about 5% to about 10%, about 10% to about 30% by weight, about 30% to about 50% by weight, about 50% to about 75% by weight, or about 75% to about 99% by weight.

[0369] Pharmaceutical compositions are administered in a manner appropriate to the disease being treated. The appropriate dose and preferred duration and frequency of administration are determined by factors such as the subject's condition, the type and severity of the disease, the specific form of the active ingredient, and the method of administration. In some embodiments, the appropriate dose and treatment plan provide a sufficient amount(s) of composition to produce therapeutic and / or preventive benefits (e.g., improved clinical outcomes) or a reduction in symptom severity. The optimal dose is usually determined using experimental models and / or clinical trials. The optimal dose varies depending on the subject's body mass, weight, and blood volume.

[0370] The amount of the conjugate or its pharmaceutically acceptable salt or solvate, and / or pharmaceutical composition administered may be sufficient to deliver a therapeutically effective dose to a particular subject. In some embodiments, the dose of the conjugate may be about 0.1 pg to about 50 mg per kilogram of body weight, 1 μg to about 50 mg per kilogram of body weight, or about 0.1 mg to about 10 mg / kg of body weight. The therapeutically effective dose may also be determined at the discretion of the physician. As merely an example, the dose of the conjugate or its pharmaceutically acceptable salt or solvate described herein for a method of treating the disease described herein is about 0.001 mg / kg to about 1 mg / kg of body weight per single dose to the subject. In some embodiments, for the method described herein, the dose of the conjugate or its pharmaceutically acceptable salt or solvate described herein is about 0.001 mg to about 1000 mg per single dose to the subject being treated. In some embodiments, the conjugate or its pharmaceutically acceptable salt or solvate described herein is administered to a subject in doses of about 0.01 mg to about 500 mg, about 0.01 mg to about 100 mg, or about 0.01 mg to about 50 mg. In some embodiments, the conjugate or its pharmaceutically acceptable salt or solvate described herein is administered to a subject in single doses of about 0.01 picomoles to about 1 mole, about 0.1 picomoles to about 0.1 mole, about 1 nanomoles to about 0.1 mole, or about 0.01 micromoles to about 0.1 millimoles. In some embodiments, the conjugate or its pharmaceutically acceptable salt or solvate described herein is administered to a subject in single doses of about 0.01 Gbq to about 1000 Gbq, about 0.5 Gbq to about 100 Gbq, or about 1 Gbq to about 50 Gbq. In some embodiments, the dose is administered once daily, 1 to 3 times per week, 1 to 4 times per month, or 1 to 12 times per year.

[0371] Pharmaceutical preparations can be packaged into unit dosage forms to facilitate administration and ensure consistent dosage with each administration. A unit dosage form may refer to a physically distinct unit suitable as a unit dosage form for the target being treated. Each unit contains a predetermined amount of the active compound, calculated to produce the desired therapeutic effect in conjunction with a pharmaceutical carrier or excipient.

[0372] IV. Treatment method In one embodiment, the Disclosure provides a method for treating a disease or condition in a subject requiring such treatment. In some embodiments, the method comprises administering a conjugate or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutical composition containing thereof, to a subject requiring such treatment. In some embodiments, methods providing therapeutic and / or preventive benefits, comprising administering a compound or pharmaceutical composition described herein to a subject requiring such treatment, are provided herein.

[0373] In some embodiments, the method involves administering a therapeutically effective amount of the conjugate or a pharmaceutically acceptable salt or solvate thereof to a subject. In some embodiments, the conjugate or a pharmaceutically acceptable salt or solvate thereof is administered in a pharmaceutical composition. In some embodiments, the subject has cancer. In some embodiments, the cancer is a solid tumor or a hematological malignancy.

[0374] In some embodiments, methods for killing cells are provided herein, comprising contacting cells with a conjugate or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the cells express a receptor described herein, e.g., PSMA. In some embodiments, the conjugate or a pharmaceutically acceptable salt or solvate thereof binds to a structure on the cell. In some embodiments, the conjugate or a pharmaceutically acceptable salt or solvate thereof emits a large number of alpha particles by spontaneous radioactive decay. In some embodiments, the conjugate or a pharmaceutically acceptable salt or solvate thereof emits a large number of beta particles, gamma rays, and / or Auger electrons by spontaneous radioactive decay. The conjugates described herein can kill cells by radiation. In some embodiments, the conjugate directly kills cells by radiation. In some embodiments, the radiation causes oxidized bases, debase sites, single-strand breaks, double-strand breaks, DNA crosslinks, chromosome rearrangements, or combinations thereof within the cell. In some embodiments, the conjugate kills cells by inducing double-strand DNA breaks. In some embodiments, the released alpha particles are sufficient to kill cells. In some embodiments, the released alpha particles are sufficient to halt cell proliferation. In some embodiments, the conjugate indirectly kills cells through the generation of reactive oxygen species (ROS), such as free hydroxyl radicals. In some embodiments, the conjugate can indirectly kill cells and exert a vaccine effect by releasing tumor antigens from one or more different cells. In some embodiments, the conjugate kills cells by the abscopal effect. In some embodiments, the cells are cancer cells. In some embodiments, the method includes killing cells using an alpha particle-emitting radionuclide.

[0375] The described conjugates can be translocated into cells after contact with them. This translocation can be mediated by cell receptors, cell membrane endocytosis, and the like. In some embodiments, a rapid rate of translocation into cancer cells, when accompanied by a slow efflux rate, may provide therapeutic benefits.

[0376] In one embodiment, the disclosed conjugate or a pharmaceutically acceptable salt or solvate thereof is configured to treat cancer by ablating tumor cells. In some embodiments, the conjugate or a pharmaceutically acceptable salt or solvate thereof does not modulate the biological properties of tumor cells and / or the surrounding stroma. In some embodiments, the conjugate or a pharmaceutically acceptable salt or solvate thereof does not modulate immune cells. In some embodiments, ablation of tumor cells may result in a downstream immunological cascade.

[0377] Non-limiting examples of cancers treated by the methods of this disclosure include melanoma (e.g., metastatic melanoma), kidney cancer (e.g., clear cell carcinoma), prostate cancer (e.g., hormone-refractory prostate cancer), pancreatic adenocarcinoma, breast cancer, colon cancer, lung cancer (e.g., non-small cell lung cancer), esophageal cancer, head and neck squamous cell carcinoma, liver cancer, ovarian cancer, cervical cancer, thyroid cancer, glioblastoma, glioma, leukemia, lymphoma, and other malignant neoplasms. In some embodiments, the subjects or population of subjects treated with the pharmaceutical compositions of this disclosure have solid tumors. In some embodiments, the solid tumors are melanoma, renal cell carcinoma, lung cancer, bladder cancer, breast cancer, cervical cancer, colon cancer, gallbladder cancer, laryngeal cancer, liver cancer, thyroid cancer, gastric cancer, salivary gland cancer, prostate cancer, pancreatic cancer, or Merkel cell carcinoma. In some embodiments, the subjects or population of subjects treated with the pharmaceutical compositions of this disclosure have hematological cancers. In some embodiments, the subjects have hematological cancers such as diffuse large B-cell lymphoma ("DLBCL"), Hodgkin lymphoma ("HL"), non-Hodgkin lymphoma ("NHL"), follicular lymphoma ("FL"), acute myeloid leukemia ("AML"), or multiple myeloma ("MM"). In some embodiments, the subjects or population of subjects to be treated have cancers selected from the group consisting of ovarian cancer, lung cancer, and melanoma.

[0378] In some embodiments, methods and compositions for treating diseases or conditions are provided herein. Exemplary diseases or conditions include refractory or recurrent malignancies whose growth can be inhibited using the therapeutic methods of the Disclosure. In some embodiments, the disease or condition is cancer. In some embodiments, the cancer is breast cancer, head and neck squamous cell carcinoma, non-small cell lung cancer, hepatocellular carcinoma, colorectal cancer, gastric adenocarcinoma, melanoma, or advanced cancer. In some embodiments, the cancers treated by the therapeutic methods of the present disclosure are selected from the group consisting of carcinomas, squamous cell carcinomas, adenocarcinomas, sarcomas, endometrial cancers, breast cancers, ovarian cancers, cervical cancers, fallopian tube cancers, primary peritoneal cancers, colon cancers, colorectal cancers, squamous cell carcinomas of the anogenital region, melanomas, renal cell carcinomas, lung cancers, non-small cell lung cancers, lung squamous cell carcinomas, gastric cancers, bladder cancers, gallbladder cancers, liver cancers, thyroid cancers, laryngeal cancers, salivary gland cancers, esophageal cancers, head and neck cancers, glioblastomas, gliomas, head and neck squamous cell carcinomas, prostate cancers, pancreatic cancers, mesotheliomas, sarcomas, hematological cancers, leukemias, lymphomas, neuromas, and combinations thereof. In some embodiments, cancers treated by the methods of the Disclosure include, for example, carcinomas, squamous cell carcinomas (e.g., cervix, eyelids, conjunctiva, vagina, lung, oral cavity, skin, bladder, tongue, larynx, esophagus), and adenocarcinomas (e.g., prostate, small intestine, endometrium, cervix, large intestine, lung, pancreas, esophagus, rectum, uterus, stomach, mammary gland, ovary). In some embodiments, cancers treated by the methods of the Disclosure further include sarcomas (e.g., myogenic sarcomas), leukemia, neuromas, melanomas, and lymphomas. In some embodiments, the cancer treated by the methods of the Disclosure is breast cancer. In some embodiments, the cancer treated by the treatment methods of the Disclosure is triple-negative breast cancer (TNBC). In some embodiments, the cancer treated by the treatment methods of the Disclosure is pancreatic cancer.

[0379] In addition to the therapeutic methods described above, the compounds and compositions described herein can be used for imaging the treatment of a disease and / or as part of the treatment of that disease. For imaging applications, such as single-photon emission computed tomography (SPECT) and positron emission tomography (PET), conjugates may contain radionuclides suitable for use as imaging isotopes, such as the isotopes listed in Table 5B. Therefore, conjugates can be administered as companion diagnostics.

[0380] Combination therapy In some embodiments, the conjugate described herein may be administered alone or in combination with one or more additional therapeutic agents. For example, combination therapy may include a composition comprising the conjugate described herein, which is co-formulated and / or co-administered with one or more additional therapeutic agents, such as one or more anticancer agents, such as cytotoxic agents or cell proliferation inhibitors, immune checkpoint inhibitors, hormone therapy, vaccines, and / or immunotherapy. In some embodiments, the conjugate is administered in combination with other treatments, including surgery, cryosurgery, and / or chemotherapy. Such combination therapy can be advantageously utilized with lower doses of the therapeutic agents administered, and thus can avoid potential toxicity or complications associated with various monotherapies.

[0381] When administered in combination, two (or more) different treatments may be delivered to a subject during the course of the subject's illness. For example, two or more treatments may be delivered after the subject has been diagnosed with the illness but before the illness is cured or resolved. In some embodiments, there is overlap because the delivery of one treatment is still in progress when the delivery of the second treatment begins. This may be referred to herein as “simultaneous delivery” or “parallel delivery.” In some embodiments, the delivery of one treatment is completed before the delivery of the other treatment begins. In some embodiments of any of these cases, the treatments become more effective when administered in combination. For example, the second treatment may be more effective if, for example, the second treatment produces a similar effect at a lower dose, or the second treatment reduces symptoms to a greater extent than would be seen if the first treatment were administered in the absence of the first treatment, or if a similar situation is seen with the first treatment. In some embodiments, the delivery is such that the reduction in symptoms or other parameters related to the illness is greater than that observed if one treatment were delivered in the absence of the other. The effects of the two treatments may be partially additive, fully additive, or even exceed additive. Delivery may be such that the effect of the first treatment, once delivered, is still detectable when the second treatment is delivered.

[0382] In some embodiments, the conjugates described herein are used in combination with chemotherapeutic agents, such as DNA damage chemotherapeutic agents. Non-limiting examples of DNA damage chemotherapeutic agents include topoisomerase I inhibitors, topoisomerase II inhibitors; alkylating agents; DNA intercalators; DNA intercalators and free radical generators such as bleomycin; and nucleoside mimetic agents. In some embodiments, the conjugates described herein are used in combination with radiosensitizers that enhance the sensitivity of tumor cells to radiotherapy. In some embodiments, the conjugates described herein are used in combination with DNA damage repair inhibitors (or DNA damage response (DDR) inhibitors).

[0383] In some embodiments, the target age range is 4 to 100 years old. In some embodiments, the target age range is 5 to 10 years old, 5 to 15 years old, 5 to 18 years old, 5 to 25 years old, 5 to 35 years old, 5 to 45 years old, 5 to 55 years old, 5 to 65 years old, 5 to 75 years old, 10 to 15 years old, 10 to 18 years old, 10 to 25 years old, 10 to 35 years old, 10 to 45 years old, 10 to 55 years old, 10 to 65 years old, 10 to 75 years old, 15 to 18 years old, 15 to 25 years old, 15 to 35 years old, 15 to 45 years old, 15 to 55 years old, and 15 years old. The age ranges are up to 65 years old, 15 to 75 years old, 18 to 25 years old, 18 to 35 years old, 18 to 45 years old, 18 to 55 years old, 18 to 65 years old, 18 to 75 years old, 25 to 35 years old, 25 to 45 years old, 25 to 55 years old, 25 to 65 years old, 25 to 75 years old, 35 to 45 years old, 35 to 55 years old, 35 to 65 years old, 35 to 75 years old, 45 to 55 years old, 45 to 65 years old, 45 to 75 years old, 55 to 65 years old, 55 to 75 years old, or 65 to 75 years old. In some embodiments, the target age range is at least 5, 10, 15, 18, 25, 35, 45, 55, or 65 years old. In some embodiments, the subjects are up to 10, 15, 18, 25, 35, 45, 55, 65, or 75 years old.

[0384] While the present disclosure and its merits have been described in detail, please understand that various changes, substitutions, and modifications may be made herein without departing from the intent and scope of the present disclosure as defined in the attached claims.

[0385] The present disclosure will be further illustrated by the following embodiments, which are for illustrative purposes only and are not intended to limit the present disclosure. [Examples]

[0386] A: Compound synthesis Example A1: Synthesis of peptides and conjugates

[0387] The linear precursor of the macrocyclic peptide is prepared by standard Fmoc solid-phase synthesis with the C-terminus amidated. The N-terminus is chloroacetylated. The peptide is cleaved from the resin by incubation with a trifluoroacetic acid (TFA) cleavage cocktail (TFA / 2,2'-(ethylenedioxy)diethanethiol / triisopropylsilane / H2O (92.5:2.5:2.5:2.5)) before filtration, concentrated under vacuum, and precipitated with ice-cold diethyl ether. The crude peptide is washed with diethyl ether, dried, and resuspended in DMSO. The pH is raised above 8 using triethylamine to enable cyclization. The cyclized peptide is purified by HPLC.

[0388] The peptide binds to the metal chelating agent DOTA, and then the radionuclide or substitute is chelated with DOTA, thereby creating a conjugate.

[0389] Example A2: Analytical Conditions

[0390] High-performance liquid chromatography (HPLC) analysis was performed on an Agilent 1260 series equipped with a binary pump G7112A, micro vacuum degasser, standard autosampler ALS G7129A, thermostat-controlled column compartment TCC G7116A, and tunable wavelength detector VWD G7114A. Data were analyzed using Agilent Technologies' OpenLab CDS 2.2 network workstation software. The HPLC solvent consisted of H2O containing 0.1% trifluoroacetic acid (mobile phase A) and acetonitrile containing 0.075% trifluoroacetic acid (mobile phase B). Conditions: A Phenomenex Gemini-NX C-18 (5 μm, 110 Å, 4.6 × 250 mm) column was used at a flow rate of 1.0 mL / min.

[0391] LCMS analysis was performed on an Agilent 1260 Infinity II HPLC and MSD (G6135B) system under the following conditions: Luna C18(2)-HST column (reverse phase, 50 mm x 3 mm, 2.5 μm); column temperature 40°C; mobile phase A: water doped with 0.05% TFA, mobile phase B: acetonitrile doped with 0.0375% TFA; mobile phase A:B was a linear gradient from 95:5 to 5:95, with the gradient held at 95:5 (mobile phase A:B) for 1 minute, followed by a linear gradient to 5:95 (A:B) over 8 minutes, and then held at 5:95 (A:B) for 3 minutes; flow rate: 0.6 mL / min; detection by UV photodiode array.

[0392] Example A3: Synthesis of C-40 and Lu-C-40

[0393] Conjugate C-40 contains the monocyclic peptide P-40 shown in Table 3.

[0394] Solid-phase peptide synthesis (SPPS) was performed in a standard manual reaction vessel under nitrogen. Rink Amide-MBHA resin was purchased from Sunresin New Materials Co. (China). Fmoc-protected amino acids were purchased from GL Biochem (China). HBTU and HATU were purchased from Highfine Biotech Co. (China). Piperidine was purchased from Damao Chemical Reagent Factory (China). Peptides and their derivatives were purified at 30°C using a Gilson GX-281 preparative HPLC system with a reversed-phase C18 column (Gemini, 5 μm, 110 Å + luna, 10 μm, 100 Å). The HPLC solvent consisted of H2O (mobile phase A) containing 0.075% trifluoroacetic acid and acetonitrile (mobile phase B).

[0395] Example A3-1: Synthesis of peptidyl resin 1

[0396] [ka]

[0397] To the swollen Rink Amide-MBHA resin (0.30 mmol, 0.32 mmol / g, 1.00 equivalent), Fmoc was removed by stirring with 20% piperidine in DMF for 20 minutes, followed by filtration and washing. Next, Fmoc-Glu-OtBu (0.39 g, 0.9 mmol), HBTU (0.32 g, 0.85 mmol), and DIEA (0.23 g, 1.8 mmol) in dry DMF were added to the resin. The mixture was stirred under nitrogen for 30 minutes. After removing the reaction solution by filtration, the resin was washed three times with DMF (10 mL). The Fmoc protecting group was removed by stirring with 20% piperidine in DMF for 30 minutes, followed by filtration and washing.

[0398] The obtained amino acids were coupled using Fmoc-protected amino acids (3.00 equivalents), HBTU (2.85 equivalents), and DIEA (6.00 equivalents) in dry DMF by shaking for 30 minutes. No prior activation of the amino acids was performed before coupling. During amino acid coupling, the Fmoc protecting group was removed by stirring with 20% piperidine in DMF for 30 minutes, followed by filtration and washing. The success of the Fmoc removal step and amino acid coupling was qualitatively monitored using the ninhydrin test.

[0399] Example A3-2: Synthesis of Lu-C-40

[0400] [ka]

[0401] [ka]

[0402] The resin was washed three times with MeOH and dried under vacuum, after which a cocktail of trifluoroacetic acid / H2O / triisopropylsilane / 3-mercaptopropionic acid (90:2.5:2.5:5.0) was added. The resulting mixture was stirred at room temperature for 2 hours. Cold isopropyl ether was added. The precipitated crude linear peptide product-2 was collected by filtration and dried under vacuum.

[0403] Cyclization of peptide-2: To a solution of crude product 2 (0.82 g) in water (250 mL) and MeCN (150 mL), Cs2CO3 (3.0 equivalents) was added. The resulting mixture was stirred at room temperature for 0.5 hours. The pH of the solution was then adjusted to 5.0 using 1.0 N HCl. After lyophilization, the crude product was purified by preparative HPLC to obtain peptide-3 (120 mg) as a white solid.

[0404] DOTA-OSu (1.5 equivalents) and DIEA (3.0 equivalents) were added to a solution of peptide-3 (120 mg, 1.0 equivalent) in DMF (6 mL). The resulting mixture was stirred at room temperature for 0.5 hours, and the crude product was purified by preparative HPLC to obtain C-40 (78 mg, purity 95.05%) as a white solid.

[0405] Lu 3+ Complex formation: To a solution of C-40 (60 mg, 95.05% purity, 1.0 equivalent) in H2O (2 mL) and MeCN (1 mL), LuCl3 (26.3 mg, 5.0 equivalents) was added, followed by 1 M Na2CO3 aqueous solution, to adjust the pH to 5-6. The resulting mixture was stirred at 40°C for 1 hour. After filtration, the crude product was purified by preparative HPLC to obtain Lu-C-40 (35.8 mg, 96.44% purity) as a white solid.

[0406] Example A4: Procedure for cyclization of a cyclic peptide

[0407] Example A4-1: α-halocarbonyl-cysteine ​​cyclization in solution

[0408] In a typical procedure, a linear peptide of the general formula Cl-CH2-C(=O)-NH-XaaN-Xaa2-Xaa3-Xaa4-(Xaa0)p-Xaa12-XaaC-CH2-SH is dissolved in water / acetonitrile. The mixture is adjusted to pH 8 with ammonia solution and stirred typically for 16 hours. After workup, a crude peptide of the general formula cyclo[CH2-C(=O)-NH-XaaN-Xaa2-Xaa3-Xaa4-(Xaa0)p-Xaa13-XaaC-CH2-S] is obtained. If this peptide is completely protected, standard treatment with a suitable TFA cleavage cocktail is then performed. Finally, the resulting crude product is purified by HPLC (e.g., C18 column; ISCO ACCQ; using 3-60% acetonitrile in water and 0.1% TFA as a modifier). This procedure demonstrates head-to-tail cyclization. However, cyclization (staple formation) can be introduced by carefully planning the addition and removal of protecting groups. This procedure can be applied to homologous analogs of cysteine ​​and lysine.

[0409] Conjugates containing the cyclic peptides listed in Table 3 were synthesized according to Examples A1 and A3, complexed with Lu, and cyclized according to the method described in Example A4-1. The LCMS properties of the selected conjugates are shown in Table 6 below.

[0410] [Table 14-1]

[0411] [Table 14-2]

[0412] [Table 14-3]

[0413] Example A4-2: α-halocarbonyl homocysteine ​​cyclization in solution The general procedure is essentially the same as α-halocarbonyl-cysteine ​​cyclization, but the C-terminal cysteine ​​is replaced with homocysteine.

[0414] Example A4-3: Macrolactamization on a solid phase In a typical procedure, a linear peptide of the general formula H-XaaN-Xaa2-Xaa3-Xaa4-(Xaa0)p-Xaa13-XaaC-(Wang resin)-OH (100 mg, 0.25 mmol / g) is vortexed at room temperature for 4 hours with a solution of TBTU (or another selected coupling reagent; 1 equivalent mole) and DIEA (or another selected base; 2 equivalent moles) in DMF (1 mL). After cyclization, the resin is washed with DMF (3 × 2 min) and DCM (2 × 2 min). After cleavage from the Wang resin via a suitable TFA cleavage cocktail, the resulting crude cyclic peptide product is purified by HPLC (e.g., C18 column; ISCO ACCQ; 3-60% acetonitrile in water, 0.1% TFA as a modifier). This procedure demonstrates head-to-tail macrocyclization. However, lactamization (staple formation) of the side chain can be introduced by carefully planning the addition and removal of protecting groups. This procedure can be applied to homologous analogs of aspartic acid and lysine. In some cases, this procedure is more suitable for cyclic peptides having seven or more amino acids. In some cases, for cyclic peptides with fewer than seven amino acids, careful selection of cyclization reagents and conditions is necessary.

[0415] Example A4-4: Macrolactamization in solution In a general procedure, a linear peptide of the general formula H-XaaN-Xaa2-Xaa3-Xaa4-(Xaa0)p-Xaa13-XaaC-OH is dissolved in DMF at a concentration ranging from 0.01 mM to 20 mM, depending on the specific sequence. The side chains of the linear peptide are masked by protecting groups. DIPEA (or another selected base, 2.1 equivalent moles) and EDCI (or another selected coupling reagent, 1.0 equivalent mole) are added to this solution. The resulting mixture is stirred at room temperature (or a selected temperature), and once complete, the DMF is concentrated by rotary evaporation. The resulting crude material is optionally dissolved in DCM (or siRNA), and the DCM (or siRNA) solution is washed with water. The DCM (or siRNA) layer is concentrated and dried under high vacuum. Regardless of whether workup is performed, the resulting crude cyclic peptide product is purified by HPLC (e.g., C18 column; ISCO ACCQ; using 3-60% acetonitrile in water and 0.1% TFA as a modifier). This procedure demonstrates head-to-tail macrocyclization. However, lactamization (staple) of the side chain can be introduced by carefully planning the addition and removal of protecting groups. This procedure can be applied to homologous analogs of aspartic acid and lysine. In some cases, this procedure is more suitable for cyclic peptides having seven or more amino acids. In some cases, for cyclic peptides with fewer than seven amino acids, careful selection of cyclization reagents and conditions is necessary.

[0416] Examples A4-5: Thioether macrolactamization on a solid phase In a typical procedure, the compound Fmoc-[(ClCH2CH2)-XaaN]-Xaa2-Xaa3-Xaa4-(Xaa0)p-Xaa13-XaaC-CH2-SH-(resin) (100 mg, 0.25 mmol / g) is vortexed at room temperature for 72 hours with continuous shaking in 0.1 M NaHCO3 in DMF / H2O (3:2) to complete cyclization. The side chains of the linear peptide are masked by protecting groups. After cleavage from the resin via a suitable TFA cleavage cocktail, the resulting crude cyclic peptide product is purified by HPLC (e.g., C18 column; ISCO ACCQ; 3-60% acetonitrile in water, 0.1% TFA as a modifier). This procedure demonstrates head-to-tail cyclization. However, side-chain cyclization (staple) can be introduced by carefully planning the addition and removal of protecting groups. This procedure can be applied to homologous analogs of cysteine ​​and Cl-homoalanine.

[0417] Example A4-6: Thioether macrolactamization in solution In a typical procedure, the linear peptide of the general formula Fmoc-[(ClCH2CH2)-XaaN]-Xaa2-Xaa3-Xaa4-(Xaa0)p-Xaa13-XaaC-CH2-SH is cyclized by vortexing at room temperature, continuously shaking a 1:1 mixture of acetonitrile containing 1 mg / mL chloropeptide and 10 mg / mL NaHCO3 with water. The side chains of the linear peptide are either not masked by protecting groups or are masked by protecting groups. If masked, the use of additional organic cosolvents (e.g., THF, DMF) may be required. Removal of protecting groups is performed by standard treatment with a suitable TFA cleavage cocktail, if necessary. The resulting crude cyclic peptide product is purified by HPLC (e.g., C18 column; ISCO ACCQ; 3-95% acetonitrile in water, 0.1% TFA as a modifier). This procedure demonstrates head-to-tail cyclization. However, side-chain cyclization (staple formation) can be introduced by carefully planning the addition and removal of protecting groups. This procedure can be applied to homologous analogs of cysteine ​​and Cl-homoalanine.

[0418] Example A4-7: Reductive amination macrocyclization in solution In a typical procedure, a linear glycine peptide of the general formula H-XaaN-Xaa2-Xaa3-Xaa4-(Xaa0)p-Xaa13-XaaC-CH2-CHO is dissolved to a concentration of 1 mM in NaOAc / AcOH buffer (0.4 M, pH=5.5, or other optimal pH), and NaBH3CN (10 equivalent moles) is added. The side chains of the linear peptide are either not masked by protecting groups or are masked by protecting groups. If masked, the use of an organic cosolvent (e.g., THF, DMF) may be necessary. The resulting solution is stirred at room temperature to complete the reaction. If necessary, the protecting groups are removed by standard treatment with a suitable TFA cleavage cocktail. The reaction product is purified by HPLC in appropriate aliquots (e.g., C18 column; ISCO ACCQ; using 3-95% acetonitrile in water and 0.1% TFA as a modifier) ​​to obtain the peptide macrocyclic molecule. This procedure can be applied to homologous analogs of formylglycine.

[0419] Example A4-8: Strecker macrocyclic formation in solution In a typical procedure, a linear glycine peptide of the general formula H-XaaN-Xaa2-Xaa3-Xaa4-(Xaa0)p-Xaa13-XaaC-CH2-CHO is dissolved in water to a concentration of 1 mM, and KCN (1.2 equivalent moles) is added. The side chains of the linear peptide are either not masked by protecting groups or are masked by protecting groups. If masked, the use of an organic cosolvent (e.g., THF, DMF) may be necessary. The resulting solution is stirred at room temperature to complete the reaction. If necessary, the protecting groups are removed by standard treatment with a suitable TFA cleavage cocktail. The reaction product is purified by HPLC in appropriate aliquots (e.g., C18 column; ISCO ACCQ; using 3-60% acetonitrile in water and 0.1% TFA as a modifier) ​​to obtain the peptide macrocyclic molecule. This procedure can be applied to homologous analogs of formylglycine.

[0420] Example A4-9: Macrocyclic formation of grubbs metathesis on resin In a typical procedure, a fully protected linear bis-alkene peptide of the general formula H-[(-CH=CH2)XaaN]-Xaa2-Xaa3-Xaa4-(Xaa0)p-Xaa13-[(CH=CH2)XaaC]-(resin) (300 mg, 0.20 mmol / g) is added to a 6 mM CH2Cl2 solution of a Grubbs catalyst or Grubbs-Hoveida catalyst (e.g., 1,3-bis-(2,4,6-trimethylphenyl)-2-imidazolidinylidene)dichloro(o-isopropoxyphenylmethylene)ruthenium; 0.5 equivalent moles). The suspension is heated to 40°C and gently stirred to complete the process. The beads are then filtered, rinsed with CH2Cl2, DMF, and MeOH respectively, and dried under high vacuum. After cleavage from the resin via a suitable TFA cleavage cocktail, the resulting crude cyclic peptide product is purified by HPLC (e.g., C18 column; ISCO ACCQ; using 3-60% acetonitrile in water and 0.1% TFA as a modifier). This procedure demonstrates head-to-tail macrocyclization. However, side-chain cyclization (staple) can be introduced by carefully planning the addition and removal of protecting groups.

[0421] Example A4-10: Macrocyclic formation of Grubbs metathesis in solution In a typical procedure, a fully protected linear bis-alkene peptide of the general formula H-[(-CH=CH2)XaaN]-Xaa2-Xaa3-Xaa4-(Xaa0)p-Xaa13-[(CH=CH2)XaaC]-OH is dissolved in DCM to a concentration of 0.5 mM and added to a 1.8 mM CH2Cl2 solution of Grubbs catalyst or Grubbs-Hobaida catalyst (e.g., 1,3-bis-(2,4,6-trimethylphenyl)-2-imidazolidinylidene)dichloro(o-isopropoxyphenylmethylene)ruthenium; 0.3 equivalent moles). The solution is stirred at 45°C for 20 hours. The resulting solution is stirred at room temperature to complete the process. After cleavage of the protecting group with a suitable TFA cleavage cocktail, the resulting crude cyclic peptide product is purified by HPLC (e.g., C18 column; ISCO ACCQ; 3-60% acetonitrile in water, using 0.1% TFA as a modifier), with or without workup. This procedure demonstrates head-to-tail macrocyclization. However, side-chain cyclization (staple) can be introduced by carefully planning the addition and removal of protecting groups.

[0422] Example A4-11: Staudinger macrocyclic formation In a typical procedure, the general formula is H-[(-N3)XaaN]-Xaa2-Xaa3-Xaa4-(Xaa0)p- Xaa13-[XaaC-SCH2PH + The linear C-terminal thioester crude peptide at [Ph2] is dissolved in DMF to a concentration of 7 mM or less. Diisopropylethylamine (2 equivalent moles) is added, and the mixture is stirred until the reaction is complete. The mixture is then concentrated using vacuum techniques to obtain the residue. The resulting cyclic peptide crude product is purified by HPLC (e.g., C18 column; ISCO ACCQ; 3-95% acetonitrile in water, 0.1% TFA as a modifier). This procedure demonstrates head-to-tail cyclization. However, cyclization from the side chain to the C-terminus can be introduced by carefully planning the addition and removal of protecting groups.

[0423] Example A4-12: Macrocyclic formation of CuAAC In a typical procedure, a linear azide-alkyne terminal peptide of the general formula H-[(-N3)XaaN]-Xaa2-Xaa3-Xaa4-(Xaa0)p-Xaa13-[(-C≡CH)XaaC]-OH or H-[(-C≡CH)XaaN]-Xaa2-Xaa3-Xaa4-(Xaa0)p-Xaa13-[(-N3)XaaC]-OH is dissolved in acetonitrile to a concentration of 0.2 mM or less. The reaction mixture is degassed for 15 minutes by bubbling with Ar or N2. Diisopropylethylamine (2 equivalent moles), 2,6-lutidine (2 equivalent moles), tris-(benzyltriazolylmethyl)amine (2 equivalent moles), and copper(I) iodide (2 equivalent moles) are added, and ar bubbling is continued for another 5 minutes. Next, the reaction mixture is stirred under an inert atmosphere until completion, and then concentrated by vacuum to obtain the residue. The resulting crude cyclic peptide product is purified by HPLC (e.g., C18 column; ISCO ACCQ; using 3-95% acetonitrile in water and 0.1% TFA as a modifier). This procedure demonstrates head-to-tail cyclization. However, side-chain cyclization (staples) can be introduced by carefully planning the addition and removal of protecting groups. This protocol can be applied to fully protected or unprotected peptides.

[0424] Example A4-13: Macrocyclic formation of naturally occurring chemical ligation In a typical procedure, the linear C-terminal thioester crude peptide of the general formula H-[(-CH2SH)XaaN]-Xaa2-Xaa3-Xaa4-(Xaa0)p-Xaa13-XaaC-SR is added to ligation buffer (6M guanidine-HCl, 200mM Na2HPO4, pH 8.5) to a concentration of 5mM or less. Thiophenol is added as 2 vol% (for example, 2 μL of thiophenol per 100 μL of ligation) to the ligation mixture, and the mixture is stirred to emulsify. The pH is adjusted to approximately 7.1 using 1M NaOH or 1M HCl solution. The reaction is stopped by diluting the entire reaction with a 10-ligation reaction volume of 50% MeCN in H2O containing 0.05% TFA, then TCEP (15 equivalent moles) is added and the reaction is allowed to proceed for 15 minutes. The reaction product is purified by HPLC in appropriate aliquots (e.g., using a C18 column; ISCO ACCQ; 3-95% acetonitrile in water, with 0.1% TFA as a modifier) ​​to obtain a macrocyclic peptide molecule. This protocol can be adapted to the application of STL (serine / threonine ligation) of appropriately modified peptides according to a general protocol. That protocol is described at =Front.Chem.2:28.doi:10.3389 / fchem.2014.00028, and the entire protocol is incorporated herein by reference.

[0425] Example A5: Synthesis of 177-Lutetium Chelate Conjugate Peptides having the structure of formula (II) or formula (III) are synthesized according to Examples A1 and A3 and cyclized according to Example A4. The peptide is conjugated with a metal chelating agent (e.g., DOTA or other chelating agents described herein) via an optional linker attached to the C-terminus of the cyclic peptide, thereby generating a conjugate containing the cyclic peptide and the metal chelating agent.

[0426] 177 General procedure for Lu labeling: [ in HCl 177Add 50 MBq of Lu[LuCl3] to a mixture of DOTA cyclic peptide constructs (1 nmol) in NaOAc buffer (5% EtOH, 0.25 M, pH 5.0-5.5, total volume 120 μL) in a 1.8 mL Eppendorf tube. Heat the resulting mixture in a thermal mixer at a shaking speed of 600 rpm at 80°C for 15-30 minutes. If necessary, the mixture is purified using a C8 column. Radiochemical purity is measured by radio-RP-HPLC and iTLC.

[0427] Example A6: Synthesis of 225-actinium chelate conjugate Peptides having the structure of formula (II) or formula (III) are synthesized according to Examples A1 and A3 and cyclized according to Example A4. The peptide is conjugated with a metal chelating agent (e.g., DOTA or other chelating agents described herein) via an optional linker attached to the C-terminus of the cyclic peptide, thereby generating a conjugate containing the cyclic peptide and the metal chelating agent.

[0428] 225 General procedure for Ac labeling: [ in 1 mM HCl 225 Ac]Ac(NO3)3 (50 kBq) is added to a mixture of DOTA cyclic peptide constructs (1 nmol) in NaOAc buffer (100 μL, 0.4 M, pH 5.5-6.5) in a 1.8 mL Eppendorf tube. The resulting mixture is heated in a thermal mixer at a shaking speed of 500 rpm at 80-100°C for 15-30 minutes. Radiochemical purity is measured by iTLC.

[0429] B: Biological assay. Example B1. In vivo pharmacokinetic studies in female CD-1 mice. This experiment, 225 This is done using a non-radioactive conjugate in which radioactive nuclides such as Ac are replaced with lanthanum. (La 3+ ) La 3+The pharmacokinetics of the labeled peptide substitutes were determined using female CD-1(ICR) mice purchased from Vital River Laboratory Animal Co., Ltd. (Beijing, China). All animal experiments were conducted in accordance with the highest control standards outlined in the NIH's "Guidelines for Laboratory Control and Use." Aliquots of the peptides in PBS (10 mM, pH 7.4) were injected into the tail vein of mice (10 mg / kg, 3 mice per test compound). Blood samples were then collected in pre-cooling tubes containing heparin sodium (3 μL, 1000 I.U. / mL) at 5, 30, 60, and 240 minutes, respectively.

[0430] General sample processing procedure: Aliquots of 12 μL dilutions (10-fold dilution for blood samples at 30, 60, and 240 minutes; 20-fold dilution for blood samples at 5 minutes), calibration standards, dilution quality controls, single blanks, or double blank samples are added to individual wells of a low-binding 96-well plate. Each sample (except double blanks) is quenched with 120 μL of IS in methanol (double blank samples are quenched with 120 μL of MeOH). The resulting mixtures are mixed at 800 rpm for 10 minutes and centrifuged at 3220 g (4000 rpm) for 15 minutes at 4°C. Aliquots (50 μL) of the supernatant are transferred to a clean low-binding 96-well plate and centrifuged at 3220 g (4000 rpm) for 5 minutes at 4°C. The samples are then injected directly for LC-MS / MS analysis.

[0431] The analyte is detected by a multiple reaction monitoring method using a SCIEX Triple Quad 6500+ system equipped with an ACQUITY UPLC HSS T3 column (100 Å, 1.8 μm, 2.1 mm × 30 mm). Mobile phase A is water / acetonitrile (95 / 5, v / v) containing 0.1% formic acid and 2 mM ammonium formate. Mobile phase B is acetonitrile / water (95 / 5, v / v) containing 0.1% formic acid and 2 mM ammonium formate. Alternatively, mobile phase A is water containing 0.1% formic acid, and mobile phase B is acetonitrile containing 0.1% formic acid. Column temperature: 60°C.

[0432] Plasma concentration-time data are used for IV-non-compartmental pharmacokinetic analysis using Phoenix WinNonlin (version 6.3, Pharsight Corp. (Mountain View, CA, USA)). A linear / logarithmic trapezoidal rule is applied to obtain PK parameters.

[0433] The pharmacokinetic profile of the conjugate, including clearance, AUC (0-inf), and elimination half-life, is determined.

[0434] Example B2: In vivo distribution study in mice Mice carrying a 22Rv1 xenograft received 50-100 μCi via the tail vein. 177 Lu-labeled peptides are administered as a bolus injection. Mice are euthanized by lateral thoracic paracentesis under anesthesia and dissected 2 hours and 24 hours after injection (n=3 per time point). Blood is collected by cardiac paracentesis immediately before euthanasia at each time point. Liver, heart, kidneys, lungs, muscles, spleen, saliva, tumors, and blood are collected in pre-weighed 20 mL glass scintillation vials, capped, and placed in a Hidex automated gamma counter (Hidex AMG) for counting and weight measurement. The percentage injection volume per gram of tissue (ID) is calculated against a known activity standard.

[0435] Example B3: Measurement of conjugate plasma protein binding HSA-HPLC method (measurement of drug-protein binding by immobilized human serum albumin-HPLC). An HPLC (Thermo Vanquish Horizon equipped with a diode array detector) gradient method for 13 minutes was used, and the HSA (human serum albumin) binding of the new compound was measured using a chemically bound protein stationary phase (ChiralPAK HSA HPLC column, 50x4mm). The HSA binding value was derived from the gradient retention time, which was converted to the logarithm of the equilibrium constant using data from the calibration set of molecules. The plasma binding percentage value of the calibrator compound was converted to a linear free energy value using the following equation: LogK = log[%PPB / (101-%PPB)]. The logarithm value of the gradient retention time from the experiment was plotted against the linearized value of the percentage bound to plasma. The retention time was converted to a linear free energy value (LogK) using the slope and intercept, and the estimated protein binding rate (%) was calculated from that using the following equation: Percent binding rate = [(101·10 LogK ) / (1 + 10 LogK )]. The aqueous mobile phase (A) was a 50 mM ammonium acetate solution, pH 7.4, and the organic mobile phase (B) was 2-propanol. The flow rate was set at 0.350 mL / min, the injection volume was 5 μL, and the sample was prepared at a concentration of 0.5 mg / mL in a 50:50 mobile phase. The initial LC conditions were carried out at room temperature, set at 0% B, increased to 50% B over 8.5 minutes, then held at 50% B for 1.5 minutes, then returned to the initial conditions, and the column was re-equilibrated for 2.5 minutes. The chromatogram was recorded at 280 nm by a diode array UV absorption detector.

[0436] The binding percentage values in Table 7 are defined as follows: 90% bound to HSA < A ≤ 100% bound to HSA, 70% bound to HSA < B ≤ 90% bound to HSA, 20% bound to HSA < C ≤ 70% bound to HSA, and 0% bound to HSA < D ≤ 20% bound to HSA.

[0437] [Table 15]

[0438] Example B4: Measurement of the binding affinity of the conjugate to the target protein

[0439] Binding to target antigens was measured using cyclic peptides and cyclic peptide conjugates. The presence or absence of metal chelated moieties does not affect the cyclic peptides of the present invention or their biological targets.

[0440] Example B4-1: Peptide binding to FOLR1

[0441] For peptide bond analysis, a Biacore 8K instrument utilizing either an SA or CAP tip was used. FOLR1-Fc-Avi (AcroBiosystems, F01-H82F9) was fixed on the tip at 25°C at a level of 500–2500 RU (depending on the molecular weight of the analyte) using the streptavidin-biotin reaction in PBS-P+ buffer (20 mM phosphate, 2.7 mM KCl, 137 mM NaCl, 0.05% Tween-20, pH 7.4). A peptide dilution series was prepared in this buffer at a final DMSO concentration of 1%, a maximum peptide concentration of 50 or 100 nM, and eight further 2-fold dilutions. SPR analysis was performed using a single-cycle kinetics method at 25°C with a flow rate of 100 μL / min in PBS-P+ containing 1% DMSO running buffer, with binding for 120 seconds and dissociation for 10,000 seconds. All data were analyzed using Biacore Insight evaluation software version 3. The data were fitted using a Langmuir 1:1 coupled model.

[0442] K of the peptide in this disclosure d The values ​​are shown in Table 8 below. In the table, K d is 0nM <A≦10nMである。

[0443] [Table 16]

[0444] Example B4-2: Peptide binding to PSMA

[0445] Peptide binding analysis was performed using a Biacore 8K instrument with SA tips. His-Avi-PSMA (AcroBiosystems, PSA-H82Qb) was immobilized on the tip at 25°C at levels of 800–2200 RU (dependent on analyte molecular weight) in HBS-P+ buffer (10 mM HEPES, 150 mM NaCl, 0.05% Tween-20, pH 7.4) using a streptavidin-biotin reaction. A peptide dilution series was prepared in this buffer at a final DMSO concentration of 1% and a maximum peptide concentration of 10–100 nM, followed by eight further 2-fold dilutions. SPR analysis was performed using a single-cycle kinetics method at 25°C at a flow rate of 100 μL / min in HBS-P+ containing 1% DMSO running buffer, with binding for 120 seconds and dissociation for 10,000 seconds. All data were analyzed using Biacore Insight evaluation software version 3. The data were fitted using a Langmuir 1:1 coupled model.

[0446] Compound K of the Disclosure d The values ​​are shown in Table 9 below. In the table, K d is 0nM <A≦10nMである。

[0447] [Table 17]

[0448] Example B4-3: Conjugate to Trop-2

[0449] Peptide binding was analyzed using a GatorPrime instrument with a SMAP probe. 1 μM biotin-labeled peptide was immobilized on the sensor at 25°C in HBS-P+ buffer (10 mM HEPES, 150 mM NaCl, 0.05% Tween-20, pH 7.4) using a streptavidin-biotin reaction. A dilution series of His-tagged Trop-2 (AcroBiosystems, TR2-H5223) was prepared in this buffer at a maximum peptide concentration of 100 nM and six further 3-fold dilutions. BLI analysis was performed at 30°C with 120 seconds of binding and 120 seconds of dissociation. All data were analyzed using GatorLaunch software. Data were fitted using a Langmuir 1:1 binding model.

[0450] Compound K of the Disclosure d The values ​​are shown in Table 10 below. In the table, K d is 0nM <A≦10nM;10nM<B≦1000nMである。

[0451] [Table 18]

[0452] Example B5: Determination of the binding affinity of the conjugate to cells expressing the target protein.

[0453] Example B5-1: Conjugate to FOLR1-expressing cells

[0454] Dilute the peptide: (1) The compound was reconstituted into a 10 mM stock using DMSO aliquots and stored at -80°C. (2) Compound dilution plates were prepared: The initial dilution dose was prepared and further serially diluted in DMSO as needed. (3) 3 μL of the diluted compound was added to 97 μL of test buffer (i.e., hPlasma / PBS) (33.3-fold dilution). (4) 10 μL of (3) was added to 90 μL of cells in a 96-well plate (further diluted 10-fold). (5) Example: If the initial dose to be tested is 1 μM => Add 1 μL of 10 mM stock to 29 μL of DMSO => If performing a stepwise 5-fold dilution, add 2 μL of the initial dose to 8 μL of DMSO and continue this process until the final dose => Add 3 μL of all diluted compounds to 97 μL of hPlasma / PBS => Add 10 μL of these to 90 μL of cells

[0455] FACS binding: (1) Wash the cells in the flask with PBS and aspirate. (2) Add 2-3 mL of Accutase and wait for about 10 minutes until the cells detach. (3) Resuspend in 10 mL of medium and count using viability staining method. (4) The cells were washed once with PBS. (5) Resuspend the samples and perform a bulk viability dye test with Zombie Violet (1:1000) at room temperature for 10 minutes in the dark. Wash with PBS at 1600 RPM for 3 minutes (3 times). (6) Seed in a FACS plate with 50-100,000 cells / well (hPlasma / PBS (Sigma, P9523-5ML), reconstitute hPlasma powder in 10mL of PBS before use). (7) Add the peptide dilution and incubate on ice for 50 minutes. (8) Wash with PBS + hPlasma at 1600 RPM for 3 minutes, three times. (9) Add a diluted solution of SA-647 (1:1000) and incubate on ice for 30 minutes. (10) Wash with PBS + hPlasma at 1600 RPM for 3 minutes, three times. (11) Read with Cytoflex (use automatic to find cells. Maintain PB450 and APC baselines below or around 1000)

[0456] EC of the compounds disclosed herein 50 The values ​​are shown in Table 11 below. In the table, EC 50 is 0nM <A≦100nMである。

[0457] [Table 19]

[0458] Example B5-2: Conjugate to PSMA-expressing cells

[0459] Biotin-labeled compounds

[0460] LnCap cells, 2e 6 cells / mL

[0461] FACS buffer = 1x PBS + 1% BSA

[0462] SYTOX Viability Dye (1) The cells were washed once with PBS. (2) The cells were incubated with 5 mL of Accutase at 37°C for 2–5 minutes. The flask was gently shaken until the cell layer detached. (3) Add 15 mL of PBS to the flask and transfer to a 50 mL conical tube. (4) Spun down at 1600 rpm for 3 minutes. (5) The cells were resuspended in 2 mL of PBS and the number of cells was measured. (6) Adjust the cell density to 2e6 cells / mL using PBS, then add 100 μL / well to the plate and mix well. (7) Spun down at 1600 rpm for 3 minutes. (8) Add 100 μL of the compound to each well. Prepare serially diluted compounds with PBS, from 1 μM to 0.01 nM, 1:3 dilution, 10-point curve. (9) Incubated for a total of 50 minutes (10) The wells were washed with 150 μL of PBS, spun down at 1600 rpm for 3 minutes, and discarded. (11) SA-A647 was added, diluted 1:1000 with FACS buffer, and added to each well at a rate of 100 μL / well. (12) Incubated on ice for 50 minutes (13) Washed with 200 μL of PBS, spun at 1600 rpm for 3 minutes, and discarded. (14) Resuspend in 100 μL of SYTOX and dilute 1:1000 in FACS buffer. (15) Acquisition

[0463] EC of the compounds disclosed herein 50 The values ​​are shown in Table 12 below. In the table, EC 50 is 0nM <A≦100nM;100nM<B≦1000nMである。

[0464] [Table 20]

[0465] Example B5-3: Conjugate to Trop-2 expressing cells

[0466] Conjugates to Trop-2 expressing cells were conjugated using A431 cells according to Example A5-2. EC of the compounds disclosed herein 50 The values ​​are shown in Table 13 below. In the table, EC 50 is 0nM <A≦100nMである。

[0467] [Table 21]

[0468] The examples and embodiments described herein are for illustrative purposes only, and various modifications or changes suggested to those skilled in the art are included within the spirit and scope of this application and the appended claims.

Claims

1. A conjugate comprising: a) a targeting moiety comprising a monocyclic peptide of 5 to 40 amino acid residues; b) a metal chelator configured to bind a radionuclide; and c) an alpha particle-emitting radionuclide bound to said metal chelator; The conjugate provided that said monocyclic peptide does not contain a disulfide bond.

2. 2. The conjugate of claim 1, wherein the alpha particle-emitting radionuclide is actinium-225, astatine-211, thorium-227, or radium-223.

3. The monocyclic peptide consists of 10, 11, 12, 13, 14, or 15 amino acid residues, or 2. The conjugate of claim 1, wherein the monocyclic peptide consists of 5, 6, 7, 8, 9, 10, 11, or 12 amino acid residues.

4. The targeting moiety is (i) a carcinoembryonic antigen, a tight junction protein, an adhesion protein, an eph-related tyrosine kinase receptor (TKR), or a transporter protein; (ii) a transmembrane glycoprotein; (iii) prostate-specific membrane antigen (PSMA), tumor-associated calcium signal transducer 2 (Trop-2), folate receptor 1 (FOLR1), nectin cell adhesion molecule 4 (nectin-4), carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5), mesothelin, EPH receptor A2 (EPHA2), tumor-associated calcium signal transducer 2 (Trop-2), somatostatin receptor type 2 (SSTR2), carbonic anhydrase IX (CAIX), delta-like 3 (DLL3), fibroblast activation protein alpha (FAP-α), B7-H4, tumor endothelial marker 8 (TEM8), NaPi2b, claudin 18.2, tumor-associated glycoprotein 72 (TAG72), or CD70; or (iv) an oncofetal protein, a tumor surface marker, a receptor protein, a ligand protein, a cell adhesion protein, or an immunomodulatory protein. The conjugate of claim 1 , which binds to

5. A conjugate comprising: a) a cyclic binding peptide that binds to a cell surface protein, the cyclic binding peptide being cyclized by a non-disulfide bond and consisting of 5 to 40 amino acid residues; b) a metal chelator configured to bind to a radionuclide; c) The conjugate, wherein the cell surface protein is a transmembrane glycoprotein, and the transmembrane glycoprotein is prostate-specific membrane antigen (PSMA), tumor-associated calcium signal transducer 2 (Trop-2), somatostatin receptor type 2 (SSTR2), or carbonic anhydrase IX (CAIX).

6. A conjugate comprising: a) a binding peptide that binds to a cell surface protein; b) a metal chelator configured to bind a radionuclide; and c) a linker that covalently attaches the binding peptide to the metal chelator; The conjugate, wherein the cell surface protein is a carcinoembryonic antigen, a tight junction protein, an adhesion protein, a transporter receptor, or a tyrosine kinase receptor (TKR).

7. The conjugate of claim 6, wherein the binding peptide is a monocyclic peptide and the conjugate further comprises an alpha particle-emitting radionuclide bound to the metal chelator.

8. The cell surface protein of claim 1, wherein the cell surface protein is a carcinoembryonic antigen, the carcinoembryonic antigen comprising:

7. The conjugate of claim 5 or 6, which is (i) carcinoembryonic antigen (CEA) or alpha-fetoprotein (AFP), (ii) carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5), or (iii) tumor-associated calcium signal transducer 2 (Trop-2).

9. The conjugate of claim 5 or 6, wherein the cell surface protein is an EPH-associated tight junction protein, and the EPH-associated tight junction protein is a claudin (such as claudin 2, 3, 4, 7, 8, 12, 15, or 18), occludin, oligodendrocyte-specific protein (OSP), peripheral myelin protein (PMP), or a junctional adhesion molecule.

10. The cell surface protein is an adhesion protein, and the adhesion protein is nectin cell adhesion molecule 4 (nectin 4); or The conjugate of claim 5 or 6, wherein the adhesion protein is selected from integrins, cadherins, selectins, and immunoglobulin-like cell adhesion molecules.

11. The conjugate of claim 5 or 6, wherein the cell surface protein is a tyrosine kinase receptor (TKR), and the tyrosine kinase receptor is an EPH-related tyrosine kinase receptor or an epidermal growth factor receptor (EGFR), a fibroblast growth factor receptor (FGFR), a vascular endothelial growth factor receptor (VEGFR), an ErbB receptor, a RET receptor, or a discoidin domain receptor (DDR).

12. The conjugate of claim 5 or 6, wherein the cell surface protein is a transport receptor, and the transport receptor is folate receptor 1 (FOLR1).

13. The conjugate of claim 5 or 6, wherein the binding peptide consists of 5 to 40 amino acid residues, 5 to 20 amino acid residues, 5 to 15 amino acid residues, or 5 to 14 amino acid residues.

14. The conjugate of any one of claims 1, 5, and 7, wherein the cyclic peptide is cyclized by a peptide bond, an alkyl bond, an alkenyl bond, an ester bond, a thioester bond, an ether bond, a thioether bond, a phosphate ether bond, an azo bond, a C-N-C bond, a C=N-C bond, a C=N-O bond, an amide bond, a lactam bridge, a carbamoyl bond, a urea bond, a thiourea bond, an amine bond, or a thioamide bond.

15. A conjugate comprising: (i) a targeting moiety comprising a cyclic peptide having the structure of formula (III): (ii) a metal chelator configured to bind to a radionuclide. 【Chemistry 1】 (In the formula, each of XaaN, Xaa2, Xaa3, Xaa4, Xaa0, Xaa13, and XaaC is independently an amino acid residue; p is 0, 1, 2, 3, 4, 5, 6, 7, or 8; Each of the amino acid residues in the cyclic peptide is joined by a peptide bond, but XaaN and XaaC are connected via -LN-Lcyc-Lc-; L N and L C are each independently an optionally substituted C 1 -C 6 alkylene, an optionally substituted C 1 -C 6 heteroalkylene, or a bond, wherein the alkylene or heteroalkylene is optionally substituted; L cyc is a ring-closing group containing a structure selected from -C(=O)-CH 2 -S-, -S-, -CH=CH-, -NH-, -succinimido-S-, -C(=O)-CH 2 -NH-, and -C(=O)-CH 2 -O-; The cyclic peptide is a monocyclic, disulfide bond-free conjugate.

16. The conjugate comprising an alpha particle-emitting radionuclide bound to the metal chelator; The conjugate of claim 15, wherein the alpha particle-emitting radionuclide is actinium-225.

17. The conjugate of claim 15 or 16, wherein each of the amino acids is independently selected from a natural amino acid or an amino acid in Table 4A to Table 4G.

18. The monocyclic peptide, 【Chemistry 2】 18. The conjugate of claim 17 having the structure:

19. The conjugate is a) synthesizing said peptide sequence by solid phase peptide synthesis; b) cyclizing the peptide by forming an intramolecular non-peptide bond; c) conjugating the metal chelator to the peptide; and d) Optionally, labeling the conjugate with a radionuclide.

7. The conjugate of claim 1, 5 or 6, prepared by one or more of the following:

20. The conjugate of any one of claims 1 to 7, 15, 16, and 18, wherein the metal chelator comprises DOTA, DOTP, DOTMA, DOTAM, DOTAGA, DTPA, NTA, EDTA, DO3A, DO2A, NOC, NOTA, TETA, DiAmSar, CB-Cyclam, CB-TE2A, DOTA-4AMP, H4pypa, H4octox, H4octapa, p-NO2-Bn-neunpa, or NOTP.

21. The conjugate of claim 20, wherein the metal chelator is DOTA.

22. The conjugate of any one of claims 1 to 7, 15, 16, 18, and 21, wherein the conjugate comprises a linker covalently bonding the cyclic peptide to the metal chelator.

23. A pharmaceutical composition comprising a conjugate according to any one of claims 1 to 22 and a pharma- ceutically acceptable excipient or carrier.

24. Use of a conjugate according to any one of claims 1 to 22 in the manufacture of a medicament for treating cancer.